{
  "doc_id": "baggrund-for-medicinraadets-anbefaling-vedr-lenvatinib-som-mulig-standardbehandling-til-hepatocellulaert-karcinom-vers-10-med-bilag_adlegacy",
  "created_date": "unknown_year",
  "country": "DK",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "B\nM\nv\ns\ns\nh\nk\nVersionsnr\nBag\nMe\nved\nsom\nsta\nhep\nkar\nr.: 1.0\ngg\ned\ndr\nm\nan\npa\nrc\ngru\ndici\nrør\nm m nda\nato\ncino\nun\nin\nre\nmu\nar\noc\nom\nnd\nnr\nen\nuli\nrd\nce\nm\nd fo råd\nnde\nig\ndbe\nellu\nm\nor\ndet\ne le eha\nulæ\nts\nen\nan\nær\ns an nva\nndl\nrt\nnb\nat\nlin\nbe\nti\nng\nefaling\ninib\ng til",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Om Medicinrådet",
      "text": "Medicinrådet er et uafhængigt råd, som udarbejder anbefalinger og vejledninger om lægemidler til de fem regioner.\nMedicinrådet vurderer, om nye lægemidler og nye indikationer kan anbefales som mulig standardbehandling og udarbejder fælles regionale behandlingsvejledninger.\nNye lægemidler vurderes i forhold til effekt, eksisterende behandling og pris. Det skal give lavere priser og\nlægemidler, der er til størst mulig gavn for patienterne.\nDe fælles regionale behandlingsvejledninger er vurderinger af, hvilke lægemidler der er mest hensigtsmæssige til behandling af patienter inden for et terapiområde og dermed grundlag for ensartet høj kvalitet for patienterne på\ntværs af sygehuse og regioner.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Om anbefalingen",
      "text": "Anbefalingen er Medicinrådets vurdering af, om omkostningerne ved behandling lægemidlet er rimelige i forhold til lægemidlets kliniske værdi.\nSe Medicinrådets metodehåndbog for yderligere information.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Dokumentoplysninger",
      "text": "Godkendelsesdato 10. april 2019\nIkrafttrædelsesdato 10. april 2019\nDokumentnummer 44829\nVersionsnummer 1.0\n© Medicinrådet, 2019. Publikationen kan frit refereres med tydelig kildeangivelse.\nMedicinrådet, Dampfærgevej 27-29, 3. th., 2100 København Ø\nSprog: dansk\nFormat: pdf\nUdgivet af Medicinrådet, 10. april 2019\nSide 1 af 8\nIndho\n1 Læg\n2 Me\n3 For\n4 Bag\n5 Me\n6 Hør\n7 Res\n8 Ove\n9 Sam\n10 Ver\n11 Bila\nold\ngemiddelinforma\nedicinrådets anbe rmål ....................\nggrund................\nSagsbehandlin\nedicinrådets vurd ring ....................\nsumé af økonomi ervejelser omkrin\nmmensætning af rsionslog ............\nag .......................\nationer ................................\nefaling ..................................\nngstid og proces for Medicin dering af samlet klinisk merv\nisk beslutningsgrundlag .....\nng alvorlighed/forsigtighed fagudvalg og kontaktinform\nnrådets vurd værdi ........\nd .................\nmation til M\ndering\nMedici\ng ........\ninråde\net .......\nSi\nide 2 af 8",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "Lægemidlets oplysninger",
      "text": "Handelsnavn Lenvima\nGenerisk navn Lenvatinib\nFirma Eisai\nATC-kode L01XE29\nVirkningsmekanisme Lenvatinib er en multireceptortyrosinekinase inhibitor der hæm vækstfaktorreceptorerne VEGF 1-3, FGF 1-4, PDGF α og proto\nonkogenerne KIT og RET.\nAdministration/dosis Lenvatinib administreres oralt som tabletter. Dosis er 8 mg (ved\nkropsvægt < 60 kg) eller 12 mg (ved kropsvægt ≥ 60 kg) én gan dagligt. Behandlingen fortsættes, så længe klinisk fordel observ\neller indtil der opstår uacceptable bivirkninger.\nEMA-indikation Lenvatinib er indiceret som monoterapi til behandling af voksne patienter med fremskreden eller ikkeresektabelt hepatocellulært\nkarcinom (HCC), som ikke tidligere har fået systemisk behandli",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "2 Medicinrådets anbefaling",
      "text": "Medicinrådet anbefaler lenvatinib som mulig standardbehandling til voksne patienter med fremskre ikkeresektabelt hepatocellulært karcinom (HCC), som ikke tidligere har fået systemisk behandling.\nDet kliniske spørgsmål, som ligger til grund for anbefalingen, er som følger:\nHvad er den kliniske merværdi af lenvatinib til voksne patienter med fremskredent eller ikkereseptab hepatocellulært karcinom, som er kandidater til systemisk behandling, sammenlignet med sorafenib?\nSi\nmmer\nod\nng\nveres,\ne\nt\ning.\neden eller belt\nide 3 af 8",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "3 Formål",
      "text": "Formålet med Baggrund for Medicinrådets anbefaling vedrørende lenvatinib som mulig standardbeh til hepatocellulært karcinom er at skabe gennemsigtighed om det materiale, der ligger til grund for\nMedicinrådets anbefaling.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "4 Baggrund",
      "text": "Lenvatinib er indiceret til systemisk behandling af patienter med fremskreden eller ikkeresektabelt hepatocellulært karcinom, som ikke tidligere har fået systemisk behandling\nYderligere information findes i ”Medicinrådets vurdering af klinisk merværdi for lenvatinib til behan hepatocellulært karcinom”.\nSagsbehandlingstid og proces for Medicinrådets vurdering\nMedicinrådet modtog den foreløbige ansøgning den 24. maj 2018. Protokollen blev godkendt af\nMedicinrådet og sendt til ansøger den 11. september 2018.\nDet endelige datagrundlag for Medicinrådets vurdering blev modtaget den 14. november 2018. Ansø\nudbad sig et clock-stop i processen, som løb fra den 11. december 2018 til den 20. januar 2019.\nMedicinrådet traf beslutning om den kliniske merværdi den. 13 marts 2019.\nMedicinrådet har gennemført vurderingen af lenvatinib på 15 uger og 2 dage.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "5 Medicinrådets vurdering af samlet klinisk merværdi",
      "text": "Medicinrådet vurderer, at lenvatinib til voksne patienter med fremskredent eller inoperabelt hepatoce carcinom med performancestatus 0-1 og bevaret leverfunktion svarende til Child-Pugh A og B (7),\nsammenlignet med sorafenib, giver:\n• Ingen klinisk merværdi (meget lav evidenskvalitet)\nMedicinrådet finder, at lenvatinib og sorafenib kan ligestilles som førstelinjebehandling til patienter hepatocellulært karcinom.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "6 Høring",
      "text": "Ansøger har indgivet høringssvar den 19. marts 2019. Høringssvaret har ikke givet anledning til ænd\nvurderingen af den kliniske merværdi. Høringssvaret er vedlagt som bilag.\nSi\nhandling\nndling af øger\nellulært\nmed\ndringer i ide 4 af 8",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "7 Resumé af økonomisk beslutningsgrundlag",
      "text": "Amgros vurderer, at behandling med lenvatinib er forbundet med m med sorafenib. Meromkostningerne er udelukkende drevet af lægem\nMed den nuværende aftalepris (SAIP) på lenvatinib vurderer Amgro sammenlignet med den kliniske merværdi, som lægemidlet tilbyder.\n8 Overvejelser omkring alvorlighed/forsigtigh\nMedicinrådet har ikke fundet anledning til at inddrage forhold vedrø anbefalingen.\nmeromkostni\nmiddelomko\nos, at omko\nhed\nørende alvo\ninger per patient samm ostningerne for lenvati\nostningerne ikke er rim orlighed eller forsigtigh\nSi\nmenlignet\ninib.\nmelige\nhed i ide 5 af 8\n9 Sammensætning af fa\nMedicinrådets fagudvalg vedrøre\nFormand\nBritta Weber\nAfdelingslæge, ph.d.\nMedlemmer\nGerda Elisabeth Villadsen\nOverlæge, ph.d., klinisk lektor\nMerete Krogh\nOverlæge\nKirsten Kjeldgaard Vistisen\nOverlæge\nLone Galmstrup Madsen\nSpecialeansvarlig overlæge, ph.d.\nHar ikke udpeget\nMette Skalshøi Kjær\nOverlæge, klinisk lektor\nMette Kudsk Brink\nFarmaceut\nAmy Daugaard Asmussen\nKvalitetskoordinator, sygeplejersk\nNiels Jessen\nProfessor, overlæge\nTóra Haraldsen\nPatient/patientrepræsentant",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Medicinrådets sekretariat",
      "text": "Medicinrådet\nDampfærgevej 27-29, 3. th.\n2100 København Ø\n+ 45 70 10 36 00 medicinraadet@medicinraadet.dk",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "Sekretariatets arbejdsgruppe",
      "text": "Gedske Thomsen (projekt- og met\nThea Christensen (sundhedsvidens\nAnette Pultera Nielsen (fagudvalg\nAnnemette Anker Nielsen (teamle\nagud\nende l\nke, MH todean\nskabe\ngskoor\neder)\ndval\nleverk\nHH\nnsvarl\nelig ko rdinato\nlg og kræft\nlig)\nonsule\nor)\ng kontaktinformatio\nIndstillet af\nLægevidenskabelige S\nUdpeget af\nRegion Midtjylland og\nRegion Syddanmark\nRegion Hovedstaden\nRegion Sjælland\nRegion Nordjylland\nDansk Selskab for Gas\nDansk Selskab for Syg\nInviteret af formanden\nDansk Selskab for Klin\nDanske Patienter ent)\non ti\nSelskab\ng invit stroen\ngehusa\nnisk F\nil Me ber\nteret a nterolo\napotek\nFarmak\nedic\naf form ogi og\nkslede\nkolog\ncinrå\nmande\ng Hepa else\ngi\nSi\nådet\nen\natolog\nide 6\nt\ngi\naf 8\n10 Ve\nVersion\nersionslo\nn Dato\nog\no\nÆndring\n9 Godkendt af Medic\ncinråd\ndet.\nSide 7 af 8",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "11 Bilag",
      "text": "Bilagsliste:\n• Amgr\n• Amgr\n• Hørin\n• Vurde\n• Ansøg\n• Proto\nros’ beslutningsgrundlag ros’ sundhedsøkonomiske analyse\nngssvar fra ansøger ering af den kliniske merværdi af lenv\ngers endelige ansøgning okol for vurdering af den kliniske merv\nvatinib\nværdi af len\nnvatini\nib\nSide 8 af 8\nAmgros I/S\nDampfærgevej 22\n2100 København Ø\nDanmark\nT +45 88713000\nF +45 88713008\nMedicin@amgros.dk",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "Dette dokument er Amgros’ vurdering af lenvatinib (Lenvima) som mulig standardbehandling til patienter med ubehandlet, avanceret, inoperabel HCC i voksne med fremskreden stadie (BCLC stadie C) med",
      "text": "leverfunktion svarende til Child-Pugh A eller B. Vurderingen er baseret på lægemidlets gennemsnitlige\ninkrementelle omkostninger (baseret på SAIP) sammenholdt med Medicinrådets vurdering af den kliniske merværdi.\nDato for Medicinrådsbeslutning 10-04-2019\nFirma Eisai (ansøger)\nLægemiddel Lenvatinib (Lenvima)\nIndikation Patienter med ubehandlet, avanceret, inoperabel HCC i voksne med fremskreden stadie (BCLC stadie C) med leverfunktion svarende til\nChild-Pugh A eller B",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Amgros’ vurdering",
      "text": "• Amgros vurderer at der ikke er et rimeligt forhold mellem meromkostningerne og den kliniske\nmerværdi for lenvatinib (Lenvima) som mulig standardbehandling til patienter med ubehandlet, avanceret, inoperabel HCC i voksne med fremskreden stadie (BCLC stadie C) med leverfunktion\nsvarende til Child-Pugh A eller B\nOverordnet konklusion\nMedicinrådet har vurderet, at lenvatinib (Lenvima) sammenlignet med sorafenib (Nexavar) giver ingen klinisk merværdi.\nBehandling med lenvatinib (Lenvima) er forbundet med meromkostninger sammenlignet med sorafenib\n(Nexavar) til nævnte indikation. Amgros vurderer, at der ikke er rimeligt forhold mellem den kliniske\nmerværdi for lenvatinib (Lenvima), sammenlignet med behandling med sorafenib (Nexavar).\nMeromkostninger drives af prisen på lenvatinib (Lenvima) og komparator.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Andre overvejelser",
      "text": "Amgros har indgået en aftale med Eisai om indkøb af lenvatinib (Lenvima) til en SAIP, so\nKonklusionen er baseret på SAIP.\nDa lenvatinib (Lenvima) har forskellige dosis alt efter vægt, vil patientens vægt have stor resultatet. Resultatet af Amgros’ analyse baseret på dosis efter vægt resulterer i merom\nlenvatinib (Lenvima) sammenlignet med sorafenib (Nexavar).\nKonklusion for populationen\nTabel 1 Merværdi, meromkostninger og Amgros’ vurdering (baseret på SAIP)\nUsikkerhed for\nPopulation Komparator Merværdi klinisk merværdi\nVoksne patienter med HCC i fremskredent stadie og\nvoksne patienter med inoperabel HCC, som ikke\ntidligere er behandlet Ingen klinisk Meget lav\nSorafenib (Nexavar) systemisk. Patienterne har merværdi evidenskvalitet\nperformance status 0-1 og bevaret leverfunktion\nsvarende til Child-Pugh A og\nB\nKonklusionen er baseret på at Medicinrådet har valgt sorafenib som komparator for pat vurderingen af meromkostninger og klinisk værdi beror på denne.\nSupplerende informationer (resumé af resultaterne fra afrapporteringe\nKonklusion på omkostnings- og budgetkonsekvensanalyserne\nResultatet fra Amgros’ afrapportering på omkostningsanalyserne er gengivet i det følgen gennemgang af analyse og resultater henvises til afrapporteringen på\nAmgros’ afrapportering - Inkrementelle omkostninger per patient\nBehandling med lenvatinib (Lenvima) er forbundet med meromkostninger sammenligne med komparator.\nI tabel 2 ses de inkrementelle omkostninger for lenvatinib (Lenvima) og sorafenib (Nexav\nom er lavere end AIP.\nr betydning på mkostninger for\nAmgros’\nkonklusion om forholdet mellem\ni\nmeromkostninger\nog merværdi\nIkke rimeligt tientpopulationen, og\ngen)\nnde. For uddybende\nros.dk.\net med behandling var).\nAmgros’ hovedanalyse resulterer i gennemsnitlige meromkostninger per patient for lenvatinib (Lenvi sammenlignet med sorafenib (Nexavar) på ca. XXXXXX DKK.\nTabel 2: Resultat af Amgros hovedanalyse for lenvatinib (Lenvima) sammenlignet med sorafenib, DKK, SAIP\nOmkostningselement Lenvatinib (Lenvima) Sorafenib (Nexavar) Inkrementelle omkos\n(DKK)\nLægemiddelomkostninger XXXXXXX DKK XXXXXXX DKK XXXXXX DKK\nHospitalsomkostninger 172.070 DKK 169.826 DKK 2.244 DKK\nOmkostninger udenfor\n13.854 DKK 14.100 DKK 247 DKK\nhospital\nTotale\ngennemsnitsomkostninger XXXXXXX DKK XXXXXXX DKK XXXXXX DKK per patient\nHvis analysen udføres på baggrund af AIP, bliver de inkrementelle omkostninger per patient for lenva\n(Lenvima) sammenlignet med sorafenib (Nexavar) ca. 153.000 DKK. Lægemiddelomkostningerne for\nlenvatinib (Lenvima) er 290.388 DKK og for sorafenib (Nexavar) er lægemiddelomkostningerne 139.1\nAIP.\nAmgros’ afrapportering – Budgetkonsekvenser\nAmgros vurderer at anbefaling af lenvatinib (Lenvima) som mulig standardbehandling, vil resultere i budgetkonsekvenser på ca. XXXXXXXX DKK per år. Hvis analysen udføres med AIP, vil budgetkonsekve\nvære på ca. 2,4 mio. DKK per år.\nvima)\nstninger\natinib\n109 DKK i enserne\nLE\nEN\nN\nNV\nVA\nAT\nT\nTIN\nHE\nNIB\nEPA\nB\nATO\n(L\nOCELL\nLE\nLUL\nENVIMA)\nLÆRT KARCINOM\nAMGROS 27. marts 2019",
      "start_page": 11,
      "end_page": 13
    },
    {
      "heading": "Baggrund",
      "text": "Lenvatinib (Lenvima) er en multi-receptortyrokinase inhibitor indiceret til behandling af patienter med hepatocellulært karcinom (HCC) i fremskreden stadie, eller patienter med inoperabel HCC, som ikke tidligere er be- handlet systemisk. Omkring 400 patienter diagnosticeres årligt, ca. 40 patienter behandles på nuværende tidspunkt med 1. linje systemisk behandling med multi-kinaseinhibitor. Amgros’ vurdering tager udgangspunkt i do-\nkumentationen indsendt af Eisai.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Analyse",
      "text": "I analysen estimeres de inkrementelle omkostninger per patient og de samlede budgetkonsekvenser for regionerne forbundet med behandling med lenvatinib (Lenvima) sammenlignet med behandling med sorafenib\n(Nexavar) til patienter med ubehandlet, avanceret, inoperabel HCC i voksne med fremskreden stadie (BCLC stadie C) med leverfunktion svarende til Child-Pugh A elller B.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Inkrementelle omkostninger og budgetkonsekvenser",
      "text": "Amgros har vurderet de gennemsnitlige meromkostninger per patient ved brug af lenvatinib (Lenvima) sammenlignet med komparator. De inkrementelle omkostninger er angivet i SAIP.\nI det scenarie Amgros vurderer er mest sandsynligt er de gennemsnitlige inkrementelle omkostninger per patient ved brug af lenvatinib (Lenvima) sammenlignet med sorafenib (Nexavar) ca. XXXXXX DKK. Hvis analysen udfø-\nres med AIP bliver de inkrementelle omkostninger ca. 153.000 DKK.\nAmgros vurderer at budgetkonsekvenserne for regionerne per år ved anbefaling lenvatinib (Lenvima) som standardbehandling vil være på ca. XXXXXXXX DKK per år. Hvis analysen udføres med AIP, er budgetkonsekvenserne\nca. 2,4 mio. DKK per år.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Konklusion",
      "text": "Amgros kan konkludere, at behandling med lenvatinib (Lenvima) er forbundet med meromkostninger sammenlignet med komparator. Meromkostningerne er i denne analyse udelukkende drevet af lægemiddelomkostninger\nfor lenvatinib (Lenvima) og sorafenib (Nexavar).",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "2 LENVATINIB (LENVIMA)",
      "text": "Lis\nAIP\nDKK\nDR\nHC\nSPC\nst\nP\nK\nRG\nCC\nC\nte ov\nLENVAT\nve\nTIN\ner fo\nAp\nDa\nDi\nHe\nSu\nNIB (LENV\nork\npo\nan\niag\nep\num\nVIM\nko\note\nnsk\ngn\npat\nmm\nMA)\nortel\nekerne\nke kro nose R\ntocellu\nmary o\nlse\nes in oner\nRelat\nulær\nof Pro\ner\nndkø\ntered\nrt ka odu\nøbspris\nde Grupper arcinom\nuct Characteristics\nINDH\nOpsumme\nListe over f\n1 Baggrun\n1.1 Problem\n1.2 Patient\n1.3 Behand\n1.3.1 Ko\n1.4 Medici\n2 Vurderin\n2.1 Model,\n2.1.1 Mo\n2.1.2 An\n2.1.3 Om\n2.2 Følsom\n3 Resultat\n3.1 Ansøge\n3.1.1 An\n3.1.2 Re\n3.2 Ansøge\n3.3 Amgro\n3.3.1 An\n3.3.2 Re\n3.4 Amgro\n3.4.1. Re\n4 Budgetk\n4.1 Resulta\n4.2 Scenar\n5 Diskussio\n6 referenc\n4 LENVA\nHOLD\nering\nforkortelser\nnd\nmstilling\ntpopulation\ndling med len omparator\ninrådets klini ng af indsend\n, metode og odelbeskrive\nnalyseperspe\nmkostninger\nmhedsanalyse\nter\ners hovedana ntagelser i an\nesultat af ans ers følsomhe\nos’ hovedanal ntagelser i Am\nesultat af Am os’ følsomhed\nesultat af Am konsekvense\nater af budge rieanalyse\non\ncer\nATINIB (LENVIMA)\nnvatinib\niske spør dt økono\nforudsæ\nelse\nektiv\ner\nalyse\nnsøgers h søgers ho\nedsanalys\nlyse\nmgros ho mgros hov\ndsanalyse\nmgros’ føl r\netkonsek\n(Len\nrgsm\nomis\nætnin\nhove\noved\nser\noved\nveda\ne\nlsom\nkvens\nnvima\nmål\nsk an nger\nedana\ndanal\ndanal\nanaly\nmhed\nsana\na)\nnalys\nalyse\nlyse\nlyse\nse\ndsana\nalyse\nse\ne\nalyse\nen\ne",
      "start_page": 15,
      "end_page": 16
    },
    {
      "heading": "LOG",
      "text": "Ansøgning\nLægemiddelfirma: Eisa\nHandelsnavn: Lenv\nGenerisk navn: Lenv\nIndikation: Beh\nATC-kode: L01X",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Proces",
      "text": "Ansøgning modtaget hos Amgros:\nEndelig rapport færdig:\nSagsbehandlingstid fra endelig ansø\nArbejdsgruppe:",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "Priser",
      "text": "Denne rapport bygger på analyser u steder er analysens resultat yderlige",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "5 LENVATINIB (LENVIMA)",
      "text": "ai\nvima\nvatinib\nhandling til hepa\nXE29\nøgning:\nudført på baggru ere angivet på b\natoce\nund s baggr\nellulært kar sygehusap\nrund af list\nrcinom\n133 dage\nLouise Greve Dal\nLine Brøns Jense\nLianna Christens\nMark Friborg\nPernille Winther potekernes indkøbsp\ntepriser (AIP).\nl\nen\nsen\nr Joha priser\nansen\n(SAIP\nn\nP). Enkelte",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "1 BAGGRUND",
      "text": "Lenvatinib (Lenvima) er en multi-receptortyrokinase inhibitor indiceret til behandling af patienter med hepatocellulært karcinom (HCC) i fremskreden stadie, eller patienter med inoperabel HCC, som ikke tidligere er\nbehandlet systemisk. Eisai (herefter omtalt som ansøger) er markedsføringstilladelsesindehaver af lenvatinib\n(Lenvima) og har den 14.11.2018 indsendt en ansøgning til Medicinrådet om anbefaling af lenvatinib (Lenvima)\nsom standardbehandling på danske sygehuse af den nævnte indikation. Som et led i denne ansøgning vurderer\nAmgros, på vegne af Medicinrådet de økonomiske analyser, ansøger har sendt som en del af den samlede ansøgning til Medicinrådet. Denne rapport er Amgros’ vurdering af de fremsendte økonomiske analyser\n(herefter omtalt som analysen).",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "1.1 Problemstilling",
      "text": "Formålet med analysen er at estimere de inkrementelle omkostninger forbundet med behandling af hepatocellulært karcinom (HCC) i fremskreden stadie, eller patienter med inoperabel HCC, som ikke tidligere er behandlet systemisk, i form af de gennemsnitlige inkrementelle omkostninger per patient og de samlede budgetkonsekvenser for regionerne ved anbefaling af lenvatinib (Lenvima) som standardbehandling på danske sygehuse af den\nnævnte indikation. I analyserne sammenlignes behandling med lenvatinib (Lenvima) med behandling med sorafenib (Nexavar) der er defineret i Medicinrådets protokol som nuværende standardbehandling.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "1.2 Patientpopulation",
      "text": "HCC er en mindre hyppigt forekommende kræftform i Danmark. Incidensen er for perioden 2011-2015 429 nye\ntilfælde per år(1). I Danmark havde 652 patienter HCC i 2015, hvilket afspejler en lav overlevelse for denne patientgruppe. Etårsoverlevelsen er 37% for mænd og 40% for kvinder, mens femårsoverlevelsen kun er 9% for\nmænd og 11% for kvinder(1).\nUdvikling af HCC forekommer oftest i patienter der har levercirrose. Leverfunktionen hos patienter med leversygdomme opdeles efter hvor god leverfunktionen er, og benævnes i kategorierne Child-Pugh A, B og C, fra\nbedst til værst leverfunktion(1).\nX",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "1.3 Behandling med lenvatinib (Lenvima)",
      "text": "HCC udgør et sygdomskontinuum, hvor Barcelona Clinic Liver Cancer (BCLC) stadiesystemet ofte bruges til stadieinddeling og ligeledes beslutte, hvilken behandling patienten har gavn af. Stadierne går fra A til C. I det\nfremskredne stadie (BCLC C) har patienter stadig leverfunktion svarende til Child-Pugh A eller B men kandiderer ikke længere til lokal behandling, og vurderes med henblik på 1. linje systemisk behandling(1).\nIndikation\nLenvatinib (Lenvima) er indiceret til behandling af voksne patienter med HCC i fremskredent stadie og voksne patienter med inoperabel HCC, som ikke tidligere er behandlet systemisk. Patienterne har performance status 0-\n1 og bevaret leverfunktion svarende til Child-Pugh A og B(1).\nLenvatinib (Lenvima) er i forvejen indiceret som monoterapi til behandling af voksne patienter med differentieret thyreoideakarcinom refraktært over for radioaktivt jod og i kombination med everolimus til\nbehandling af voksne patienter med fremskredet nyrecellekarcinom efter én forudgående behandling rettet mod vaskulær endothelvækstfaktor(1).\nVirkningsmekanisme\nLenvatinib (Lenvima) er en multi-receptortyrosinkinase inhibitor, der hæmmer vækstfaktorreceptorer VEGF receptor 1-3, FGF receptor 1-4 og PDGF receptor α samt proto-onkogenerne RET og KIT(1).",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "6 LENVATINIB (LENVIMA)",
      "text": "Dosering\nLenvatinib (Lenvima) administreres peroralt som tabletter:\n• 8 mg ved kropsvægt <60 kg\n• 12 mg ved kropsvægt ≥60 kg",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "1.3.1 Komparator",
      "text": "Medicinrådet har defineret komparator som:\n• 400 mg sorafenib (Nexavar) to gange dagligt så længe klinisk fordel observeres eller indtil der opstår\nuacceptable bivirkninger. Sorafenib (Nexavar) administreres peroralt som tabletter af 200 mg (2 tabletter 2 gange dagligt)\nTabel 1: Definerede population og komparator\nPopulation Komparator\nVoksne patienter med HCC i fremskredent stadie og voksne patienter med inoperabel HCC, som ikke tidligere er behandlet systemisk.\nSorafenib (Nexavar)\nPatienterne har performance status 0-1 og bevaret leverfunktion svarende til Child-Pugh A og B",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "1.4 Medicinrådets kliniske spørgsmål",
      "text": "Medicinrådet har vurderet den kliniske merværdi af behandling med lenvatinib (Lenvima) sammenlignet med sorafenib (Nexavar) ud fra følgende kliniske spørgsmål.\n• Hvad er den kliniske merværdi af lenvatinib (Lenvima) til voksne patienter med fremskredent eller inoperabelt hepatocellulært karcinom, som er kandidater til systemisk behandling, sammenlignet med\nsorafenib (Nexavar)?",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "2 VURDERING AF INDSENDT ØKONOMISK ANALYSE",
      "text": "I analysen af gennemsnitlige behandlingsomkostninger per patient sammenlignes behandling med lenvatinib\n(Lenvima) med behandling med sorafenib (Nexavar) til voksne patienter med HCC i fremskredent stadie og voksne patienter med inoperabel HCC, som ikke tidligere er behandlet systemisk.\nAmgros havde flere indvendinger mod den initiale model, som ansøger indsendte. Det er kun den seneste indsendte model, som præsenteres herunder.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "2.1.1 Modelbeskrivelse",
      "text": "Ansøger har indsendt en partitioned survival model for behandling af patienter i den nævnte population. Modellen estimerer andelen af patienter i hvert stadie baseret på parametriske funktioner. Stadierne består af Progres-\nsionsfri overlevelse (PFS), Progression af sygdom (PD) og Overlevelse (OS). Til hvert sygdomsstadie er beregnet\nden tid patienten befinder sig i stadiet og de behandlingsrelaterede omkostninger. De gennemsnitlige omkostninger per patient relaterer sig derfor til et givent sygdomsstadie og den tid patienten befinder sig i dette.\nAnsøger har ekstrapoleret ud fra data givet fra studiet kudo et al (2018)(2). Ansøger har valgt distribution lognormal for både de ekstrapolerede OS og ekstrapolerede PFS data, der viste bedste fit. Ansøger har ligeledes\nargumenteret for den kliniske plausibilitet.\nLenvatinib (Lenvima) er forbundet med senere progression sammenlignet med sorafenib (Nexavar), men ens overlevelse. Der kan være usikkerheder forbundet med dette som kan skyldes ubalance mellem baseline karakteristika i behandlingsarmene.\nAnalysen estimerer de gennemsnitlige samlede omkostninger forbundet med behandlingerne med en tidshorisont på 25 år og inkluderer omkostninger for lægemidler, monitorering og bivirkninger.\nAmgros’ vurdering\nAmgros accepterer ansøgers valg af distributioner, da der er valgt de distributioner med bedste fit.\nAmgros vurderer, at den overordnede modeltilgang er acceptabel.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "2.1.2 Analyseperspektiv",
      "text": "Analysen anvender et begrænset samfundsperspektiv. Tidshorisonten i analysen er 25 år. Omkostningerne er\ndiskonteret med en faktor på 4%.\nAmgros’ vurdering\nAnalysens perspektiv og diskonteringsraten er i tråd med Amgros’ retningslinjer, Jf. Amgros Metodevejledning\nom, hvad der må inkluderes i en økonomisk analyse.\nAmgros vurderer, at tidshorisonten er tilstrækkelig lang til at opfange betydelige relevante forskelle mellem de sammenlignede interventioner i analysen, eftersom få patienter er i live efter 25 år.\nAmgros godtager analysens perspektiv og tidshorisonten.",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "8 LENVATINIB (LENVIMA)",
      "text": "Det følgende afsnit om omkostninger redegør for hvordan og hvilke omkostninger ansøger har inkluderet i analysen",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Lægemiddelomkostninger",
      "text": "Alle anvendte lægemiddelpriser er på SAIP-niveau.\nTabel 2 illustrerer de lægemiddelpriser, som anvendes i analysen.\nTabel 2: Anvendte lægemiddelpriser, SAIP (marts 2019)\nLægemiddel Styrke Pakningsstørrelse Pris pr pak- Kilde ning (DKK)\nLenvitinib (Len- 4 mg 30 stk. (blister) XXXXXXXXX Amgros\nvima)\n10 mg\nSorafinib 200 mg 112 stk. (blister) XXXXXXXXX Amgros\nAnsøger har i deres analyse anvendt estimater baseret på medianer, for dosis per dag per patient for henholdsvis lenvatinib (Lenvima) og sorafenib (Nexavar).\nAnsøger har i den indsendte model gjort det muligt at til- og fravælge spild ifm. behandling med lenvatinib (Lenvima). Antallet af dage med spild under behandling er valgt til 7 dage. Ansøgers argumentation for kun at inklu-\ndere 7 dages spild beror på, at det har begrænsede betydning for omkostningerne. Den begrænsede betydning\ner bekræftet af kliniske eksperter i NICE evalueringen af lenvatinib (Lenvima). De 7 dage med spild er vurderet til\nat være klinisk plausibel og er valideret af en kliniker. Ansøger har i deres hovedanalyse valgt at ekskludere spild.\nØvrige omkostninger før og efter progression\nOmkostninger til øvrig behandling er de omkostninger, der er specifik forbundet med enten et progressionsfrit sygdomsstadie (PFS-stadie) eller sygdomsstadie (PD-stadie). Omkostningerne er dermed ikke knyttet til enten\nbehandling med lenvatinib (Lenvima) eller sorafenib (Nexavar), men til den gennemsnitlige tid en patient befinder sig i det givne stadie, hvilket relaterer sig til hvilken behandling patienten modtager.\nAnsøger har estimeret ressourceforbruget med behandling i PFS og PD gennem spørgeskemaer indsamlet om ressourceforbruget for sorafenib (Nexavar). Ansøger har efterfølgende fået valideret estimaterne af en dansk\nkliniker.\nAnsøger har estimeret forbrug af antal ambulatorisk besøg hos onkolog, AFP test, leverfunktionstest, INR, komplet blodcelletal, biokemiske test, endoskopi, CT scanning, MRI scanning, hospitalisering, sygeplejerske og hjem- mepleje. Værdisætningen af ressourceforbruget er sket ud fra danske laboratoriemedicinske vejledninger, DRGog DAGS-takster 2018 og Amgros’ katalog for enhedsomkostninger.\nAnsøger antager at INR tages for 50% af patienterne der befinder sig i PFS-stadiet, og at 0% får taget INR i PDstadiet. Ansøger antager også at patienter i PFS-stadiet får lavet komplet blodcelletal og lavet endoskopi 25%\noftere end patienter i PD-stadiet.\nAnsøger antager at 46% af patienterne indlægges 0,16 gang per måned i PFS-stadiet og at 48% af patienterne indlægges 0,4 gang per måned i PD-stadiet. Derudover antager ansøger at frekvensen for hjemmehjælp og sygeplejerskehjælp er 0,5 i PFS-stadiet og 1 i PD-stadiet for alle patienter.\nTabel 3 illustrerer ressourceforbrug, andel patienter der oplever ressourceforbruget og frekvensen per måned for henholdsvis PFS-stadiet og det PD-stadie.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "9 LENVATINIB (LENVIMA)",
      "text": "Tabel 3: ressourceforb\nAmbulatorisk besø\nAFP\nLeverfunktion\nINR\nKomplet blodcelle\nBiokemi\nEndoskopi\nCT scanning\nMRI af abdomen\nIndlæggelse\nSygeplejerske\nHjemmepleje\nTabel 4 illustrerer v\n10 LENVATINIB (LENVI\nbrug og andel patienter der op\nPFS% af patienter øg 100%\netal 75%\nværdisætningen af ressource\nIMA)\nplever ressourceforbruget\n-stadie\nFrekvens pr. måne\neforbruget fra tabel 3.\nt\ned\n% af patienter\nPD-st\nr\ntadie\nFrekvens pr. måned\nTabel 4: Værdis\nAmbulatorisk\nAFP\nLeverfunktio\nINR\nKomplet blod\nBiokemi\nEndoskopi\nCT scanning\nMRI af abdom\nIndlæggelse\nSygeplejerske\nHjemmepleje\nTabel 5 illustre\n11 LENVATINIB\nsætnin\nk besø on\ndcelle\nmen\ne\ne\nerer s\nB (LENVI\nngen af øg\netal\nsamled\nIMA)\nf resso de om\nourcefo\nmkostn\norbruge\nninger\net\nr for re\nessou\nKr.\nurceforbrug\net sta\nadierne\nReference\nAmbulant DAGS takster:\nBG50A+DG30L (Sundhedsdatastyrelsen, 2017)\nRegion Sjælland Laboratoriemedicinske vejledninger: Klinisk Bio-\nkemi; AFP (Region Sjælland,\nRegion Sjælland Laboratoriemedicinske vejledninger: Klinisk Bio-\nkemi; Albumin;\nALAT+ASAT+Bilirubiner;P+Protein\n(Region Sjælland, 2018)\nRegion Sjælland Laboratoriemedicinske vejledninger: Klinisk Bio-\nkemi; Koagulationsfaktor II+VII+X\n(Region Sjælland, 2018)\nRegion Sjælland Laboratoriemedicinske vejledninger: Klinisk Bio-\nkemi; DIFF; maskinel+Hæmoglobin;B+Trombocytter;B (Region\nSjælland, 2018)\nRegion Sjælland Laboratoriemedicinske vejledninger: Klinisk Bio-\nkemi; Gamma-Glutamyltransferase;P+eatinkinase MB;P (Region\nSjælland, 2018)\nDRG-takster 2018: PG05F (Sundhedsdatastyrelsen, 2018b)\nDRG-takster 2018: PG14G (Sundhedsdatastyrelsen, 2018b)\nDRG-takster 2018: PG14C (Sundhedsdatastyrelsen, 2018b)\nDRG-takster 2018: 0719 (Sundhedsdatastyrelsen, 2018b)\nAmgroskatalog: Nurse (AMGROS,\nAmgroskatalog: Social and\nhealthcare staff, untrained\n(AMGROS, 2018) e PFS og PD.\nTabel 5: Samlede omkostninger for ressourceforbruget PFS og PD\nProgressionsfri-stad\nHospitalsomkostninger 5.762,53 kr.\nKommunale omkostninger 403,81 kr.\nTotal 6.166,35 kr.\nOmkostninger til bivirkninger\nAnsøger har inkluderet bivirkningsomkostninger for begge læge fra en engangsomkostning for henholdsvis lenvatinib (Lenvima)\ndiet, når patienten skifter til PD-stadie. Frekvensen af bivirkning\nkluderer grad 3 og 4 bivirkninger hvor ≥ 5% af patienterne oplev grad 3 og 4 der sker i ≤ 5% af patienterne, blev inkluderet hvis d\ngrad 3 og 4 der er sket i ≤ 5% af patienterne, og som blev vurder\nAnsøger antager at alle bivirkninger behandles ambulant og vær besøg, Pat. Mindst 7 år, på 672 kr. Tabel 6 illustrerer bivirkninge\nlenvatinib (Lenvima) og sorafenib (Nexavar).\nTabel 6: % af patienter og antal event per patient for henholdsvis lenvat\nGrad 3- og 4 % af patienterne bivirkninger\nLenvatinib Sorafeni\nForhøjet aspartatami-\n5,04 8,00 notransferase\nAsteni 2,94 2,32\nForhøjet Bilirubin 6,51 4,84\nDiarré 4,20 4,21\nTræthed 3,78 3,58\nForhøjet gamma-\n5,46 4,00 glutamattranseferase\nHypertension 23,32 14,32\nPalmar-plantar eryt-\n2,94 11,37 hrodysaesthesia\nMRI af abdomen 5,46 3,37\nIndlæggelse 5,67 1,68\nSygeplejerske 7,56 2,95",
      "start_page": 22,
      "end_page": 24
    },
    {
      "heading": "12 LENVATINIB (LENVIMA)",
      "text": "die (PFS) Progredierede-stadie (PD)\n9.176,40 kr.\n807,62 kr.\n9.984,02 kr.\nemidler. Bivirkningsomkostninger er beregnet udog sorafenib (Nexavar) i pre-progressions-sta-\nger er taget fra studiet kudo et al. (2018), og inver dem i hver behandlingsarm.(2) Bivirkninger af\ndette vurderes klinisk relevant. Bivirkninger af\nret klinisk relevant er diarré, asteni og træthed.\nrdisættes ud fra DAGS-taksten 2017, Ambulant erne og frekvensen af bivirkninger for henholdsvis\ntinib og sorafenib (Nexavar), 3-4 grad bivirkninger\nAntal event pr. patient ≥1 event\nib Lenvatinib Sorafenib\nPatientomkostninger\nPatientomkostninger er ikke inkluderet i modellen. Ansøger antager, at der ingen forskel er i patientomkostninger.\nAmgros’ vurdering\nAnsøgers estimater af dosis per dag per patient adskiller sig fra protokollen, hvor Medicinrådet vurderer at størstedelen af patienter vejer over 60 kg, og dermed skal have 12 mg/dag. Amgros mener at ansøgers valg af\nmedian estimater for dosis per patient for henholdsvis lenvatinib (Lenvima) og sorafenib (Nexavar) underestimerer de reelle omkostninger. De valgte dosis for lægemidlerne afspejler at størstedelen af\npatienterne vejer under 60 kg. Amgros udarbejder sin egen hovedanalyse hvor de gennemsnitlige estimater af\ndosis per patient per dag anvendes. Dette vurderer Amgros er mere plausibelt i henhold til klinisk praksis.\nAmgros’ vurderer, ligeledes at omkostninger for spild har begrænset betydning for analysen. Amgros’ inkluderer\ndog spild i deres egen hovedanalysen, da 7 dages spild virker plausibelt.\nAmgros vurderer, at estimeringen af monitoreringsomkostningerne skal forbeholdes med en vis usikkerhed, da ressourceestimaterne kun er valideret af én dansk onkolog.\nAmgros vurderer, at estimeringen af bivirkningsrelaterede omkostninger er acceptabel.\nAmgros accepterer at ansøger ikke har inkluderet patientomkostninger, da lægemidlerne gives oralt.\nAmgros har valgt gennemsnitsestimater som værdi for dosis per patient per dag, som er højere end ansøgers estimerede værdi. Amgros udarbejder en ny hovedanalyse på baggrund af dette.\nAmgros inkluderer spild af 7 dage i hovedanalysen.",
      "start_page": 24,
      "end_page": 25
    },
    {
      "heading": "2.2 Følsomhedsanalyser",
      "text": "Ansøger har udarbejdet følsomhedsanalyser og præsenteret det i et tornadodiagram. Der er ændret på en parameter af gangen. Ud fra følsomhedsanalyserne ses at ændring af den inkrementelle omkostning per patient med\nbehandling med lenvatinib (Lenvima) sammenlignet med behandling med sorafenib (Nexavar), er mest følsom overfor lægemiddelprisen.\nAnsøger har yderligere udarbejdet tre scenarieanalyser:\n1. 2. linjebehandling inkluderes\n2. Spild inkluderes\n3. Kaplan-Meier data er anvendt uden at blive ekstrapoleret\nAmgros’ vurdering\nAmgros mener at de indsendte følsomhedsanalyser, belyser usikkerheden af resultatet. Amgros mener at en følsomhedsanalyse med ændring af dosis per patient per dag er en vigtig usikkerhed at belyse, og udarbejder en\nfølsomhedsanalyse hvor dosis per patient per dag varierer -+20%.\nAmgros vurderer, at scenarie analysen med 2. linjebehandling ikke er relevant, da der inkluderes behandling som\nikke anvendes i Danmark. Denne analyse kan derfor ikke anvendes til at være plausibel i dansk klinisk praksis.\nAmgros mener at scenariet med spild bør være inkluderet i hovedanalysen.\nAmgros mener ikke at scenarieanalysen med data, der kun baserer sig fra Kaplan-Meier estimater er relevant, da denne analyse belyser en tidshorisont der ikke inkluderer alle inkrementelle omkostninger af klinisk relevans.\nAmgros har udarbejdet sin egen analyse hvor spild er inkluderet i hovedanalysen\nAmgros udarbejder en følsomhedsanalyse der belyser usikkerheden af dosis per patient per dag.",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "3.1.1 Antagelser i ansøgers hovedanalyse",
      "text": "• Tidshorisonten er 25 år i analysen for lenvatinib (L\n• Det antages at estimater for dosis per patient per\n• Der inkluderes ikke spild",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "3.1.2 Resultat af ansøgers hovedanalyse",
      "text": "Ansøgers resultater er præsenteret i tabel 7.\nTabel 7: Resultat af ansøgers hovedanalyse for lenvatinib (Lenvim\nOmkostningselement Lenvatinib (Lenvima)\nLægemiddelomkostninger XXXXXXX DKK\nHospitalsomkostninger 168.828 DKK\nOmkostninger udenfor hos-\n13.589 DKK\npital\nTotale gennemsnitsomkost-\nXXXXXXX DKK ninger per patient",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "3.2 Ansøgers følsomhedsanalyser",
      "text": "Figur 1 illustrerer ansøgers følsomhedsanalyser i et tornad parametre, hvor ændring har størst betydning for resultate",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "14 LENVATINIB (LENVIMA)",
      "text": "Lenvima) og sorafenib (Nexa r dag er baseret på medianer\nma) sammenlignet med sorafeni\nSorafenib Inkr\n(Nexavar)\nXXXXXXX DKK\n166.636 DKK\n13.831 DKK\nXXXXXXX DKK dodiagram. Diagrammet vise\net.\navar)\nr.\nib (Nexavar), DKK, S rementelle omko\n(DKK)\nXXXXXX DKK\n2.192 DKK\n- 243 DKK\nXXXXXX DKK er vertikalt katego\nSAIP\nostning\nK\nK\norisere\nger\net, de\nTabel 8 illustrerer ansøgers scenarieanalyser hvor inkludering af 2. linje behand\nrie hvor kun Kaplain-Meier data er benyttet.\nTabel 8: Resultat af ansøgers scenarieanalyse, DKK, SAIP\nScenarie Lenvatinib (Lenvima) Sorafenib\n(Nexavar)\n2. linjebehandling inklude-\nXXXXXXX DKK XXXXXXX DKK ret\nSpild inkluderet XXXXXXX DKK XXXXXXX DKK\nKaplan-Meier data brugt XXXXXXX DKK XXXXXXX DKK",
      "start_page": 26,
      "end_page": 27
    },
    {
      "heading": "3.3.1 Antagelser i Amgros hovedanalyse",
      "text": "Amgros anvender ansøgers hovedanalyse, men med følgende justeringer:\n• Amgros anvender gennemsnitsværdier for estimaterne af dosis per pa\ntinib (Lenvima) og sorafenib (Nexavar)\n• Amgros inkluderer spild",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "3.3.2 Resultat af Amgros hovedanalyse",
      "text": "Som beskrevet i afsnit 2.1.3, mener Amgros, at analysen er forbundet med est\npatient, der ikke virker plausibelt set i henhold til dansk klinisk praksis.\nJusteringen af estimaterne for dosisdispensering per dag har betydning for ana med lenvatinib (Lenvima) efter justeringerne bliver forbundet med højere mer\nTabel 9: Resultat af Amgros hovedanalyse for lenvatinib (Lenvima) sammenlignet med s\nOmkostningselement Lenvatinib (Lenvima) Sorafenib (Nexavar)\nLægemiddelomkostninger XXXXXXX DKK XXXXXXX DKK\nHospitalsomkostninger 172.070 DKK 169.826 DKK\nOmkostninger udenfor hos-\n13.854 DKK 14.100 DKK\npital\nTotale gennemsnitsomkost-\nXXXXXXX DKK XXXXXXX DKK ninger per patient",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "15 LENVATINIB (LENVIMA)",
      "text": "dling og spild er belyst og et scena-\nInkrementelle omkostninger\n(DKK)\nXXXXXX DKK\nXXXXXX DKK\nXXXXXX DKK atient per dag for henholdsvis lenatimater for dosisdispensering per\nalysens resultater, da behandling romkostninger.\nsorafenib, DKK, SAIP\nInkrementelle omkostninger\n(DKK)\nXXXXXX DKK\n2.244 DKK\n247 DKK\nXXXXXX DKK\nDe inkrementelle omkostninger for lenvatinib (Lenvima) sammenlignet med sorafenib (Nexavar) er ca. XXXXXX\nDKK. Laves analysen med AIP bliver de inkrementelle omkostninger ca. 153.000 DKK.",
      "start_page": 27,
      "end_page": 28
    },
    {
      "heading": "3.4.1. Resultat af Amgros’ følsomhedsanalyse",
      "text": "Som tidligere nævnt anvender ansøger median dosisdispensering som et estimat for den gennemsnitlige patient.\nDenne tilgang kan underestimere den reelle dosis, der ikke er i tråd med medicinrådets vurdering af en gennemsnitlig patient i Danmark. Da der er stor usikkerhed ved fordelingen af hvilken vægt patienterne har (over eller\nunder 60 kg) udarbejder Amgros en følsomhedsanalyse der justerer mg/dag for en patient ≤ 60 kg og ≥ 60 kg.\nTabel 10: Resultat af Amgros følsomhedsanalyse med dosis fordelt på en patient ≤ 60 kg og ≥ 60 kg per dag, DKK, SAIP\nAnalyse Lenvatinib (Lenvima) Sorafenib Inkrementelle omkostninger\n(DKK)\nAmgros’ hovedanalyse\nXXXXXXX DKK XXXXXXX DKK XXXXXX DKK\n(basecase)\n≤ 60 kg XXXXXXX DKK XXXXXXX DKK XXXXXX DKK\n≥ 60 kg XXXXXXX DKK XXXXXXX DKK XXXXXXX DKK\nUd fra Amgros’ følsomhedsanalyse ses at de inkrementelle meromkostninger per patient, har stor betydning for om patienten er ≤ 60 kg og ≥ 60 kg.",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "4 BUDGETKONSEKVENSER",
      "text": "Budgetkonsekvenserne er baseret på antagelsen om, at lægemidlet vil blive anbefalet som standardbehandling.\nAnalysen tager derfor udgangspunkt i to scenarier:\nA. Lægemidlet bliver anbefalet som standardbehandling af Medicinrådet til indikationen, som denne analyse omhandler\nB. Lægemidler bliver ikke anbefalet som standardbehandling\nBudgetkonsekvenser er differencen mellem budgetkonsekvenserne i de to scenarier.\nPatientpopulation\nAnsøger har estimeret at såfremt lenvatinib (Lenvima) anbefales, vil 15 patienter blive behandlet med lenvatinib\n(Lenvima). Dette baseres på incidensen af HCC på 429 patienter årligt i Danmark og at ca. 40 patienter behandles\nmed nuværende 1. linjebehandling af HCC(1,3). Ansøger antager, at hvis lenvatinib (Lenvima) ikke anbefales vil 0\npatienter blive behandlet med lenvatinib (Lenvima).\nAnsøger har indsendt budgetkonsekvenser for 1 år, da ansøger antager ens markedsoptag per år. Budgetkonsekvenserne er estimeret til at være det samme alle år.\nAnsøger har yderligere lavet en scenarieanalyse af budgetkonsekvenserne, hvor et optag på 10-20 patienter per år estimeres.\nAmgros’ vurdering af estimeret patientpopulation\nAnsøger har argumenterer for populationsstørrelsen ud fra incidensen og nuværende antal patienter behandlet med sorafenib (Nexavar), som er defineret i Medicinrådets protokol. Amgros mener at optaget af patienter virker plausibelt og accepterer ligeledes ansøgers scenarieanalyse af budgetkonsekvenserne.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "4.1 Resultater af budgetkonsekvensanalysen",
      "text": "Resultatet af budgetkonsekvenserne justeret ud fra resultatet af Amgros’ hovedanalyse.\nTabel 11: Resultat af budgetkonsekvensanalyse, DKK, SAIP\nAnbefales som standardbehandling Anbefales ikke som standardbehandling\nLenvatinib (Lenvima) XXXXXXXXX DKK 0 DKK\nAnbefales lenvatinib (Lenvima) vil det resultere i budgetkonsekvenser på ca. XXXXXXXX DKK per år. Hvis analysen\nudføres med AIP, er budgetkonsekvenserne ca. 2,4 mio. DKK per år.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "4.2 Scenarieanalyse",
      "text": "I nedenstående tabel præsenteres scenarieanalysen af henholdsvis lavt og højt patientantal hvis lenvatinib (Lenvima) anbefales.\nTabel 12 illustrerer resultatet af scenarieanalysen for budgetkonsekvenserne.",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "17 LENVATINIB (LENVIMA)",
      "text": "Tabel 12: Resultat af scena\nLavt patientantal (8 patie ter)\nHøjt patientantal (20 pat enter)\nAntages det at kun 8 pat getkonsekvenser på XXX\nAntages det at 20 patien sekvenser på XXXXXXXX",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "18 LENVATINIB (LENVIMA)",
      "text": "arie budgetkonsekvensan\nAnbefales som en- XXX\nti- XXX tienter vil blive behan\nXXXXXX DKK per år.\nnter vil modtage behan\nDKK per år.\nnalyse, DKK, SAIP m standardbehan\nXXXXXX DKK\nXXXXXX DKK ndlet med lenvati\nndling med lenva\nndling\ninib (Lenvim atinib (Lenv\nAnbefales ikke som standardbehandling\n0 DKK\n0 DKK ma) hvis lægemidlet anbefales, ses budvima) hvis det anbefales, ses budgetkon-",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "5 DISKUSSION",
      "text": "Behandling med lenvatinib (Lenvima) er forbundet med betydelige meromkostninger sammenlignet med behandling med sorafenib (Nexavar). Analysens resultater påvirkes i høj grad af prisen på lenvatinib (Lenvima).\nHospitalsomkostninger og tværsektorielle omkostninger har lille betydning for resultatet.\nAmgros vurderer, at estimeringen af behandlingsomkostningerne er meget følsom overfor dosisjustering, som er afhængig af vægten, og derfor er forbundet med en vis usikkerhed. Der er forbundet stor usikkerhed med det\nestimerede antal patienter der vil blive behandlet per år, hvis lenvatinib (Lenvima) anbefales, og dermed stor usikkerhed omkring budgetkonsekvenserne.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "6 REFERENCER",
      "text": "1. Medicinrådet. Protokol for vurdering af den kliniske merværdi af lenvatinib til hepatocellulært karcinom.\n2018;Document number: 26738 version 1.\nREGION\nLÆGEM\nNERN\nMIDD\nNES\nDELOR\nRGAN\nNISAT\nTION\nAMGROS I/S\nDAMPFÆRGEVEJ 27-29\n2100 KØBENHAVN Ø\nTLF: 8871 3000\nWWW.AMGROS.DK",
      "start_page": 32,
      "end_page": 33
    },
    {
      "heading": "Comments in response to the Medical Council’s assessment of clinical added value for lenvatinib for the treatment of hepatocellular carcinoma 19/03/2019",
      "text": "Eisai would like to thank the Medical Council for considering the additional evidence and clarification of the REFLECT trial in the previous response, and amending its “assessment of overall clinical\nadded value and overall evidence level”. This amendment will allow Danish patients to be treated with\nthe most appropriate treatment option as early as possible and in line with their tolerance profile.\nPlease find below Eisai’s comments in relation to the clinical value assessment report of lenvatinib in hepatocellular carcinoma (HCC) received on 13 03 19.",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "1. Review of studies (section 6.1.1 of report)",
      "text": "Baseline characteristics\n“No significant difference in baseline characteristics between lenvatinib and sorafenib in the\nREFLECT study, however, notes that hepatitis C aetiology is unevenly distributed. The academic\ncommittee does not expect that the imbalance between the study arms will have a significant impact on the impact estimates”\nComment\nThere were notable differences in baseline characteristics which may have favoured sorafenib (as discussed in Section 4.2 of the original submission and in the response document).\n The proportion of patients with AFP levels ≥200 ng/mL, a marker of poor HCC prognosis, was higher in the lenvatinib arm (46.4%) than the sorafenib arm (39.3%)\n The proportion of patients with aetiology of HCV was lower in the lenvatinib arm (19%) than in the sorafenib arm (26.5%). Evidence suggests that patients with HCV aetiology may derive\nmore clinical benefit from sorafenib than patients with other aetiologies, particularly HBV",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "2. Results and assessment (section 6.1.2 of report)",
      "text": "Overall survival\n“lenvatinib is placed in the category of no clinical added value”\nComment\nIt is notable that after adjustment for the baseline imbalance in AFP levels, the HR favoured lenvatinib when OS was adjusted for the baseline imbalance in AFP levels. Lenvatinib was nominally superior to\nsorafenib, HR was 0.856 with upper limit of the 95% CI <1 (95% CI: 0.736, 0.995], p=0.0342).\nAnalyses that adjust for imbalances in baseline characteristics that are considered prognostic of outcome, are likely to be the least biased and most applicable to patients, as stated in the EMA\n“Guideline on the evaluation of anticancer medicinal products in man”. In addition the HR also\nfavoured lenvatinib when OS was adjusted for the baseline imbalance in HCC aetiologies (HR 0.855,\n95% CI: 0.721 to 1.013).\nThese results confirm that the direction of imbalance between groups is likely to have biased OS in favour of sorafenib.\nPost-progression therapies\n“The Committee notes that there is not much difference in the proportion of patients who after the study received other medical treatment for their cancer disease between the lenvatinib and sorafenib\n(33% and 39%, respectively). Since the absolute and relative efficacy estimates do not detect\nstatistically significant or clinically significant differences in survival for lenvatinib compared to sorafenib, the expert estimates that lenvatinib does not offer any clinical added value to the survival\ntarget”\nComment\nThere was a notable imbalance between the treatment arms regarding the proportion of patients who received post-treatment anti-cancer therapy (including procedures and medications) during survival\nfollow-up.\nA higher proportion of subjects in the sorafenib than in the lenvatinib arm received post-treatment anticancer therapy: 51.1% (243/476) versus 43.1% (206/478) respectively)1. Further, a higher\nproportion of subjects in the sorafenib arm rather than in the lenvatinib arm (9.5% vs 3.1%) received\npost-treatment anticancer therapy with investigational drugs, including regorafenib, mostly within clinical trials. Additionally, 121 of the 156 patients that received an anticancer medication postprogression on lenvatinib received sorafenib2. This imbalance in treatment with new agents is an\nartifact of clinical trial design rather than reflective of clinical practice.\n In the overall population, the HR (95% CI) for lenvatinib versus sorafenib was 0.87 (0.75,\n1.01) in the adjusted analysis (post-hoc analysis of OS results adjusted by use of posttreatment anti-cancer therapy) compared with 0.92 (0.79, 1.06) in the unadjusted analysis\n Furthermore, as per the exploratory analysis provided in the response document3, lenvatinib first-line followed by any subsequent anti-cancer medication demonstrated a longer OS than\nsorafenib followed by any subsequent anti-cancer medication. Patients who received any\nsubsequent medication had a 4-month OS benefit if they began on lenvatinib vs sorafenib (21 vs 17 months)\nThese results also confirm that the direction of imbalance in subsequent therapies is likely to have biased OS in favour of sorafenib.\nAdverse events\n“Overall, the committee considers that there are no significant differences in the adverse reaction profiles, which mean that a product is preferred over the other”\nComment\nLenvatinib and sorafenib have safety profiles that are consistent with other VEGF/VEGFR-targeted therapies; however, the nature and extent of adverse events (AEs) differed between the two agents\nbased on their different mechanisms of action. The mechanism of action of sorafenib has been\n1 European Medicines Agency Assessment report, section 2.4.2, 28 June 2018, Available at\n“The committee concludes that the two analyses provide consistent results. Since the smallest\nclinically relevant difference is achieved, the efficacy target is assigned an important clinical added value”\nComment\nEisai would like to thank the scientific committee for considering the additional evidence.\nQuality of life\nComment\nAll published data has been provided as part of the response document submitted on December 19,\n2018. The QoL impact of lenvatinib and sorafenib was broadly equivalent across the majority of\nfunction and symptom areas; however it is notable that there was a statistically significant and\nclinically meaningful delay in worsening for lenvatinib compared with sorafenib across several domains including diarrhoea, nutrition and pain.\nMedical Council's assessment of clinical added value for lenvatinib for the treatment of hepatocellular carcinoma\n“The Medicines Council finds that lenvatinib and sorafenib can be treated as first line therapy in patients with HCC”\nComment\nEisai would like to thank the Medicines Council for considering the evidence and providing Danish patients access to a treatment alternative in first line therapy for HCC.\nConclusion\nThe REFLECT trial is the first study in 10 years to demonstrate a proven overall survival benefit by statistical confirmation of non-inferiority when compared with sorafenib, and as such represents an\nadvancement in HCC therapy.\nThe clinical benefits of Lenvatinib were demonstrated in the REFLECT trial, a randomized, multicenter, head-to-head, open-label Phase III study comparing lenvatinib to sorafenib, which\nshowed:\n Non-inferiority of OS: 13.6-month median OS (95% CI: 12.1-14.9) vs 12.3 months (95% CI:\n10.4-13.9) (HR: 0.92 [95% CI: 0.79-1.06])\n A statistically significant and clinically meaningful improvement across all secondary efficacy endpoints:\n4 Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. J\nOncol 2009;2009:567486.",
      "start_page": 34,
      "end_page": 36
    },
    {
      "heading": "Definition af klinisk merværdi:",
      "text": "Medicinrådet kategoriserer lægemidlets kliniske merværdi i en af følgende kategorier:\nKategori 1. Stor merværdi: Vedvarende og stor forbedring i effektforhold der ikke tidligere er opnået med et relevant\nbehandlingsalternativ. Eksempler herpå er sygdomsremission, markant stigning i overlevelsestid, langvarigt fravær af\nalvorlige sygdomssymptomer eller udtalt fravær af alvorlige bivirkninger.\nKategori 2. Vigtig merværdi: Markant forbedring, eksempelvis lindring af sygdomstilstand, moderat stigning i\noverlevelsestid, lindring af alvorlige symptomer, fravær af alvorlige bivirkninger og væsentligt fravær af andre bivirkninger.\nKategori 3. Lille merværdi: Moderat forbedring, f.eks. reduktion i ikkealvorlige sygdomssymptomer eller fravær af\nbivirkninger.\nKategori 4. Ingen merværdi: Ingen merværdi sammenlignet med standardbehandling/andre behandlinger.\nKategori 5. Negativ merværdi: Negativ merværdi sammenlignet med standardbehandling/andre behandlinger.\nKategori 6. Ikkedokumenterbar merværdi: Ikkedokumenterbar merværdi sammenlignet med standardbehandling/\nandre behandlinger. Effektforskellen kan ikke kvantificeres ud fra det videnskabelige datagrundlag.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Om Medicinrådet:",
      "text": "Medicinrådet er et uafhængigt råd, som udarbejder anbefalinger og vejledninger om lægemidler til de fem regioner.\nMedicinrådet vurderer, om nye lægemidler og nye indikationer kan anbefales som standardbehandling og udarbejder fælles regionale behandlingsvejledninger.\nNye lægemidler vurderes i forhold til effekt, eksisterende behandling og pris. Det skal give lavere priser og lægemidler,\nder er til størst mulig gavn for patienterne.\nDe fælles regionale behandlingsvejledninger er vurderinger af, hvilke lægemidler der er mest hensigtsmæssige til behandling af patienter inden for et terapiområde og dermed grundlag for ensartet høj kvalitet for patienterne på tværs\naf sygehuse og regioner.\n© Medicinrådet, 2019. Publikationen kan frit refereres med tydelig kildeangivelse.\nMedicinrådet, Dampfærgevej 27-29, 3. th., 2100 København Ø\nSprog: dansk\nFormat: pdf\nUdgivet af Medicinrådet, den 13. marts 2019.",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "Side 2 af 21",
      "text": "Forko\nBCLC:\nCHMP:\nCI:\nEMA:\nEPAR:\nEORTC\nEORTC\nESMO:\nGRADE\nHCC:\nHR:\nITT:\nMeSH:\nOS:\nPICO:\nRFA:\nRR:\nSAE:\nSD:\nortels\nC QLQ\nC QLQ\nE:\nser\nQ-C30\nQ-HCC\nC18:\nBarce\nComm\nKonf\nEurop\nEurop\nEurop\nQues\nEurop\nQues\nEurop\nSyste\nDevel\nHepa\nHaza\nInten\nMedi\nSamle\nFokus\nKomp\nRadio\nRelat\nSerio\nStand\nelona Clinic Liver Cancer mittee for Medicinal Products for Human U\nidensinterval\npean Medicines Agency pean Public Assessment Report\npean Organisation for Research and Treatm tionnaire-Core 30\npean Organisation for Research and Treatm tionnaire-Hepatocellular carcinoma 18\npean Society for Medical Oncology em til vurdering af evidens (Grading of Rec\nlopment and Evaluation System) atocellulært carcinom\nard ratio ntion to treat\ncal Subject Heading et overlevelse (Overall Survival)\nserede forskningsspørgsmål baseret på Pop parator og Outcome (effektmål)\nofrekvensbehandling\ntiv risiko ous Adverse Event\ndard afvigelse (Standard deviation)\nUse\nment of Can ment of Can\ncommendati\npulation, Int\nncer Quality of Life ncer Quality of Life\nions Assessment, tervention,",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "Indhold",
      "text": "1 Formål......................................................\n2 Baggrund .................................................\n3 Metode .....................................................\n4 Litteratursøgning .....................................\n5 Databehandling ........................................\n6 Klinisk merværdi .....................................\nKonklusion klinisk spørgsmål .........\n6.1.1 Gennemgang af studier ............\n6.1.2 Resultater og vurdering ...........\n6.1.3 Evidensens kvalitet ..................\n6.1.4 Konklusion ..............................\n7 Andre overvejelser ...................................\n8 Rådets vurdering af samlet klinisk mervæ\n9 Relation til eksisterende behandlingsvejle\n10 Referencer ............................................\n11 Sammensætning af fagudvalg og konta\n12 Bilag 1: GRADE-evidensprofiler ........\nCochrane Risk of Bias .....................\nGRADE-evaluering af evidenskvalit\nærdi og sam edning .......\naktinformat\nteten til vur\nmlet evidens\ntion til Med\nrdering af d\nsnivea\ndicinrå\nden kl\nau ......\nådet ..\nliniske\ne merv\nværdi\naf Le\nenvati\nSid\ninib .... 20\nde 4 af 21",
      "start_page": 41,
      "end_page": 41
    },
    {
      "heading": "1 Formål",
      "text": "Formålet med Medicinrådets vurdering af klinisk merværdi af lenvatinib til hepatocellulært carcinom er at vurdere den kliniske merværdi i forhold til et eller flere lægemidler til samme patientgruppe (komparatorer).\nMed udgangspunkt i den kliniske merværdi og en omkostningsanalyse udarbejdet af Amgros vurderer\nMedicinrådet, om lenvatinib anbefales som mulig standardbehandling.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "2 Baggrund",
      "text": "Hepatocellulært carcinom\nPrimær leverkræft (hepatocellulært karcinom, HCC) er en mindre hyppigt forekommende kræftform i\nDanmark, som oftest forekommer i patienter med levercirrose [1]. Leverfunktionen hos patienter med\nleversygdomme såsom cirrose kan opdeles efter, hvor god leverfunktionen er og benævnes i kategorierne\nChild-Pugh A, B og C, fra bedst til værst leverfunktion.\nDer forekommer ca. 430 nye tilfælde af HCC om året, hvor mændene tegner sig for knap ¾ af tilfældene [2].\nVed udgangen af 2015 havde 652 patienter HCC, hvilket afspejler den lave overlevelse for denne patientgruppe. Etårsoverlevelsen er således 37 % for mænd og 40 % for kvinder, mens femårsoverlevelsen\nkun er 9 % for mænd og 11 % for kvinder [2].\nNuværende behandling\nHCC udgør et sygdomskontinuum, hvor Barcelona Clinic Liver Cancer (BCLC) stadiesystemet ofte bruges til stadieinddeling og ligeledes til at beslutte, hvilken behandling patienten har gavn af. Stadierne inddeles\nefter tumorstadie, leverfunktionsstatus, fysisk status og kræftrelaterede symptomer. Overordnet opdeles\nHCC-patienter i de med tidlig HCC, som har mulighed for kurativ terapi, de med intermediær og fremskreden sygdom, som har gavn af livsforlængende og palliative behandlinger og endeligt patienter, der\nhar terminal sygdom, som tilbydes symptomatisk behandling [3].\nPatienter med tidlig sygdom (BCLC A) vurderes med henblik på kirurgisk fjernelse af tumor, levertransplantation eller perkutan ablation (dvs. destruktion af kræftceller ved hjælp af kemiske substanser\neller hyper-/hypotermi, hvor især radiofrekvensbehandling (RFA) har vundet indpas i Danmark) med mulighed for helbredelse. Femårsoverlevelsen er omkring 50-75 % afhængigt af behandlingen [3].\nI intermediærstadiet (BCLC stadie B) har patienterne store eller flere levertumorer og leverfunktion svarende til Child-Pugh A eller B, men de har ikke kræftrelaterede symptomer og har ikke makrovaskulær invasion\neller spredning uden for leveren. Patienter med sygdom i dette stadie vurderes med henblik på lokal\nkemoterapi i leveren (transarteriel kemoembolisering) [3].\nI det fremskredne stadie (BCLC stadie C) har patienter stadig leverfunktion svarende til Child-Pugh A eller\nB, men kandiderer ikke længere til lokal behandling idet de har kræftsymptomer og/eller vaskulær invasion eller spredning uden for leveren [3]. De vurderes således med henblik på førstelinje systemisk behandling\nmed multikinaseinhibitoren sorafenib. Det anslås, at ca. 40 patienter behandles med sorafenib om året [4].\nDen 30. januar 2018 anbefalede Medicinrådet regorafenib som mulig standardbehandling til andenlinje\nsystemisk behandling til patienter med HCC, med performancestadie 0-1 og leverfunktion svarende til Child-\nPugh A, som tidligere er behandlet med og har tolereret sorafenib [5].\nPatienter med ekstensiv tumorinvolvering førende til dårligt alment helbred og/eller som har leverfunktion svarende til Child-Pugh C behandles symptomatisk [3].",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "Side 5 af 21",
      "text": "Anvendelse af det nye lægemiddel\nLenvatinib er indiceret til behandling af patienter med HCC i fremskredent stadie eller patienter med inoperabel HCC, som ikke tidligere er behandlet systemisk. Lenvatinib kan således anvendes som\nførstelinjebehandling ligesom sorafenib.\nLenvatinib er en multireceptortyrosinkinaseinhibitor, der hæmmer vækstfaktorreceptorerne VEGF receptor\n1-3, FGF receptor 1-4 og PDGF receptor α samt proto-onkogenerne RET og KIT, som alle er centrale for kræftudvikling.\nLenvatinib administreres peroralt som tabletter. Dosis er 8 mg (ved kropsvægt < 60 kg) eller 12 mg (ved\nkropsvægt ≥ 60 kg) én gang dagligt. Fagudvalget vurderer, at hovedparten at de danske HCC-patienter vejer\nmere end 60 kg. Lenvatinib administreres, så længe klinisk fordel observeres, eller indtil der opstår\nuacceptable bivirkninger.\nLenvatinib er i forvejen indiceret som monoterapi til behandling af voksne patienter med differentieret thyreoideakarcinom, som er refraktært over for radioaktivt jod og til behandling af voksne patienter med\nfremskreden nyrecellekarcinom [6,7].",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "3 Metode",
      "text": "De præspecificerede metoder i protokollen er udarbejdet af Medicinrådet. Ansøgningen er valideret af\nMedicinrådet.\nAnsøger har anvendt og fulgt den præspecificerede metode, jf. protokol som blev godkendt i Medicinrådet\nden 10. september 2018.",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "4 Litteratursøgning",
      "text": "Ansøger har i overensstemmelse med protokollen foretaget en systematisk litteratursøgning efter kliniske studier, som omhandler lenvatinib til behandling af leverkræft. Ansøgers PRISMA-diagram og\nlitteraturgennemgang fremgår af ansøgningen.\nI søgningen fandt ansøger en publikation af ét studie, som opfyldte kriterierne opstillet i protokollen. Studiet\ndanner basis for Medicinrådets vurderingen af klinisk merværdi for lenvatinib. Studiet er et fase III-studie,\nsom sammenligner effekten af lenvatinib og sorafenib til behandling i første linje af patienter med leverkræft. Studiet er:\n• REFLECT: Kudo M., Lenvatinib versus sorafenib in first-line treatment of patients with\nunresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet\nAnsøger har desuden leveret en alternativ analyse af progressionsfri overlevelse baseret på data fra\nREFLECT-studiet. Denne analyse er ikke tidligere publiceret. Fagudvalget benytter den alternative analyse\nsom supplement til vurderingen af effektmålet progressionsfri overlevelse, idet analysemetoden anvendt i studiepublikationen kan føre til overestimering af lenvatinibs effekt grundet forskel i drop-out mellem\nstudiearmene. Ligeledes har ansøger indsendt en supplerende overlevelsesanalyse for subgruppen af\npatienter, som modtager potentiel livsforlængende behandling efter deltagelse i REFLECT-studiet. Disse\ndata er tidligere publiceret i form af konference abstracts på Gastrointestinal Cancers Symposium of the",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "Side 6 af 21",
      "text": "American Society of Clinical Oncology (ASCO GI) 2019 [9]. Fagudvalget har orienteret sig i\nsubgruppeanalyserne, men har ikke inddraget dem i vurderingen, idet subgrupperne ikke er specificeret i vurderingens protokol.\nTil en kvalitativ gennemgang af bivirkninger har fagudvalget inddraget EMAs public assessment reports\n(EPAR) for lenvatinib [10].\nFra evidens til kategori. Medicinrådet vurderer den kliniske merværdi af et lægemiddel ud fra den indsendte\nendelige ansøgning, evt. suppleret med andet materiale. I protokollen blev effektmålene angivet som ”kritiske”,\n”vigtige” og ”mindre vigtige”. I vurderingen af klinisk merværdi vægter de kritiske højest, de vigtige næsthøjest og\nde mindre vigtige indgår ikke.\nDen kliniske merværdi kategoriseres først enkeltvis pr. effektmål, hvorefter der foretages en vurdering af den\nsamlede kategori for lægemidlet på tværs af effektmålene. Kategoriseringen pr. effektmål foretages på baggrund af\nabsolutte og relative værdier for det enkelte effektmål. Den relative effekt beskrives med et estimat og et\nkonfidensinterval, der sammenholdes med generiske væsentlighedskriterier. Den absolutte effekt sammenholdes med\nden i protokollen beskrevne ”mindste klinisk relevante forskel”. Den endelige kategorisering af lægemidlets kliniske\nmerværdi er en delvis kvalitativ proces, hvor der foretages en vurdering af det samlede datagrundlag på tværs af effektmålene.\nVurdering af evidensens kvalitet foretages med udgangspunkt i GRADE og udtrykker tiltroen til evidensgrundlaget for de enkelte effektstørrelser og den endelige kategori for klinisk merværdi. Evidensens kvalitet inddeles i fire\nniveauer: høj, moderat, lav og meget lav. GRADE-metoden er et internationalt anerkendt redskab til systematisk\nvurdering af evidens og udarbejdelse af anbefalinger. I denne vurdering er metoden anvendt til at vurdere evidensens\nkvalitet.",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "5 Databehandling",
      "text": "Medicinrådet har ikke fundet anledning til at foretage ændringer af beregninger foretaget af ansøger eller supplere med yderligere beregninger.\nKonfidensintervaller for forskellen i medianen for overlevelse og progressionsfri overlevelse og forskellen for overlevelsesraterne for 12 og 24 måneder er udeladt, da der ikke findes en hensigtsmæssig måde at\nberegne disse.\nAlle anførte konfidensintervaller er angivet som 95 % konfidensintervaller.",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "Konklusion klinisk spørgsmål",
      "text": "Hvad er den kliniske merværdi af lenvatinib til voksne patienter med fremskredent eller inoperabelt hepatocellulært karcinom, som er kandidater til systemisk behandling, sammenlignet med sorafenib?\nFagudvalget vurderer, at lenvatinib til patienter med hepatocellulært carcinom giver en ingen klinisk merværdi (meget lav evidenskvalitet).",
      "start_page": 44,
      "end_page": 44
    },
    {
      "heading": "6.1.1 Gennemgang af studier",
      "text": "Ansøger identificerede ét klinisk studie omhandlende lenvatinib til besva\nNedenfor følger en beskrivelse af studiet.\nKarakteristika\nREFLECT: Resultaterne fra REFLECT-studiet er publiceret i 2018 [8].\nnon-inferioritets fase 3-studie. Studiets formål var at evaluere den samled\nmed lenvatinib sammenlignet med sorafenib. ClinicalTrials.gov: NCT01\nI studiet blev 954 patienter randomiseret i forholdet 1:1 til enten lenvatin\nlenvatinib var 12 mg/dag (ved kropsvægt ≥ 60 kg) eller 8 mg/dag (ved kr sorafenib var 400 mg to gange dagligt. Behandlingspausering og dosisre\nlægemiddelrelateret toksicitet. Effektanalysen blev baseret på alle random\ntreat), mens sikkerhedsanalysen kun inkluderede patienter, som modtog opfølgningstid var 27,7 måneder i lenvatinibarmen og 27,2 måneder i so\nnovember 2016). Den mediane behandlingstid var henholdsvis 5,7 måne\n(sorafenib). Effektmålene i studiet er angivet i skemaet nedenfor.\nTabel 1. Effektmål i REFLECT-studiet\nPrimært effektmål Sekundære effektmål\nSamlet overlevelse Progressionsfri overlevelse\nTid til progression\nObjektiv responsrate\nLivskvalitet\nSikkerhed (bivirkninger)\nFarmakokinetik\nPopulation\nPopulationen i studiet er præsenteret i tabellen nedenfor.\nTabel 2. Patientkarakteristika i REFLECT-studiet\nPatientkarakteristika\nLenvatinib (n = 478)\nAlder (median, interval) 63 (20-88)\n% kvinder 15 %\nEastern Cooperative Oncology Group 0: 64 %\nperformance status 1: 36 %\nChild-Pugh klasse A: 99 %\nB: 1 %\nMakroskopisk portåre-invasion Ja: 23 %\nNej: 77 %\nEkstrahepatisk spredning Ja: 61 %\nNej: 39%\nUnderliggende cirrhosis Ja: 74 %\nNej: 26 %\nÆtiologi- kronisk leversygdom Hepatitis B: 53 %\nHepatitis C: 19 %\nAlkohol: 8 %\nAndet: 8 %\nUkendt: 13 %\nBarcelona Clinic Liver Cancer stadie B (intermediær): 22 %\nC (fremskreden): 78 %\narelse af det kliniske spørgsmål.\n. Studiet er et randomiseret, ublindet,\nde overlevelse i patienter behandlet\nnib eller sorafenib. Doseringen af\nropsvægt < 60 kg). Doseringen af\neduktion var tilladt ved miserede patienter (intention to\nbehandling. Den mediane\norafenibarmen (data cutoff i eder (lenvatinib) og 3,7 måneder\nSorafenib (n = 476)\nA: 99 %\nB: 1%\nJa: 19 %\nNej: 81 %\nJa: 62 %\nNej: 38 %\nJa: 76 %\nNej: 24 %\nHepatitis B: 48 %\nHepatitis C: 26 %\nAlkohol: 4 %\nAndet: 7 %\nUkendt: 14 %\nB (intermediær): 19 %\nC (fremskreden): 81 %",
      "start_page": 45,
      "end_page": 45
    },
    {
      "heading": "Side 8 af 21",
      "text": "Fagudvalget finder, at der ikke er nogen betydende forskelle i baselinekarakteristika mellem lenvatinib- og sorafenibarmen i REFLECT-studiet, men bemærker dog at hepatitis C-ætiologi er ulige fordelt. Fagudvalget\nforventer ikke, at ubalancen mellem studiearmene vil have betydende indflydelse for effektestimaterne.\nFagudvalget vurderer, at patientkarakteristika i studiet ikke afviger væsentligt fra den danske patientpopulation, men fremhæver dog at populationen i studiet afviger fra den danske population, på den\nmåde, at HCC i Danmark i højere grad opstår hos patienter med alkoholrelateret cirrose, hvorimod HCC i studiepopulationen primært er relateret til viral hepatitis. Dog vurderer fagudvalget, at populationerne i\nDanmark og studiet er sammenlignelige, da andelen af HCC-patienter med cirrose er af samme størrelse\n(leverfunktionen har betydning for prognose).",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "6.1.2 Resultater og vurdering",
      "text": "Resultater og vurdering af de effektmål, som fagudvalget har præspecificeret som hhv. kritiske og vigtige,\nfølger nedenfor.\nSamlet overlevelse, OS (kritisk)\nOverlevelse er et kritisk effektmål, da HCC er en dødelig sygdom. Fagudvalget ønsker effektmålet opgjort\nsom median overlevelse samt overlevelsesrater ved 12 og 24 måneder.\nTabel 3. Vurdering af klinisk merværdi: Samlet overlevelse\nForhåndsdefineret grundlag for vurdering Resultater\nMedian overlevelse: 3 måneder Median overlevelse: 1,3 måneder\nAbsolutte 12 måneders overlevelse: 8 %-point 12 måneders overlevelse: 5 %-point\nforskelle 24 måneders overlevelse: 4 %-point 24 måneders overlevelse: 3,7 %-point\nStor merværdi Øvre konfidensgrænse < 0,85\nRelative forskelle Vigtig merværdi Øvre konfidensgrænse < 0,95\nLille merværdi Øvre konfidensgrænse < 1,00\nIngen merværdi Øvre konfidensgrænse > 1,00 HR: 0,92 [0,79;1,06]\nNegativ merværdi Nedre konfidensgrænse > 1.00\nEvidensens Lav kvalitet\nFørste kolonne indeholder de i protokollen og metodehåndbogen præspecificerede grundlag for vurderingen. Anden\nkolonne indeholder data på de absolutte og relative værdier fra resultatafsnittet, som indgår i Medicinrådets vurdering.\nHR: Hazard ratio\nMedian overlevelse\nI lenvatinibarmen er den mediane samlede overlevelse 13,6 måneder, mens den i sorafenibarmen er 12,3 måneder. Det svarer til en forskel på 1,3 måneder til fordel for lenvatinib. Fagudvalget har vurderet, at en\nforskel på 3 måneder eller derover er klinisk relevant. Lenvatinib lever ikke op til dette krav.\nDen relative effektforskel for den mediane overlevelse hazard ratio (HR) er 0,92 [0,79;1,06] og viser, at der\nikke er statistisk signifikant forskel på behandlingerne. Lenvatinib indplaceres i kategorien ingen klinisk\nmerværdi, da konfidensintervallet indeholder 1.",
      "start_page": 46,
      "end_page": 46
    },
    {
      "heading": "Side 9 af 21",
      "text": "Overlevelsesrater\nEfter 12 måneders behandling er 55 % af patienterne i live i lenvatinibarmen, mens det tilsvarende tal for sorafenibarmen er 50 %. Der er altså en forskel på 5 %-point til fordel for lenvatinib. Denne forskel er\nmindre end den forskel på 8 %-point, som er defineret i protokollen, som den mindste klinisk relevante forskel.\nVed 24 måneders behandling ses en forskel i overlevelse på 3,7 %-point, idet 29,9 % af patienterne er i live i lenvatinibarmen, og 26,2 % er i live i sorafenibarmen. Denne forskel er mindre end de 4 %, som fagudvalget\nhar vurderet klinisk relevant.\nDen relative effektforskel HR: 0,92 [0,79;1,06] for overlevelsesraterne viser også, at der ikke er statistisk\nsignifikant forskel på behandlingerne. Lenvatinib indplaceres i kategorien ingen klinisk merværdi, da\nkonfidensintervallet indeholder 1.",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "Samlet vurdering for overlevelse",
      "text": "Fagudvalget bemærker, at der ikke er stor forskel i andelen af patienter, som efter studiet modtog anden medicinsk behandling mod deres kræftsygdom mellem lenvatinib- og sorafenibarmen (33 % og 39 %\nhenholdsvis). Da de absolutte og relative effektestimater ikke påviser statistisk signifikant eller klinisk\nbetydende forskel i overlevelse for lenvatinib sammenlignet med sorafenib, vurderer fagudvalget, at lenvatinib tilbyder ingen klinisk merværdi for effektmålet overlevelse.\nEvidensens kvalitet er lav.\nBivirkninger (kritisk)\nBivirkninger har betydning for patientens livskvalitet og er et kritisk effektmål i vurderingen af lenvatinib.\nFagudvalget ønsker bivirkninger ved lenvatinib belyst ved andelen af patienter, der ophører behandling pga.\nbivirkninger, andelen af patienter som dosisreduceres og antallet af bivirkninger grad 3-5. Dernæst ønsker\nfagudvalget også at foretage en kvalitativ vurdering af bivirkningsprofilerne.\nAndel af patienter der ophører behandling grundet bivirkninger\nTabel 4. Vurdering af klinisk merværdi: Andel af patienter der ophører behandling grundet bivirkninger\nForhåndsdefineret grundlag for vurdering Resultater\nAbsolutte forskelle 5 %-point 2 %-point [-2;5]\nStor merværdi Øvre konfidensgrænse < 0,75\nRelative forskelle Vigtig merværdi Øvre konfidensgrænse < 0,90\nLille merværdi Øvre konfidensgrænse < 1,00\nIngen merværdi Øvre konfidensgrænse > 1,00 RR: 1,23 [0,79;1,90]\nNegativ merværdi Nedre konfidensgrænse > 1.00\nEvidensens kvalitet Meget lav\nRR: relativ risiko",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "Side 10 af 21",
      "text": "Behandlingsophør på grund af bivirkninger ønskes belyst, idet dette er et mål for, hvor stor en del af patienterne, som oplever så alvorlige eller generende bivirkninger, at de må stoppe behandlingen og dermed\nmuligvis ikke har fået gavn af at modtage lægemidlet.\nVed behandling med lenvatinib ophører ca. 9 % af patienterne med behandlingen på grund af bivirkninger.\nDet tilsvarende tal for sorafenib er ca. 7 %. Lenvatinib medfører således, at 2 %-point flere patienter ophører\nbehandling sammenlignet med sorafenib. Forskellen er dog ikke så stor, at fagudvalget vurderer den som\nklinisk relevant. Den forhåndsdefinerede grænse for om forskellen er klinisk relevant er 5 %-point.\nDet relative effektestimat for behandlingsophør grundet bivirkninger (relative risiko (RR) = 1,23 [0,79; 1,90]\nviser at der ikke er statistisk signifikant forskel på grupperne. Da konfidensintervallet indeholder 1,\nindplaceres lenvatinib i kategorien ingen klinisk merværdi, hvad angår behandlingsophør grundet bivirkninger.\nAndel af patienter der dosisreduceres\nTabel 5. Vurdering af klinisk merværdi: Andel af patienter der dosisreduceres\nForhåndsdefineret grundlag for vurdering Resultater\nAbsolutte forskelle 10 %-point -1 %-point [-7; 5]\nStor merværdi Øvre konfidensgrænse < 0,75\nRelative forskelle Vigtig merværdi Øvre konfidensgrænse < 0,90\nLille merværdi Øvre konfidensgrænse < 1,00\nIngen merværdi Øvre konfidensgrænse > 1,00 RR: 0,97 [0,82; 1,14]\nNegativ merværdi Nedre konfidensgrænse > 1.00\nEvidensens kvalitet Meget lav\nRR: Relativ risiko\nDosisreduktion ses for henholdsvis ca. 37 % og 38 % af patienterne i lenvatinib- og sorafenibarmen. Der er\nen forskel på ca. 1 %-point mellem behandlingerne, som fagudvalget ikke finder klinisk relevant. Den\nforhåndsdefinerede forskel for, hvornår forskellen er klinisk relevant, er 10 %-point.\nDet relative effektestimat for dosisreduktion viser også, at der ikke er signifikant forskel mellem behandlingerne. Konfidensintervallet for den relative risiko på RR: 0,97 [0,82;1,14] indeholder 1, hvilket\nindplacerer lenvatinib i kategorien ingen klinisk merværdi, hvad angår dosisreduktion.",
      "start_page": 48,
      "end_page": 48
    },
    {
      "heading": "Side 11 af 21",
      "text": "Antal grad 3-5 bivirkninger\nTabel 6. Vurdering af klinisk merværdi: Antal grad 3-5 bivirkninger\nForhåndsdefineret grundlag for vurdering Resultater\nAbsolutte forskelle 10 % relativ forøgelse eller reduktion svarende til -0,20 [-0,42; 0,01] events/patient-år\n0,18 events/patient-år\nStor merværdi Øvre konfidensgrænse < 0,75\nRelative forskelle Vigtig merværdi Øvre konfidensgrænse < 0,90\nLille merværdi Øvre konfidensgrænse < 1,00\nIngen merværdi Øvre konfidensgrænse > 1,00 Rate ratio: 0,89 [0,78;1,01]\nNegativ merværdi Nedre konfidensgrænse > 1,00\nEvidensens kvalitet Meget lav\nAntallet af bivirkninger grad 3-5 er opgjort til 517 events i lenvatinibarmen og 430 events i sorafenibarmen.\nImidlertid er behandlingsvarigheden forskellig i de to arme, da den mediane behandlingstid var henholdsvis\n5,7 måneder (lenvatinib) og 3,7 måneder (sorafenib).\nNår der justeres for behandlingsvarighed, ses 1,59 events/patient-år i lenvatinibarmen og 1,80 events/patientår i sorafenibarmen. Forskellen mellem de to behandlinger er 0,20 events/patient-år til fordel for lenvatinib,\nhvilket er en større forskel end den forhåndsdefinerede grænse på 0,18 events/patient-år, svarende til en 10 % relativ forøgelse eller reduktion.\nDet relative effektestimat (rate ratio) 0,89 [0,78;1,01] indikerer, at risikoen for en bivirkning pr. patient-år er\nmindre ved lenvatinib end sorafenib. Men forskellen er ikke statistisk signifikant, hvilket indplacerer\nlenvatinib i kategorien ingen klinisk merværdi.\nKvalitativ gennemgang af bivirkninger\nSom supplement til de ovenstående kvantitative vurderinger af bivirkninger har fagudvalget ønsket at beskrive forskelle i bivirkningsprofilerne for lenvatinib og sorafenib. Da REFLECT-studiet direkte\nsammenligner lenvatinib og sorafenib, er der taget udgangspunkt i publikationen for studiet [8] samt i EMA\nEuropean public assessment report for lenvatinib [10]. Nedenfor er en kort gennemgang af de væsentligste\nforskelle.\nUønskede hændelser observeret hyppigst for lenvatinib\nI lenvatinibarmen sås oftere forhøjet blodtryk end i sorafenibarmen (42 % versus 30 %). Forhøjet blodtryk\nhåndteres ofte medicinsk i klinikken.\nØget udskillelse af protein fra nyrerne (proteinuri) blev observeret i 25 % af patienter i behandling med lenvatinib, mens det tilsvarende tal for sorafenib var 11 %. Proteinuri kan være et symptom på nefrotisk\nsyndrom og bør derfor overvåges løbende. Såfremt der opstår fulminant nefrotisk syndrom kan håndteringen\naf dette være svær og kan føre til seponering, og det kan udelukke efterfølgende behandling. Fagudvalget\nbemærker dog, at grad ≥ 3 proteinuri kun ses i 6 % af patienterne i lenvatinibarmen og 2 % i sorafenibarmen.\nLigeledes er hypothyroidisme også hyppigere i patienter i lenvatinibbehandling (16 %) end i patienter i sorafenibbehandling (2 %).",
      "start_page": 49,
      "end_page": 49
    },
    {
      "heading": "Side 12 af 21",
      "text": "Uønskede hændelser observeret hyppigst for sorafenib\nPatienter, som blev behandlet med sorafenib, oplevede flere hånd-fod-hudreaktioner end patienterne i lenvatinibarmen (52 % versus 27 % henholdsvis). Fagudvalget vurderer, at hånd-fod-hudreaktion oftest kan\nhåndteres ved dosisjustering samt forskellige former for symptomlindring såsom fedtcreme og trykaflastning\n(skoindlæg).\nDiarré blev også observeret mere hyppigt i sorafenibbehandlede patienter end i lenvatinibbehandlede patienter (46 % versus 39 %). Diarré kan ofte afhjælpes medicinsk eller ved dosisjustering.\nHårtab sås i 25 % af sorafenibbehandlede patienter, men kun i 3 % af lenvatinibbehandlede patienter.\nKonklusion\nOverordnet set er både lenvatinib og sorafenib associeret med mange bivirkninger, idet næsten alle patienter\n(94 % for lenvatinib og 95 % for sorafenib) oplever en eller flere bivirkninger (enhver grad).\nFagudvalget forventer, at en del af de observerede bivirkninger kan håndteres medicinsk eller ved dosisjustering. I REFLECT-studiet dosisreduceres en stor andel af patienterne (37 % af patienterne i\nlenvatinibarmen og 38 % i sorafenibarmen). Ligeledes ses pausering af behandling i 40 % af\nlenvatinibbehandlede patienter og 32 % af sorafenibbehandlede patienter.\nFagudvalget fremhæver, at for patienter med hudlidelser er der dårlige erfaringer med at anvende sorafenib, og at lenvatinib her kan finde anvendelse. Konkret ses færre tilfælde af ≥ 3 hånd-fod-hudreaktioner i\nlenvatinibarmen (3 % versus 11 %).\nFagudvalget bemærker også, at EMA i sin gennemgang af lenvatinib fremhæver levertoksicitet som en problematik, idet der sås flere alvorlige og dødelige leverrelaterede bivirkninger i lenvatinibarmen end i\nsorafenibarmen, og at ansøger derfor er blevet pålagt at udføre et fase 4-forsøg for at karakterisere levertoksiciteten bedre.\nOverordnet set vurderer fagudvalget, at der ikke er væsentlige betydende forskelle i bivirkningsprofilerne, som gør, at et produkt foretrækkes frem for det andet.",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "Samlet vurdering for bivirkninger",
      "text": "Gennemgangen af data for behandlingsophør grundet bivirkninger, dosisreduktion som følge af bivirkninger samt antallet af grad 3-5 bivirkninger viser ingen klinisk betydende eller statistiske signifikante forskelle\nmellem lenvatinib og sorafenib. Ved gennemgang af bivirkningsprofilerne (type og frekvens) ses der ikke\nbetydende forskelle, som betyder, at fagudvalget foretrækker et produkt fremfor et andet. Fagudvalget\nvurderer derfor, at lenvatinib tilbyder ingen klinisk merværdi sammenlignet med sorafenib for effektmålet bivirkninger.\nEvidensens kvalitet er meget lav.\nProgressionsfri overlevelse (vigtig)\nEffektmålet ”progressionsfri overlevelse” er medtaget som et mål for effekten af førstelinjebehandling og virker som et supplement til data for effektmålet ”samlet overlevelse”. Patienter, der progredierer under\nbehandling med lenvatinib og sorafenib, kan modtage behandling i anden linje. Effektmålet ”samlet\noverlevelse” afspejler derfor effekten af både første- og evt. andenlinjebehandling.",
      "start_page": 50,
      "end_page": 50
    },
    {
      "heading": "Tabel 7. Vurdering af klinisk merværdi: Progressionsfri overlevelse",
      "text": "Forhåndsdefineret grundlag for vurdering Resultater\nAbsolutte forskelle Median progressionsfri overlevelse: 3 måneder 3,7 måneder\nStor merværdi Øvre konfidensgrænse < 0,75\nRelative forskelle Vigtig merværdi Øvre konfidensgrænse < 0,90 HR: 0,66 [0,57;0,77]\nLille merværdi Øvre konfidensgrænse < 0,10\nIngen merværdi Øvre konfidensgrænse > 1,00\nNegativ merværdi Nedre konfidensgrænse > 1.00\nEvidensens kvalitet Meget lav\nHR: Hazard ratio\nFor patienter behandlet med lenvatinib eller sorafenib var den mediane tid til progression henholdsvis 7,4 og\n3,7 måneder. Det giver en forskel i median tid til progression på 3,7 måneder. Det overskrider den forskel på\n3 måneder, som fagudvalget har forhåndsdefineret som klinisk relevant.\nDen relative effektforskel viser, at der er en signifikant forskel på progressionsfri overlevelse mellem de to grupper. Hazard ratio var 0,66 [0,57;0,77]. Da den øvre grænse for konfidensintervallet < 0,90, kvalificerer\ndet til at indplacere lenvatinib i kategorien ”vigtig merværdi”, hvad angår progressionsfri overlevelse.\nIfølge lenvatinibs EPAR [10] anvender ansøger en censureringsmetode i dataanalysen af progressionsfri overlevelse, som kan medføre overestimering af lenvatinibs effekt. Det skyldes, at flere patienter forlader\nstudiet (drop out) i lenvatinibarmen end i sorafenibarmen. Herved er der flere censureringer i\nlenvatinibarmen, hvilket betyder, at eventuelle progressionshændelser ikke inkluderes i analysen. Hvis\nanalysen justeres, så censureringen tager højde for uligheden i antallet af patienter, som forlader studiet, er forskellen i progressionsfri overlevelse på 3,6 måneder, HR 0,72 [0,63; 0,83].\nFagudvalget konkluderer, at de to analyser giver overensstemmende resultater. Da den mindste klinisk\nrelevante forskel er opnået, tildeles effektmålet en vigtig klinisk merværdi.\nEvidensens kvalitet er meget lav.\nLivskvalitet (vigtig)\nFagudvalget ønskede livskvalitet opgjort efter 1, 2 og 3 måneders behandling ved hjælp af livskvalitetsværktøjet EORTC QLQ-C30 summary score. Ansøger har ikke leveret de ønskede data, men\noplyser, at livskvaliteten falder i begge arme efter opstart af behandling. Ansøger har målt livskvalitet ved\nEORTC QLQ-C30 og EORT QLQ-HCC18 og har lavet analyser af tid til meningsfuld forværring.\nSummaryscoren er ikke signifikant forskellig mellem de to arme baseret på hazard ratio (HR 0,87\nDa de efterspurgte opgørelser efter 1, 2 og 3 måneders behandling ikke er til rådighed, vurderer fagudvalget, at den kliniske merværdi ikke kan bestemmes. Lenvatinib har derfor en ikkedokumenterbar merværdi for\neffektmålet livskvalitet.",
      "start_page": 51,
      "end_page": 51
    },
    {
      "heading": "6.1.3 Evidensens kvalitet",
      "text": "Evidensens kvalitet for den kliniske merværdi, som lenvatinib tilbyder, er samlet set vurderet som værende meget lav.\nDer er udarbejdet en GRADE-profil for det kliniske spørgsmål. Evidensens kvalitet er nedgraderet for\ninkonsistens (der foreligger kun ét studie), risiko for bias (ublindet studie) og imprecision (der foreligger kun ét studie, konfidensintervallet for den relative effekt overlapper 1). Yderligere overvejelser vedrørende\nevidensens kvalitet kan ses i bilag 2.",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "6.1.4 Konklusion",
      "text": "Fagudvalget vurderer, at lenvatinib til voksne patienter med fremskredent eller inoperabelt hepatocellulært carcinom med performancestatus 0-1 og bevaret leverfunktion svarende til Child-Pugh A og B (7) giver\ningen klinisk merværdi sammenlignet med sorafenib (meget lav evidenskvalitet).\nEvidensens kvalitet vurderes at være meget lav.\nFagudvalget har primært lagt vægt på, at der ikke ses klinisk betydende eller signifikant forskellig overlevelsesgevinst ved lenvatinib sammenlignet med standardbehandlingen. Fagudvalget bemærker, at der\nses en gevinst på 3,6-3,7 måneder i progressionsfri overlevelse ved lenvatinibbehandling, men da denne ikke reflekteres i en øget overlevelse sammenlignet med standardbehandlingen, er den kliniske betydning uvis.\nFagudvalget vurderer, at en længere progressionsfri overlevelse ikke nødvendigvis resulterer i øget livskvalitet for HCC-patienter, da en del patienter vil være symptomfri trods progression. Fagudvalget\nbemærker, at ansøger ikke har leveret data, som viser en betydende forskel i livskvalitet mellem lenvatinib og standardbehandlingen.\nFagudvalget vurderer også, at der overordnet set ikke er væsentlige betydende forskelle i bivirkningsprofilerne, som gør, at lenvatinib foretrækkes fremfor standardbehandlingen eller omvendt.\nFagudvalget fremhæver, at for patienter med hudlidelser er der dårlige erfaringer med at anvende sorafenib, og at lenvatinib her er et godt behandlingsalternativ, idet der ses færre hudrelaterede bivirkninger ved\nlenvatinib sammenlignet med sorafenib.\nTabel 8. Oversigt over effektmål og merværdier i vurderingen\nEffektmål Vigtighed Merværdi\nSamlet overlevelse Kritisk Ingen\nBivirkninger Kritisk Ingen\nProgressionsfri overlevelse Vigtig Vigtig\nLivskvalitet Vigtig Ikkedokumenterbar",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "7 Andre overvejelser",
      "text": "Fagudvalget har ikke ønsket at ligestille lenvatinib og sorafenib til førstelinjebehandling af HCC af hensyn til efterfølgende behandlingsmuligheder.",
      "start_page": 52,
      "end_page": 52
    },
    {
      "heading": "Side 15 af 21",
      "text": "8 Rådets vurdering\nMedicinrådet vurderer, at lenv carcinom med performancesta\n• Ingen klinisk mervæ\nMedicinrådet finder, at lenvat\nHCC.\n9 Relation til eksist\nDer er ingen behandlingsvejle\ng af samlet klinisk merværd vatinib til voksne patienter med frems\natus 0-1 og bevaret leverfunktion svar ærdi (meget lav evidenskvalitet)\ntinib og sorafenib kan ligestilles som f terende behandlingsvejled\nedninger indenfor leverkræftområdet.\ndi og samlet evidensniveau skredent eller inoperabelt hepatocellulært\nrende til Child-Pugh A og B (7) giver:\nførstelinjebehandling til patienter med dning",
      "start_page": 53,
      "end_page": 53
    },
    {
      "heading": "10 Referencer",
      "text": "1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1\n2. NORDCAN databasen [internet]. [citeret 15. september 2017]. Tilgængelig fra: h\ndep.iarc.fr/NORDCAN/DK/frame.asp\n3. (DLGCG) U af DLGCG. Nationale kliniske retningslinjer for udredning og behan\nlevercancer (HepatoCellulært Carcinom, HCC). [internet]. 2012. Tilgængelig fra:\n4. Opfølgningsprogram for kræft i øvre mave-tarm (2015) SST [internet]. 2015 [cite\n2017]. Tilgængelig fra:\n5. Medicinrådet. Medicinrådets anbefaling vedrørende regorafenib som standardbeh\nhepatocellulært karcinom [internet]. 2018. Tilgængelig fra: file:///C:/Users/THI/O\nRegioner/Sager/levatinib/litteratur/anbefaling_regorafenib-til-hcc_30012018.pdf\n6. EMA - European Medicines Agency. Produktresumé lenvatinib nyrecellekarcinom\nTilgængelig fra:\ned_001855.jsp&mid=WC0b01ac058001d124\n7. EMA - European Medicines Agency. Produktresumé lenvatinib thyreoidekarcino\nTilgængelig fra:\ned_001855.jsp&mid=WC0b01ac058001d124\n11 Sammensætning af f\nMedicinrådets fagudvalg vedrøre\nFormand\nBritta Weber\nAfdelingslæge\nMedlemmer\nGerda Elisabeth Villadsen\nOverlæge\nMerete Krogh\nOverlæge\nKirsten Kjeldgaard Vistisen\nOverlæge\nLone Galmstrup Madsen\nSpecialeansvarlig overlæge, ph.d.\nHar ikke udpeget\nMette Skalshøi Kjær\nOverlæge, klinisk lektor\nMette Kudsk Brink\nFarmaceut\nAmy Daugaard Asmussen\nKvalitetskoordinator, sygeplejersk\nNiels Jessen\nProfessor, overlæge\nTóra Haraldsen Dahl\nPatient/patientrepræsentant\nTidligere medlemmer, som har tage",
      "start_page": 54,
      "end_page": 55
    },
    {
      "heading": "Medicinrådets sekretariat",
      "text": "Medicinrådet\nDampfærgevej 27-29, 3.\n2100 København Ø\n+ 45 70 10 36 00 medicinraadet@medicinraadet.dk",
      "start_page": 55,
      "end_page": 55
    },
    {
      "heading": "Sekretariatets arbejdsgruppe",
      "text": "Gedske Thomsen (projekt- og me\nThea Christensen (sundhedsviden\nAnette Pultera Nielsen (fagudvalg\nAnnemette Anker Nielsen (teamle\nfagudval\nende leverk\nke, MHH et del i proc\nk\netodeansvar\nnskabelig ko gskoordinat\neder)\nlg og kræft\ncessen\nrlig)\nonsule\ntor)\ng kontaktinformation t t\nIndstillet af\nLægevidenskabelige Selska\nUdpeget af\nRegion Midtjylland og invi\nRegion Syddanmark\nRegion Hovedstaden\nRegion Sjælland\nRegion Nordjylland\nDansk Selskab for Gastroen\nDansk Selskab for Sygehus\nInviteret af formanden\nDansk Selskab for Klinisk F\nDanske Patienter n: Aleksander Krag, Professor.\nent)\ntil M aber\niteret\nnterol\nsapote\nFarma\nMedic\naf for logi og\neksled\nakolo\ncinr\nrmand\ng Hep delse\nogi\nSid\nråde\nden\npatolo\nde 18\net\nogi\naf 21\n12 Bilag 1: GRAD\nCochrane Risk\nRisiko for bias i REFLE\nRisk of bias\nRandom sequence generation\n(selection bias)\nAllocation concealmen\n(selection bias)\nBlinding of participant\nOverlevelse\nBivirkninger\nLivskvalitet\nProgressionsfri overlev\nBlinding of outcome as\nOverlevelse\nBivirkninger\nLivskvalitet\nProgressionsfri overlev\nIncomplete outcome da\n(attrition bias)\nSelective reporting\n(reporting bias)\nOther bias\nDE-evidensprofiler\nk of Bias\nECT-studiet.\nVurdering\n• Lav risiko for bias\nnt • Lav risiko for bias ts and personnel (performance bi\n• Lav risiko for bias\n• Høj risiko for bias\n• Høj risiko for bias\nvelse • Lav risiko for bias ssessment (detection bias)\n• Lav risiko for bias\n• Høj risiko for bias\n• Høj risiko for bias\nvelse • Lav risiko for bias ata • Lav risiko for bias\n• Uklar risiko for bias\n• Lav risiko for bias\nBegrundelse\nPatienter blev randomiseret 1:1 vha. et interaktivt\nvoice-web responssystem i en blokstørrelse på 2.\nPatienter blev stratificeret efter region (Asia-\nPacific/Western), makroskopisk portalvene invasion\n(ja/nej), ekstrahepatisk spredning (ja/nej), samtidig makroskopisk portalvene invasion og ekstrahepatisk\nspredning (Ja/nej), performance statur (0/1) og vægt\n(</≥ 60 kg).\nRandomiseringen blev genereret af en uafhængig statistiker, og investigatorerne blev bekendt med\ngruppeallokeringen direkte gennem det interaktive voice-web responssystem.\nias)\nStudiet var ikke blindet. Det forventes ikke, at\nmanglende blinding påvirker effektmålet.\nStudiet var ikke blindet. Det kan påvirke patients og\ninvestigators opmærksomhed på, om der opstår bivirkninger.\nStudiet var ikke blindet. Data for livskvalitet kommer\nfra spørgeskemaer, patienterne har udfyldt. Udfaldet\nkan derfor være påvirket af, at patienten ved, hvad vedkommende behandles med.\nStudiet var ikke blindet. Det forventes ikke, at\nmanglende blinding påvirker effektmålet.\nStudiet var ikke blindet. Det forventes ikke af\nmanglende blinding påvirker effektmålet.\nStudiet var ikke blindet. Det kan påvirke\ninvestigators vurdering af, om en uønsket hændelse er relateret til lægemidlet.\nStudiet var ikke blindet. Data for livskvalitet kommer\nfra spørgeskemaer, patienterne har udfyldt. Udfaldet\nkan derfor være påvirket af, at patienten ved, hvad vedkommende behandles med.\nStudiet var ikke blindet. Effektmålet blev vurderet af\ninvestigator. Resultaterne blev bekræftet af blindet\nuafhængig review. Derfor forventes det ikke, at\nmanglende blinding påvirker effektmålet.\nA nsøger rapporterer på ITT-populationen.\nAnsøger rapporterer ikke på effektmålet EQ-5D i hverken publikationen eller den endelige ansøgning.\nDet fremgår på clinicaltrials.gov, at ansøger også vil\nbenytte denne skala til at måle livskvalitet.",
      "start_page": 55,
      "end_page": 56
    },
    {
      "heading": "Side 19 af 21",
      "text": "GRADE-evaluering af evidenskvalit\nCertainty assessment\n№ of Risk of\nStudy design Inconsistency Indirect studies bias\nOverall survival (median og overlevelsesrate)\n1 randomised not serious a not seriou trials serious\nBivirkninger: Andel af patienter der ophører behandling grundet bivirkninge\n1 randomised serious c serious a not seriou trials\nBivirkninger: Andel af patienter der dosisreduceres\n1 randomised serious d serious a not seriou trials\nBivirkninger: Antal grad 3-5 bivirkninger\n1 randomised serious e serious a not seriou trials\nteten til vurdering af den kliniske merværdi af Lenvatinib\n№ of patients Effect\nCertainty Importance\nOther Relative Absolute tness Imprecision Lenvatinib Sorafenib\nconsiderations (95 % CI) (95 % CI) us serious b none -/478 -/476 HR 0,92 Median: 1,3 mdr ⨁⨁◯◯ CRITICAL\n(0,79 to LOW\n1,06) Rate 12 mdr: 5 %point\nRate 24 mdr: 3,6\n%-point\ner\nus serious b none 42/476 (8,8%) 34/475 (7,2 RR 1,23 2 more per 100 ⨁◯◯◯ CRITICAL\n%) (0,80 to (from 1 fewer to 6 VERY LOW\n1,90) more) us serious b none 176/476 181/475 RR 0,97 1 fewer per 100 ⨁◯◯◯ CRITICAL\n(37,0%) (38,1 %) (0,82 to (from 5 more to 7 VERY LOW\n1,14) fewer) us serious a none 1,59/- 1,8/- Rate ratio 0,21 ⨁◯◯◯ CRITICAL\n0,89 events/patient-år VERY LOW\n(0,78 to",
      "start_page": 57,
      "end_page": 57
    },
    {
      "heading": "Side 20 af 21",
      "text": "Certainty assessment № of patients Effect\nCertainty Importance\n№ of Risk of Other Relative Absolute\nStudy design Inconsistency Indirectness Imprecision Lenvatinib Sorafenib studies bias considerations (95 % CI) (95 % CI)\nProgressionsfri overlevelse\n1 randomised not serious a not serious serious a none -/478 -/476 HR 0,66 Median: 3,7 mdr ⨁⨁◯◯ IMPORTANT\ntrials serious (0,57 to LOW\nLivskvalitet\n1 randomised serious f serious a serious g serious a none Summaryscoren for livskvalitetsværktøjet EORTC QLQ-C30 er ⨁◯◯◯ IMPORTANT trials ikke signifikant forskellig mellem de to arme i REFLECT-studiet, VERY LOW\nHR, 0,87 [0,754; 1,013]",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "Forklaringer",
      "text": "a. Vurderingen er baseret på et studie.\nb. Konfidensintervallet for den relative effekt overlapper 1. Og der er kun et studie, som ligger til grund for estimatet.\nc. Studiet var ikke blindet. Det kan påvirke patientens og investigators opmærksomhed på, om der opstår bivirkninger, samt om det skal føre til behandlingsophør.\nd. Studiet var ikke blindet. Det kan påvirke patientens og investigators opmærksomhed på, om der opstår bivirkninger, samt om det skal føre til dosisreduktion.\ne. Studiet var ikke blindet. Det kan påvirke patientens og investigators opmærksomhed på, om der opstår bivirkninger.\nf. Studiet var ikke blindet. Patientens vurdering af livskvalitet kan være influeret af kendskab til behandling. Herudover er EQ-5D-data ikke inkluderet i publikationen\nfor REFLECT-studiet (Kudo et al. 2018), men fremgår som effektmål på clinicaltrials.gov.\ng. Livskvalitetsdata er ikke opgjort som specificeret i protokollen.",
      "start_page": 58,
      "end_page": 58
    },
    {
      "heading": "Side 21 af 21",
      "text": "Application for the added value of LE\nCarcinoma",
      "start_page": 59,
      "end_page": 59
    },
    {
      "heading": "Contents",
      "text": "1 Basic information ...............................\n2 Abbreviations ....................................\n3 Summary...........................................\n4 Literature search ................................\nDatabases and search strategy ..........\n4.1 Relevant studies ...........................\n4.2 Main characteristics of included stud\n5 Clinical questions................................\n5.1 Clinical question 1........................\n5.1.1 Presentation of relevant studie\n5.1.2 Results per study ..................\nKudo et al. 2018 [1] .........................\nOverall survival (OS) .....................\nAdverse Events (AE) .....................\nProgression-free survival (PFS).......\nQuality of life ..............................\n5.1.3 Comparative analyses............\n6 References ........................................\n7 Appendices........................................\nLiterature search....................................\nInclusion and exclusion criteria..........\nSearches and results ........................\nExclusion........................................\nPRISMA flow charts .........................\nMain characteristics of included studies ....\nStudy characteristics ........................\nResults per study.............................\nResults per PICO (clinical question) ....\ne\nENV\nudies ..\nes......\nas\nVIM\nsses\nMA\nssm\nA f\nme\nfor\nent\nr H\no\nHep\nof\npat\ncli\ntoc\nlinic\ncell\nPag\ncally\nlular\nge 1 of 58\n1 Basic infor\nTABLE 1.1: CONTACT\nName\nTitle\nArea of responsibil\nPhone\nE-mail\nName\nTitle\nArea of responsibil\nPhone\nE-mail\nApplication form\norma\nT INFO lity\nlity\nm ve\nation\nORMAT\nrsion\nn\nTION\nn 2.0\nJarno Kotajärvi\nPrice and Reimbur\nConsultant\n+358 9 825 64 277 market.access@d\nKaija Rinne\nConsultant, Health\nConsultant\n+358 9 825 64 254 market.access@d\nrseme\ndra.fi\nh Econ\ndra.fi\nent Exp nomic\npert\ncs\nPa\nge 2 of 58\nTABLE 1.2: OVERVIEW OF THE PHARMACEUTICAL\nProprietary name LENVIMA\nGeneric name Lenvatinib\nMarketing authorization Eisai Europe Ltd.\nholder in Denmark\nATC code L01XE29",
      "start_page": 59,
      "end_page": 61
    },
    {
      "heading": "Pharmacotherapeutic group Antineoplastic agents, protein kinase inhibitors",
      "text": "Active substance(s) Lenvatinib\nPharmaceutical form(s) Hard capsule\nMechanism of action Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1\n(FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors\nFGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.\nDosage regimen Hepatocellular Carcinoma\nThe recommended daily dose of lenvatinib is 8 mg (two 4 mg capsules) once daily for patients with a body weight of < 60 kg and 12 mg (three 4 mg capsules) once\ndaily for patients with a body weight of ≥ 60 kg. Dose adjustments are based only\non toxicities observed and not on body weight changes during treatment. The daily\ndose is to be modified, as needed, according to the dose/toxicity management plan.\nTherapeutic indication LENVIMA is indicated as monotherapy for the treatment of adult patients with relevant for assessment (as advanced or unresectable hepatocellular carcinoma (HCC) who have received no\ndefined by the European prior systemic therapy.\nMedicines Agency, EMA)\nOther approved therapeutic LENVIMA is indicated as monotherapy for the treatment of adult patients with indications progressive, locally advanced or metastatic, differentiated\n(papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).\nWill dispensing be restricted Yes. LENVIMA treatment should be initiated and supervised by a health care\nto hospitals? professional experienced in the use of anticancer therapies.\nCombination therapy and/or Not applicable co-medication\nPackaging – types, LENVIMA 4 mg hard capsules.\nsizes/number of units, and Polyamide/Aluminium/PVC/Aluminium blisters containing 10 capsules. Each carton\nconcentrations contains 30 capsules\nOrphan drug designation No\n2 Ab\nAbbrevia\nAE\nAFP\nALP\nALT\nANC\nAST\nBCLC\nBID\nBP\nBW\nCBR\nCI\nCT\nDCR\nECOG PS\nEMA\nEORTC\nEPAR\nEU\nFAS\nHBV\nHCC\nHCV\nHIV\nHR\nHRQoL\nIQR\nLCL\nMRI\nND\nNYHA\nOS\nPD\nPFS\nPK\nPPS\nPPS\nQD\nSAP\nSY\nTACE\nTEAE\nUCL\nULN\nApplica\nbbre\nation/\nS\nation\neviat\n/term\nn form\ntions\nDefinition\nAdverse Event\nAlfa-fetoprotein\nAlkaline phosphatase\nAlanine aminotransferase\nAbsolute neutrophil count\nAspartate aminotransferase\nBarcelona Clinic Liver Cancer\nTwice daily\nBlood pressure\nBody weight\nClinical benefit rate\nConfidence interval\nComputed tomography\nDisease control rate\nEastern Cooperative Oncology G\nEuropean Medicines Agency\nEuropean Organization for Resea\nEuropean public assessment rep\nEuropean Union\nFull analysis set\nHepatitis B virus\nHepatocellular carcinoma\nHepatitis C virus\nHuman immunodeficiency virus\nHazard ratio\nHealth Related Quality of Life\nInterquartile range\nLower Control limit\nMagnetic resonance imaging\nLymph node\nNew York Heart Association\nOverall survival\nPharmacodynamic\nProgression-free survival\nPharmacokinetic\nPer protocol analysis set\nPer protocol analysis set\nOnce daily\nStatistical analysis plan\nSubject years\nTransarterial chemoembolizatio\nTreatment-emergent adverse ev\nUpper control limit\nUpper limit of normal m version 2.0\nGroup P arch a\nports\nn\nvents\nPerfor\nand Tre\nrmanc\neatme\nce Stat ent of C\ntus\nCancer\ner\nPa\nge 4 o\nof 58",
      "start_page": 61,
      "end_page": 62
    },
    {
      "heading": "3 Summary",
      "text": "Currently, there are limited systemic treatment options available for 1st line unresectable HCC patients:\nsorafenib is the only systemic agent that has been approved for first line treatment of advanced HCC. There\nis a significant need for new treatments in advanced unresectable HCC that delay progression without negatively impacting patients’ HRQoL.\nLenvatinib is a receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that inhibits VEGF receptors (VEGFR1, VEGFR2 and VEGFR3), FGF receptors (FGFR1, FGFR2, FGFR3 and FGFR4) and other RTKs\ninvolved in tumor proliferation (including platelet derived growth factor receptor PDGFRα, KIT, and RET).\nLenvatinib has been approved as a monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systematic therapy.\nLenvatinib is the first treatment in 10 years to demonstrate a proven overall survival benefit by statistical confirmation of non-inferiority versus sorafenib. In addition:\n- Lenvatinib demonstrated a statistically significant and clinically meaningful benefit in terms of\nprogression-free survival (PFS) compared with sorafenib.\n- Importantly, results from the EORTC-QLQ (C30 and HCC18) suggest that lenvatinib treatment leads\nto a clinically meaningful delay in several HRQoL domains, including Role Functioning, Pain,\nDiarrhoea, Body Image, and Nutrition.\n- The adverse event profile of lenvatinib is manageable and predictable.\nIn addition, in the context of the assessment of OS it is important to note the following:\n Imbalances in baseline characteristics which were potentially important prognostic factors may affect the treatment benefit seen with lenvatinib. Baseline imbalances of note in REFLECT included\nthe proportion of patients with AFP levels ≥200 ng/mL (46.4% in the lenvatinib arm and 39.3% in\nthe sorafenib arm) and the proportion of patients with an aetiology of HCV (19% in the lenvatinib arm (and 26.5% in the sorafenib arm).\no Notably, after adjustment for imbalances in baseline AFP, lenvatinib was found to be nominally superior to sorafenib in terms of OS. In the presence of imbalances for strong\npredictors of outcomes, adjustment for such covariates generally improves the precision of the analysis\n More patients had post-progression treatment in the sorafenib arm than in the lenvatinib arm (51% of patients in the sorafenib group had post-progression treatment compared with only 43% in the\nlenvatinib group). As a result the overall survival results may favour sorafenib.\no When adjusted for post-treatment anticancer therapy, the HR for OS favoured lenvatinib\n Finally, the exploratory analysis presented in section 5.1.3 demonstrate that, based on the REFLECT\ndata adjusted for imbalances in baseline characteristics an incremental mean OS benefit of at least three months may be reasonable\nLenvatinib represents advancement in the management of HCC. Several other investigational therapies\nhave failed to meet non-inferiority or superiority endpoints for OS versus sorafenib. Patients should be\ngiven the opportunity to get the best possible treatment options. Lenvatinib introduction will lead to a\npredictable and manageable budget impact due to a small target population and no additional resource requirement for the treatment of adverse events.",
      "start_page": 63,
      "end_page": 63
    },
    {
      "heading": "4 Literature search",
      "text": "The literature search strategy was carried out as defined in the protocol. Only one relevant published\narticle [1] found via literature search. The more detailed information is described in the Appendice\nLiterature search covering inclusion and exclusion criteria, reasons for exclusion of each reference and flow charts showing the number of references identified and the number of included and excluded references.\nIn addition to the literature search, EMA’s relevant scientific discussions for both lenvatinib and comparator sorafenib are included in this application [2,3]. As the newest publicly available EPAR of lenvatinib does not\ninclude HCC indication the preliminary EPAR is used for this application. For the same reasons, for the\ncomparator sorafenib the original scientific discussion for the HCC indication is used instead of the newer assessment report as it is focusing on the extension of indication.\nDatabases and search strategy\nThe literature search was conducted on 14th September 2018 in the databases MEDLINE (via PubMed) and\nCENTRAL (via Cochrane Library). Both indexed (eg Medical Subject Headings, MeSH) and Free Text Search\nhas been used.\nThe searches include the generic name and trade name, combined with terms for the indication:\nlenvatinib AND hepatocellular carcinoma\nLenvima AND hepatocellular carcinoma\nDatabase: MEDLINE via PubMed\nTime period covered: from 1946 to date of search.\nSearch string: (\"lenvatinib\"[Supplementary Concept] OR \"lenvatinib\"[All Fields]) AND (\"carcinoma,\nhepatocellular\"[MeSH Terms] OR (\"carcinoma\"[All Fields] AND \"hepatocellular\"[All Fields]) OR\n\"hepatocellular carcinoma\"[All Fields] OR (\"hepatocellular\"[All Fields] AND \"carcinoma\"[All Fields]))\nSearch results: 43\nAs can be expected based on the PubMed search strategy shown above, the search with keywords\n“Lenvima” and “hepatocellular carcinoma” yielded the same results as the search with “lenvatinib” and\n“hepatocellular carcinoma”.\nDatabase: CENTRAL via Cochrane Library\nTime period covered: from 1996 to date of search\nSearch results for “lenvatinib AND hepatocellular carcinoma“: 18\nSearch results for “Lenvima AND hepatocellular carcinoma”: 0",
      "start_page": 64,
      "end_page": 64
    },
    {
      "heading": "4.1 Relevant studies",
      "text": "Only one study was found relevant and included in this assessment (Table 4.1). It was found via both\nsearched databases. Reasons for exclusion of other preliminary results are described in the Appendix\nLiterature search.\nTABLE 4.1: RELEVANT STUDIES INCLUDED IN THE ASSESSMENT\nReference (title, author, journal, year) Trial name NCT Dates of study (start and number expected completion date)\nLenvatinib versus sorafenib in first-line treatment of REFLECT 01761266 Study Start March 14, 2013.\npatients with unresectable hepatocellular study Expected completion date carcinoma: (E7080- March 2019\na randomised phase 3 non-inferiority trial Kudo, M., G000-304)\nFinn, R.S., Qin, S., et al. Lancet 2018 [1]",
      "start_page": 65,
      "end_page": 65
    },
    {
      "heading": "4.2 Main characteristics of included studies",
      "text": "Two studies have been conducted with lenvatinib in HCC, a phase 1/2 proof-of-concept, dose-finding study\n(202, NCT00946153) and phase 3 non-inferiority study (304, NCT01761266, REFLECT study) of lenvatinib versus sorafenib [2]. As per the protocol only the phase 3 study REFLECT is used in this the assessment [4].\nREFLECT was a multicenter, randomised, open-label, non-inferiority phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in subjects with unresectable\nHCC.\nA total of 954 subjects who met all inclusion criteria and no exclusion criteria were randomised in a 1:1\nratio to one of the following treatment groups:\n Lenvatinib: 12 mg (if baseline BW ≥60 kg) or 8 mg (if baseline BW <60 kg) QD oral dosing\n Sorafenib: 400 mg twice daily (BID) oral dosing\nAllocation of randomisation numbers was performed using an interactive voice/web response system\n(IxRS®) based on the following stratification factors:\n Region: Region 1 (Asia-Pacific); Region 2 (Western regions, such as EU, North America, other)\n Macroscopic portal vein invasion (MPVI) or extrahepatic spread or both: Yes; No\n Eastern Cooperative Oncology Group performance status (ECOG PS): PS = 0; PS = 1\n BW: <60 kg; ≥60 kg.\nEnrolment in Study 304 occurred between 01 Mar 2013 (first subject gave informed consent) and 30 Jul\n2015 (last subject enrolled) at 183 study sites (number of sites initiated) in Asia, North America, European\nUnion, Russia, and Israel [2]. A resulting total of 154 sites in 20 countries were involved in this study [1].\nThe data cut-off for the primary analysis occurred on 13 Nov 2016 after the occurrence of 700 deaths.\nA total of 1,492 subjects were screened for entry into the study. Of these, 538 subjects were screening\nfailures, and 954 subjects (63.9%) were randomly assigned in a 1:1 ratio to receive either lenvatinib (478\nsubjects) or sorafenib (476 subjects). Of the 954 randomised subjects, two in the lenvatinib and one in the\nsorafenib arm were not treated. The two subjects in the lenvatinib arm were not treated because they met\nexclusion criteria and were randomised in error. The subject in the sorafenib arm chose not to take study\ntreatment. Therefore, 476 subjects in the lenvatinib and 475 subjects in the sorafenib arm received at least\none dose of study treatment (Figure 4.1).\nInclusion and exclusion criteria are presented in appendices, Table 7.2.\nFIGURE 4.1: TRIAL PROFILE [1]\nA non-inferiority test of overall survival (OS) between lenvatinib and sorafenib was done using a 2-sided\n95% confidence interval (CI) of hazard ratio (HR) (lenvatinib:sorafenib). The HR and the corresponding 2sided 95% CI were estimated using a Cox proportional hazard model with treatment group as a factor, and\nstratified by the randomisation (IxRS) stratification factors.\nSuperiority hypotheses were tested for OS using a stratified log-rank test with the randomisation (IxRS) stratification factors. No multiplicity adjustments were needed for testing of the non-inferiority and\nsuperiority of OS due to the closed testing principle. Two interim analyses were performed. Since the study\nwas not stopped at the first or second interim analysis, non-inferiority for OS was tested first at the final analysis with a non-inferiority margin of 1.08, which indicated that lenvatinib preserved at least 60%\n(corresponding to δ = 0.60) of the sorafenib treatment effect versus placebo as observed in the sorafenib\nSHARP and Asia-Pacific trials [5,6]. Non-inferiority was declared if the upper limit of the 2-sided 95% CI for\nHR was <1.08 at the final analysis. If non-inferiority was declared for OS, then superiority (corresponding to\nδ =1) was to be tested for OS. Superiority would be declared if the 2-sided P value was <0.05 using the\nstratified log-rank test at the final analysis.\nAs of the data cut-off date of 13 Nov 2016, the median duration of survival follow-up was 27.7 months in\nthe lenvatinib arm and 27.2 months in the sorafenib arm.\nThe lenvatinib and sorafenib arms were generally well balanced with regard to baseline HCC disease characteristics and disease history with some exceptions.\n The proportion of subjects with baseline alpha-fetoprotein (AFP) levels ≥200 ng/mL (an adverse prognostic factor in HCC), was greater in the lenvatinib arm than in the sorafenib arm: 46% vs 39%,\nrespectively.\n In addition, the proportion of subjects with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm (26% vs 19%, respectively), an imbalance that may\nfavor sorafenib, since HCV aetiology has been recently shown to be a predictive indicator for sorafenib treatment effect and subjects with HCV appear to derive more clinical benefit from\nsorafenib therapy than subjects with other aetiologies, particularly hepatitis B virus (HBV) [7].\nAn overview of the REFLECT study can be found in appendices, Table 7.2.",
      "start_page": 65,
      "end_page": 67
    },
    {
      "heading": "5.1 Clinical question 1",
      "text": "What is the clinical added value of lenvatinib for adult patients with advanced or inoperable hepatocellular carcinoma who are candidates for systematic treatment, compared with sorafenib?",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "5.1.1 Presentation of relevant studies",
      "text": "The REFLECT study was a phase 3 trial of lenvatinib versus sorafenib in first-line treatment of patients with unresectable HCC. The primary objective of the REFLECT study was to compare OS in patients treated with\nlenvatinib versus sorafenib as a first-line treatment for unresectable stage B or C (according to BCLC staging system) HCC and Child Pugh Class A liver disease.\nThe secondary objectives of the study were:\n To compare Progression-free survival (PFS), Time-to progression and Objective response rate of subjects treated with lenvatinib versus sorafenib using (mRECIST)\n To compare the impact of treatment on generic Health Related Quality of Life (HRQoL) of subjects treated with lenvatinib versus sorafenib using the EORTC QLQ-C30 and QLQ-HCC18 questionnaires\n To compare safety and tolerability of subjects treated with lenvatinib versus sorafenib\n To characterize the PK of lenvatinib using the population approach\n To assess the PK/PD relationship between exposure and efficacy/safety.\nThe exploratory objectives of the study were:\n To compare DCR of subjects treated with lenvatinib versus sorafenib using mRECIST\n To compare the clinical benefit rate (CBR) of subjects treated with lenvatinib versus sorafenib\n To compare the impact of treatment on generic HRQoL factors for subjects treated with lenvatinib versus sorafenib using the European Quality of Life questionnaire\n To explore blood and tumour biomarkers which may correlate with clinical outcomes-related endpoints.\nAn overview of the REFLECT study can be found in appendices, Table 7.2.",
      "start_page": 68,
      "end_page": 68
    },
    {
      "heading": "5.1.2 Results per study",
      "text": "Kudo et al. 2018 [1]\nThe results of REFLECT study have been published in one article, which was also the only article identified through the literature research [1]. An overview of the results presented in this article is provided in the\nappendices, Table 7.3.\nOverall survival (OS)",
      "start_page": 68,
      "end_page": 69
    },
    {
      "heading": "Median survival",
      "text": "As of the data cut-off date of 13 Nov 2016, 73.4% of subjects in the lenvatinib and 73.5% of subjects in the\nsorafenib arms had died. As shown in Table 7.3, Table 5.1 and Figure 5.1, median OS was 13.6 months for\nlenvatinib and 12.3 months for sorafenib, with an HR of 0.92 and a 95% CI of 0.79 – 1.06. As pre-specified in\nthe protocol, the study met its primary endpoint by demonstrating non-inferiority in OS for lenvatinib compared with sorafenib. Although numerical improvement in median OS and HR was seen, the primary\nresult did not meet the statistical criteria for superiority. Published data and the EMA’s scientific discussion\nare in line regarding OS [1,2].\nThe results of the primary efficacy analysis of OS based on the full analysis set (FAS) were supported by the results of the analysis based on the PPS, for which median OS was 13.7 months for lenvatinib and 12.3\nmonths for sorafenib (HR: 0.91; 95% CI: 0.78, 1.06) [1,2].\nHR=hazard ratio.\nFIGURE 5.1: KAPLAN-MEIER ESTIMATES OF OVERALL SURVIVAL BY TREATMENT GROUP - FAS [1]",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "12-months and 24-months survival rates are presented in Table 5.1. 12-months survival was 55.0% for",
      "text": "lenvatinib and 50.0% for sorafenib. 24-months survival was 29.9% for lenvatinib and 26.2% for sorafenib.\nAlthough 12-months and 24-months overall survival has not been presented in the published article, those are presented in the EMA’s scientific discussion [1,2].\nTABLE 5.1: OVERALL SURVIVAL BASED ON RANDOMIZATION STRATIFICATION FACTORS RECORDED IN THE IXRS - FAS\nLenvatinib Sorafenib\n(N=478) (N=476) n (%) n (%)\nDeaths, n (%) 351 (73.4) 350 (73.5)\nCensored Subjects, n (%) 127 (26.6) 126 (26.5)\nLost to follow-up 5 (1.0) 11 (2.3)\nWithdrawal of consent 13 (2.7) 8 (1.7)\nAlive 109 (22.8) 107 (22.5)\nMedian Overall Survival (months)a (95% CI) 13.6 (12.1, 14.9) 12.3 (10.4, 13.9)\nOverall Survival Rate (%) (95% CI) b at\n6 Months 80.8 (76.9, 84.1) 75.2 (71.0, 78.8)\n12 Months 55.0 (50.4, 59.4) 50.0 (45.4, 54.5)\n24 Months 29.9 (25.6, 34.2) 26.2 (22.1, 30.5)\nStratified Cox Model Hazard Ratio (95% CI) c,d 0.92 (0.79, 1.06)\nData cut-off date: 13 Nov 2016.\nNoninferiority margin for the HR of lenvatinib versus sorafenib is 1.08.\na: 95% CIs are estimated with a generalized Brookmeyer and Crowley method.\nb: OS rate & 95% CI calculated using Kaplan-Meier product-limit method and Greenwood Formula.\nc: Hazard ratio is for lenvatinib vs. sorafenib, based on a Cox model including treatment group as a factor. Efron method was used for\nties.\nd: Stratified by region (Region 1: Asia-Pacific; Region 2: Western), macroscopic portal vein invasion or extrahepatic spread or both (yes,\nno), ECOG PS (0, 1) and body weight (<60 kg, ≥60 kg).",
      "start_page": 69,
      "end_page": 70
    },
    {
      "heading": "Overall survival by subgroup",
      "text": "The effect of lenvatinib and sorafenib on OS generally was consistent across subgroups, including age, sex, and BW; HR (lenvatinib:sorafenib) was <1 for most subgroups. A forest plot of HR for lenvatinib vs sorafenib\nin OS in patient subgroups appears in Figure 5.2 [1].\n The effect of lenvatinib on OS was consistent across the Western and Asia-Pacific regions, while OS for sorafenib was longer in the Western region than in the Asia-Pacific region.\no In the lenvatinib arm, median OS in the Western region (13.6 months) was consistent with\nthat observed in the Asia-Pacific region (13.5 months).\no In contrast, median OS with sorafenib in the Western region (14.2 months) was longer than\nthe median OS with sorafenib in the Asia-Pacific region (11.0 months).\n Lenvatinib also demonstrated a consistent effect in both HBV and HCV subgroups, with a median\nOS of 13.4 and 15.3 months, in contrast to 10.2 and 14.1 months with sorafenib, respectively (HR:\n0.83 for HBV and HR 0.91 for HCV subgroups, respectively).\n The effect of lenvatinib was consistent regardless of BW group (median OS 13.4 and 13.7 months\nfor BW<60 kg and ≥60 kg, respectively (HR 0.85 and 0.95, respectively).\nFIGURE 5.2: FOREST PLOT OF OS IN PATIENT SUBGROUPS - FAS [1]\nOverall survival adjusted by baseline characteristics (pre-planned supportive analyses)\nAs described in Section 4.2 Main characteristics of included studies, there were baseline imbalances\nbetween the lenvatinib and sorafenib treatment arms regarding the proportion of patients with AFP levels\n≥200 ng/mL, and in the aetiology of HCC (HBV, HCV, alcohol). Covariate analyses were performed to\nevaluate baseline factors that may have impacted OS in the overall study population, including AFP and\nHCC aetiology. A plan to perform covariate analyses for supporting the efficacy results was included in the\nstatistical analysis plan (SAP).\n For the FAS, the results adjusted by the individual baseline characteristics generally were consistent with those of the primary OS analysis (HR <1) (\n Table 5.2)\n For baseline AFP, the HR for lenvatinib:sorafenib was nominally superior (HR=0.856), and the upper\nlimit of the 95% CI was <1 (95% CI: 0.736, 0.995).\n The covariate analysis adjusted for aetiology of HCC (hepatitis B, hepatitis C, alcohol) resulted in an\nHR for lenvatinib:sorafenib of 0.855, with 95% CI of (0.721, 1.013).\nTABLE 5.2: OS WITH STRATIFICATION FACTORS IN IXRS, ADJUSTED BY BASELINE CHARACTERISTICS - FAS [1]\nBaseline Characteristics Hazard Ratio for\n(Lenvatinib: Sorafenib)\n(95% CI)\nAge (<65, ≥65 to <75, ≥75 yrs.) 0.919 (0.791, 1.067)\nSex (Male, Female) 0.916 (0.789, 1.064)\nRegion (Asia-Pacific, Western Region) 0.915 (0.789, 1.062)\nMacroscopic Portal Vein Invasion (Yes, No) 0.910 (0.784, 1.057)\nExtrahepatic Spread (Yes, No) 0.915 (0.788, 1.062)\nMacroscopic Portal Vein Invasion, Extrahepatic Spread or Both (Yes, No) 0.908 (0.783, 1.054)\nECOG PS (0, ≥1) 0.923 (0.795, 1.071)\nBody Weight (<60 kg, ≥60 kg) 0.923 (0.796, 1.071)\nAlpha-fetoprotein level at Baseline (<200 ng/mL, ≥200 ng/mL) 0.856 (0.736, 0.995)\nAntiviral Therapy for Hepatitis B or Hepatitis C (Yes, No) 0.912 (0.785, 1.059)\nNo. of Disease Sites at Baseline (1, 2, ≥3) 0.878 (0.755, 1.020)\nAetiology (HBV, HCV, Alcohol) 0.855 (0.721, 1.013)\nUnderlying Cirrhosis (Yes, No) 0.916 (0.789, 1.063)\nBCLC Staging (Stage B, Stage C) 0.918 (0.791, 1.067)\nPrior Procedure (Yes, No) 0.902 (0.777, 1.048)\nAFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG-PS, Eastern\nCooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus.",
      "start_page": 70,
      "end_page": 72
    },
    {
      "heading": "Effect of post-treatment anticancer therapy on Overall Survival",
      "text": "There was an imbalance between the treatment arms regarding the proportion of patients who received post-treatment anti-cancer therapy (including procedures and medications) during survival follow-up (\nTable 5.3). Fewer patients in the lenv\npatients in the sorafenib arm (51.1%\nvatinib arm (43.\n.1%) had post-t\ntreatm\nment anti-c\ncancer therapy than\nTABLE 5.3: ANTICANCER MEDICATIONS (NOT GIVEN FOR ANY PROCEDURE) DURING SURVIVAL FOLLOW-UP - FAS [2]\nLenvatinib Sorafenib\nWestern Asia-Pacific Total Western Asia-Pacific Total\n(N=157) (N=321) (N=478) (N-157) (N=319) (N=476)\nReceived any anti-cancer 44 (28.0) 162 (50.5) 206 (43.1) 71 (45.2) 172 (53.9) 243 (51.1)\ntherapy* during survival followup, n (%)\nReceived any anti-cancer 41 (26.1) 115 (35.8) 156 (32.6) 61 (38.9) 123 (38.6) 184 (38.7)\nmedication (not given for a procedure) during survival\nfollow-up, n (%)\nUnderwent any anti-cancer 11 (7.0) 111 (34.6) 122 (25.5) 18 (11.5) 112 (35.1) 130 (27.3)\nprocedure during survival follow-up, n (%)\n*Posttreatment anti-cancer therapy includes both posttreatment anti-cancer procedures and posttreatment anti-cancer medications received during survival follow-up.\nAs described in Section Overall survival by subgroup, in the lenvatinib arm, median OS in the Western region (13.6 months) was consistent with that observed in the Asia-Pacific region (13.5 months). In\ncontrast, median OS with sorafenib in the Western region (14.2 months) was longer than the median OS\nwith sorafenib in the Asia-Pacific region (11.0 months).\nTable 5.4 presents a post hoc analysis adjusted by use of post-treatment anti-cancer therapy. When\nadjusted for post-treatment anticancer therapy, the HR for OS was 0.87 (0.75, 1.01) compared to 0.92\n(0.79, 1.06) uadjusted. When stratified by geographic region, the HR favoured lenvatinib in both Western\nand Asia-Pacific regions when adjusted for post-treatment anti-cancer treatment. In the Western region,\nthe adjusted HR (95% CI) was 0.93 (0.70, 1.23) compared with 1.08 (0.82, 1.42) in the unadjusted analysis.\nTABLE 5.4: OVERALL SURVIVAL ADJUSTED BY USE OF POST-TREATMENT ANTICANCER TREATMENT, OVERALL AND BY\nREGION - FAS [2]\nStratified Cox Model Hazard Ratio (95% CI)*\nWithout adjustment With adjustment†\nOverall 0.92 (0.79, 1.06) 0.87 (0.75, 1.01)\nRegion\nAsia-Pacific 0.86 (0.72, 1.02) 0.83 (0.70, 1.00)\nWestern 1.08 (0.82, 1.42) 0.93 (0.70, 1.23)",
      "start_page": 72,
      "end_page": 74
    },
    {
      "heading": "Supplementary exploratory overall survival analysis",
      "text": "As presented in section 4.2 Main characteristics of included studies the proportion of subjects with baseline\nalpha-fetoprotein (AFP) levels ≥200 ng/mL (an adverse prognostic factor in HCC), was greater in the lenvatinib arm than in the sorafenib arm: 46% vs 39%, respectively. In addition, the proportion of subjects\nwith an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm\n(26% vs 19%, respectively), an imbalance that may favor sorafenib, since HCV aetiology has been recently shown to be a predictive indicator for sorafenib treatment effect and subjects with HCV appear to derive\nmore clinical benefit from sorafenib therapy than subjects with other aetiologies, particularly hepatitis B virus (HBV) [7]. Of principal concern was the imbalance in baseline AFP levels between treatment arms; AFP\nhas been demonstrated to be a strong independent predictor of outcomes regardless of treatment type [8], and the proportion of patients with AFP levels ≥200 ng/mL was higher in the lenvatinib arm (46.4%) than\nthe sorafenib arm (39.3%).\nAs presented in section 5.1.2 Effect of post-treatment anticancer therapy on Overall Survival there was an\nimbalance between the treatment arms regarding the proportion of patients who received post-treatment anti-cancer therapy.",
      "start_page": 74,
      "end_page": 75
    },
    {
      "heading": "Survival analysis",
      "text": "At the data cut-off of 13th November 2016, 73.4% of patients in the lenvatinib arm and 73.5% of patients in\nthe sorafenib arm had died. The Kaplan-Meier estimator for sorafenib PFS was 6% at the last observed data\npoint. Therefore, there is justification for using statistical survival analysis to extrapolate beyond the end of",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "REFLECT. Survival analysis is commonly used in cost-effectiveness analysis to model health benefits for the",
      "text": "lifetime of the average patient. The imbalances in baseline characteristics and post-treatment therapy can\nbe explored within estimation of parametric survival models.\nThe National Institute for Health and Care Excellence (NICE) is currently evaluating Lenvatinib (ID1089) [9].\nThe Company Submission used a multivariable adjustment to account for the imbalance in baseline characteristics.\n Current EMA guidance on adjustment for baseline characteristics in clinical trials suggests that in the presence of imbalances for strong predictors of outcomes, adjustment for such covariates\ngenerally improves the precision and efficiency of the analysis and avoids conditional bias from chance covariate imbalance [10].\nThe Evidence Review Group (ERG) conducted an independent assessment of the REFLECT clinical data and the company submission concluding it was appropriate to adjust for baseline imbalances resulting in “an\nundiscounted incremental mean OS benefit of 3.1 months”. Furthermore the ERG preferred to include the\neffect of imbalances in post-treatment therapy which resulted in an “undiscounted incremental mean OS benefit of 4.1 months” [9].\nThese results demonstrate that, based on the REFLECT data adjusted for imbalances in baseline characteristics an incremental modelled mean OS benefit of at least three months may be reasonable.\nAdverse Events (AE)\nThe information presented in this section comes from the published article and the EMA’s scientific discussion [1,2] which include information about the treatment-emergent adverse events (TEAE). TEAEs\nare defined as AEs that occurred on or after the first dose of study drug up to 30 days following last dose of study drug.",
      "start_page": 75,
      "end_page": 75
    },
    {
      "heading": "Grades 3-5 adverse events",
      "text": "The vast majority (>98%) of subjects in both the lenvatinib and sorafenib arms had at least one TEAE. Grade\n3 or higher TEAEs occurred in 357 subjects (75%) in the lenvatinib arm and 316 subjects (66.5%) in the\nsorafenib arm (\nTable 5.5).\nTABLE 5.5: SUMMARY OF TEAES - SAFETY ANALYSIS SET [1,2]\nAdverse events Lenvatinib Sorafenib\n(N=476)\n(N=475)\nn (%) n (%)\nPatient with any TEAE 470 (98.7) 472 (99.4)\nPatients with any related TEAE 447 (93.9) 452 (95.2)\nPatients with any TEAE ≥grade 3 357 (75.0) 316 (66.5)\nPatient with any related TEAE ≥grade 3 270 (56.7) 231 (48.6)\nAbbreviation: TEAE, treatment-emergent adverse event",
      "start_page": 75,
      "end_page": 76
    },
    {
      "heading": "Qualitative review of adverse events",
      "text": "As of the 13 Nov 2016 data cut-off, median duration of exposure was 5.7 months in the lenvatinib arm and\n3.7 months in the sorafenib arm; exposure to lenvatinib therapy was approximately 1.5-times longer than\nexposure to sorafenib therapy. The total number of subject years (SY) of exposure, including dose\ninterruptions, was 324.2 in the lenvatinib arm and 239.1 in the sorafenib arm. In the lenvatinib arm, 12.2%\nof subjects received study drug for 12 to 18 months; an additional 10.7% received lenvatinib for 18 months\nor longer. In the sorafenib arm, 5.9% of subjects took study drug for 12 to 18 months and 6.9% received\nsorafenib for 18 months or longer. Because of the longer treatment duration in the lenvatinib arm, safety\ndata have been analysed by subject incidence and by number of episodes adjusted for SY of exposure to study drug [2].\nAs stated above, the exposure was 1.5-times longer with lenvatinib than with sorafenib. Therefore, TEAEs\nhave also been adjusted by treatment duration (\ntable 5.6).\n The rate of TEAE episodes adjusted for treatment duration was 18.89 episodes/SY and 19.73\nepisodes/SY for the lenvatinib and sorafenib arms, respectively.\n The rate of Grade ≥3 TEAEs adjusted by treatment duration in the lenvatinib and sorafenib arms was 3.16 and 3.33 episodes/SY, respectively.\n When adjusted by treatment duration, the overall rate of SAEs was 1.26 episodes/SY for the\nlenvatinib arm and 0.97 episodes/SY for the sorafenib arm.\n When adjusted by treatment duration, the rate of fatal AEs was 0.19 episodes/SY in the lenvatinib\nand 0.15 episodes/SY in the sorafenib arm [2].\nThe most frequently reported TEAEs (in >30% of subjects in either treatment arm) were hypertension, diarrhoea, decreased appetite, and weight decreased for lenvatinib and palmar-plantar\nerythrodysaesthesia syndrome, diarrhoea, and hypertension for sorafenib. These AEs are consistent with\nthe known safety profile of the two agents [2].\nTABLE 5.6: SUMMARY OF TEAES BY TREATMENT EXPOSURE (EPISODES/SY) - SAFETY ANALYSIS SET [2]\nAdverse events Lenvatinib Sorafenib\n(N=476) (N=475)\nTotal duration= 324.2 years n (AE rate) Total duration= 239.1 years n (AE rate)\nAny TEAE episodes 6,124 (18.89) 4,718 (19.73)\nRelated TEAE episodes 3,546 (10.94) 2,865 (11.98)\nAny TEAE ≥grade 3 episodes 1,023 (3.16) 795 (3.33)\nRelated TEAE ≥grade 3 episodes 517 (1.59) 430 (1.80)\nSerious AE episodes 409 (1.26) 232 (0.97)\nFatal serious TEAE episodes † 61 (0.19) 36 (0.15)\nNon-fatal serious TEAE episodes 379 (1.17) 207 (0.87)\n*8 mg and 12 mg were the lenvatinib starting doses based on the subjects’ body weight (<60 kg, ≥60 kg) at baseline; †Fatal AE\nepisodes were counted only once per patient, if more than one fatal AE was reported for the same patient.\nAbbreviations: AE, adverse event; HCC, hepatocellular carcinoma; TEAE, treatment-emergent adverse event.",
      "start_page": 76,
      "end_page": 78
    },
    {
      "heading": "Treatment discontinuation and dose reduction due to adverse events",
      "text": "As per the published article, treatment-related TEAEs led to lenvatinib drug interruption in 190 (40%) patients, dose reduction in 176 (37%) patients, and drug withdrawal in 42 (9%) patients. In the sorafenib\narm, treatment-related TEAEs led to drug interruption in 153 (32%) patients, dose reduction in 181 (38%), and drug withdrawal in 34 (7%) patients [1].\nNote published data related to AEs are different vs. the EMA’s scientific discussion. The published article\npresents treatment-related TEAEs leading to dose reduction while the EMA’s scientific discussion presents any TEAEs leading to treatment modification. This is also applicable to treatment discontinuation where the\npublished article presents treatment-related TEAEs leading to treatment discontinuation whereas EMA’s scientific discussion presents either any AEs as a primary reason(s) or any TEAEs leading to treatment\ndiscontinuation [1,2].\nProgression-free survival (PFS)\nFor PFS, censoring rules followed Food and Drug Administration (FDA) guidance [11], where patients were censored when they discontinued treatment for any reason other than disease progression.",
      "start_page": 78,
      "end_page": 78
    },
    {
      "heading": "Median progression-free survival",
      "text": "Lenvatinib treatment resulted in a statistically significant and clinically meaningful improvement in PFS compared with sorafenib. As shown in Figure 5.3, median PFS doubled with lenvatinib compared with\nsorafenib, 7.4 months vs 3.7 months, respectively (HR = 0.66; 95% CI of 0.57, 0.77; P<0.00001). Published\ndata and the EMA’s scientific discussion are in line regarding PFS [1,2].\nThe results of the analysis of PFS based on the FAS are supported by the results of the analysis based on the per protocol analysis set (PPS). For the PPS, the median PFS was 7.4 months for lenvatinib versus 3.7\nmonths for sorafenib (HR = 0.66; 95% CI of 0.57, 0.77; P<0.00001). This analysis was presented only in\nEMA’s scientific discussion [2].\nHR=hazard ratio.\nFIGURE 5.3: KAPLAN-MEIER CURVES AND ANALYSIS OF PROGRESSION-FREE SURVIVAL WITH STRATIFICATION\nFACTORS RECORDED IN THE IXRS - FAS [2]",
      "start_page": 78,
      "end_page": 79
    },
    {
      "heading": "Progression-free survival by subgroup",
      "text": "Median PFS was longer with lenvatinib than sorafenib in each of the subgroups tested. As seen in the\noverall population, lenvatinib treatment resulted in clinically meaningful improvement in PFS compared with sorafenib; the HR (lenvatinib:sorafenib) was <1 in each subgroup tested. A forest plot of HR for\nlenvatinib vs sorafenib in PFS with stratification factors in the IxRS appears in Figure 5.4 [1,2].\nFIGURE 5.4: FOREST PLOT OF PFS IN PATIENT SUBGROUPS - FAS [1]\nQuality of life\nAs HRQoL summary score measured at 1, 2 and 3 months have not been presented in the published article either in the EMA’s scientific discussion, that information requested on the provided protocol could not be\npresented [1,2].\nAssessments of health related quality of life (HRQoL) scores were performed using the generic cancer\nHRQoL instrument (EORTC QLQ-C30), the HCC-specific module (EORTC QLQ-HCC18), and the generic HRQoL instrument, EQ-5D [2].\nDuring the Randomization Phase, the EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D were administered at Baseline, Day 1 of each cycle after Cycle 1, and at the off-treatment visit. During the Extension Phase, the\nEORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D were administered on Day 1 of each treatment and during the off-treatment visit [2].\nBaseline scores on the EORTC QLQ-C30 and EORTC QLQ-HCC18 health questionnaires were similar in the lenvatinib and sorafenib treatment groups. Following treatment, scores declined in both groups. Analysis of\ntime to clinically meaningful deterioration showed that role functioning (nominal p=0.0193), pain (nominal\np=0.0105), and diarrhoea (nominal p<0.0001) from EORTC QLQ-C30, and nutrition (nominal p=0.0113) and\nbody image (nominal p=0.0051) from EORTC QLQ-HCC18 were observed earlier in patients treated with\nsorafenib than in those treated with lenvatinib. For between-group comparison, the summary score was\nnot significantly different between the treatment arms (HR 0.87, 95% CI 0.754–1.013) [1,2].\nHR, hazard ratio; LCL, lower control limit; QLQ-C30, quality-of-life questionnaire C30; UCL, upper control limit.\nFIGURE 5.5: HAZARD RATIO OF TIME TO CLINICALLY MEANINGFUL WORSENING OF EQ-5D, EORTC QLQ-C30\nDOMAINS [1]",
      "start_page": 79,
      "end_page": 81
    },
    {
      "heading": "5.1.3 Comparative analyses",
      "text": "As only one relevant study was identified through the literature research no additional comparative analysis has been conducted.\nAs per the previous section, lenvatinib has demonstrated the following:\n A proven overall survival benefit by statistical confirmation of non-inferiority versus sorafenib.\n A statistically significant and clinically meaningful benefit in terms of progression-free survival (PFS) compared with sorafenib.\n Results from the EORTC-QLQ (C30 and HCC18) show that lenvatinib treatment leads to a clinically meaningful and statistically significant delay in several Health Related Quality of Life (HRQoL)\ndomains, for role functioning, pain and diarrhoea, body image, and nutrition.\n In addition, the adverse event profile of lenvatinib is manageable and predictable.\nCurrently, there are limited systemic treatment options available for first line unresectable HCC patients.\nSorafenib is the only systemic agent that has been approved for first line treatment of advanced HCC.\nTherefore, there is a significant need for new treatments in advanced unresectable HCC that delay progression without negatively impacting patients’ HRQoL.",
      "start_page": 81,
      "end_page": 81
    },
    {
      "heading": "6 References",
      "text": "[1] Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line\ntreatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferiority trial. Lancet 2018;391:1163–73. doi:10.1016/S0140-6736(18)30207-1.\n[2] European Medicines Agency. Assessment report: Lenvima. London (UK): Committee for Medicinal\nProducts for Human Use (CHMP) 2018:Procedure Number: EMEA/H/C/003727/II/0011/G, EMA/5.\n[3] European Medicines Agency. Scientific Discussion: Nexavar. London (UK): Committee for Medicinal\nProducts for Human Use (CHMP) 2007.\n[4] Medicinrådet. Protokol for vurdering af den kliniske merværdi af lenvatinib til hepatocellulært\nkarcinom 2018:Document number: 26738 version 1.\n[5] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in Advanced\nHepatocellular Carcinoma. N Engl J Med 2008;359:378–90. doi:10.1056/NEJMoa0708857.\n[6] Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients\nin the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10:25–34. doi:10.1016/S1470-2045(08)70285-7.\n[7] Jackson R, Psarelli E-E, Berhane S, Khan H, Johnson P. Impact of Viral Status on Survival in Patients\nReceiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III\nTrials. J Clin Oncol 2017;35:622–8. doi:10.1200/JCO.2016.69.5197.\n[8] Silva JP, Gorman RA, Berger NG, Tsai S, Christians KK, Clarke CN, et al. The prognostic utility of\nbaseline alpha-fetoprotein for hepatocellular carcinoma patients. J Surg Oncol 2017;116:831–40.\ndoi:10.1002/jso.24742.\n[9] National Institute for Health and Care Excellence. Single Technology Appraisal: Lenvatinib for\nadvanced, unresectable, untreated hepatocellular carcinoma [ID1089]. London (UK): Committee\nPapers 2018.\n[10] European Medicines Agency. Guideline on adjustment for baseline covariates in clinical trials.\nLondon (UK): Committee for Medicinal Products for Human Use (CHMP)\n2015;44:EMA/CHMP/295050/2013.\n[11] Food and Drug Administration. Guidance for Industry Clinical Trial Endpoints for the Approval of\nCancer Drugs and Biologics. Rockville (U.S.): U.S. Department of Health and Human Services, Food\nand Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologi",
      "start_page": 82,
      "end_page": 82
    },
    {
      "heading": "Literature search",
      "text": "Based on the protocol, literature was searched in MEDLINE (via PubMed) and CENTRAL (via Cochrane\nLibrary) databases. Both indexed (eg Medical Subject Headings, MeSH) and Free Text Search has been used.\nThe searches include generic and trade name, combined with terms for the indication.",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "lenvatinib AND hepatocellular carcinoma",
      "text": "Lenvima AND hepatocellular carcinoma\nThe searches were conducted on 14th September 2018.\nSearch in MEDLINE covered time period from 1946 to date of search.\nSearch in CENTRAL covered time period from 1996 to date of search.\nInclusion and exclusion criteria\nThe criteria for selection of literature has been made based on the provided protocol and are presented in\nTable 7.1.\nTABLE 7.1: INCLUSION AND EXCLUSION CRITERIA\nInclusion criteria Population: Hepatocellular carcinoma\nIntervention OR Comparator: Lenvatinib\nOutcomes: Overall survival (OS) OR Adverse Events (AE) OR Progression-free survival\n(PFS) OR Quality of life\nStudy design: Randomized clinical trial, other than phase 1 trial\nExclusion criteria Population: Other than Hepatocellular carcinoma\nIntervention OR Comparator: No Lenvatinib\nOutcomes: Does not report effect goals\nStudy design: Not randomized clinical trial OR phase 1 trial\nSearches and results",
      "start_page": 83,
      "end_page": 83
    },
    {
      "heading": "lenvatinib AND hepatocellular carcinoma",
      "text": "(\"lenvatinib\"[Supplementary Concept] OR \"lenvatinib\"[All Fields]) AND (\"carcinoma, hepatocellular\"[MeSH\nTerms] OR (\"carcinoma\"[All Fields] AND \"hepatocellular\"[All Fields]) OR \"hepatocellular carcinoma\"[All\nFields] OR (\"hepatocellular\"[All Fields] AND \"carcinoma\"[All Fields]))\n1: Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi\nH, Hirooka M, Tsutsui A, Shibata H, Tada T, ToyodaH, Nouso K, Joko K, Hiasa Y, Michitaka K; Real-life\nPractice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from\n48 clinics in Japan). Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical\npractice: Multicenter analysis. Hepatol Res. 2018 Aug 24. doi: 10.1111/hepr.13243. [Epub ahead of print]\nPubMed PMID:30144256.\n2: Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma.Exp Hematol Oncol.\n(\"lenvatinib\"[Supplementary Concept] OR \"lenvatinib\"[All Fields] OR \"lenvima\"[All Fields]) AND\n(\"carcinoma, hepatocellular\"[MeSH Terms] OR (\"carcinoma\"[All Fields] AND \"hepatocellular\"[All Fields]) OR\n\"hepatocellular carcinoma\"[All Fields] OR (\"hepatocellular\"[All Fields] AND \"carcinoma\"[All Fields]))\nAs can be expected based on the PubMed search strategy shown above, the search with keywords\n“Lenvima” and “hepatocellular carcinoma” yielded the same results as the search with “lenvatinib” and\n“hepatocellular carcinoma”:\n1: Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi\nH, Hirooka M, Tsutsui A, Shibata H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K; Real-life\nPractice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from\n48 clinics in Japan). Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical\npractice: Multicenter analysis. Hepatol Res. 2018 Aug 24. doi: 10.1111/hepr.13243. [Epub ahead of print]\nPubMed PMID: 30144256.\n2: Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol.\n1. A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080)\nVersus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma,\nNCT01761266, Https://clinicaltrials.gov/show/nct01761266, 2013 | added to CENTRAL: 31 May 2018 |\n2018 Issue 5",
      "start_page": 83,
      "end_page": 96
    },
    {
      "heading": "CLINICAL TRIAL SUMMARY AT CLINICALTRIALS.GOV",
      "text": "2. P Gholam. The role of Sorafenib in hepatocellular carcinoma. Clinical advances in hematology &\noncology, 2015, 13(4), 232‐234 | added to CENTRAL: 30 June 2015 | 2015 Issue 6, Embase\n3. J-C Nault, PR Galle, JU Marquardt. The role of molecular enrichment on future therapies in\nhepatocellular carcinoma. Journal of hepatology, 2018, (no pagination) | added to CENTRAL: 30 June\n2018 | 2018 Issue 6, Embase\n4. S Hudgens, D Misurski, G Meier. Time to clinically meaningful worsening in hepatocellular carcinoma\npatients treated with lenvatinib or sorafenib. Value in health. Conference: ISPOR 20th annual european\ncongress. United kingdom, 2017, 20(9), A416 | added to CENTRAL: 31 January 2018 | 2018 Issue 1,\nEmbase",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "5. M Muller-Schilling. Hepatocellular carcinoma: epidemiology, risk factors and current treatment\nstrategies. Journal of gastrointestinal and liver diseases. Conference: 5th romanian-german symposium\nof gastroenterology. Romania, 2018, 27(Supplement 1), 24‐25 | added to CENTRAL: 31 August 2018 |\n2018 Issue 8, Embase",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "6. K-H Han, S Qin, F Piscaglia, J-W Park, D Komov, B-Y Ryoo, X OuYang, J-H Yoon, WY Tak, M Ren, D Stepan,\nT Tamai, CE Dutcus, A-L Cheng. Efficacy and safety of lenvatinib for unresectable hepatocellular\ncarcinoma in patients with baseline hepatitis B virus (HBV). Hepatology. Conference: 68th annual\nmeeting of the american association for the study of liver diseases, AASLD 2017. United states, 2017,\n66(Supplement 1), 740A‐741A | added to CENTRAL: 30 November 2017 | 2017 Issue 11, Embase",
      "start_page": 96,
      "end_page": 96
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "7. M Kudo, RS Finn, S Qin, K-H Han, K Ikeda, F Piscaglia, A Baron, J-W Park, G Han, J Jassem, JF Blanc, A\nVogel, D Komov, TRJ Evans, C Lopez, C Dutcus, M Guo, K Saito, S Kraljevic, T Tamai, M Ren, A-L Cheng.\nLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126), 1163‐1173 | added to\nCENTRAL: 30 June 2018 | 2018 Issue 6, Embase\n8. W Sun, R Cabrera. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular\nCarcinoma: emergence of Therapies. Journal of gastrointestinal cancer, 2018, 1‐9 | added to CENTRAL:\n30 April 2018 | 2018 Issue 4, Embase\n9. M Ikeda. Chemotherapy for hepatocellular carcinoma: molecular targeted agents, hepatic arterial\ninfusion chemotherapy or both? Annals of oncology. Conference: 15th annual meeting of japanese\nsociety of medical oncology, JSMO 2017. Japan, 2017, 28(Supplement 9), ix43 | added to CENTRAL: 31\nJanuary 2018 | 2018 Issue 1, Embase",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "10. S Hudgens, D Misurski, G Meier. Detrimental impact of toxicity on quality of life in hepatocellular\ncarcinoma patients treated with lenvatinibor sorafenib. Value in health. Conference: ISPOR 20th annual\neuropean congress. United kingdom, 2017, 20(9), A411‐A412 | added to CENTRAL: 31 January 2018 |\n2018 Issue 1, Embase",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "11. A Vogel, S Qin, M Kudo, S Hudgens, T Yamashita, J-H Yoon, L Fartoux, K Simon, CL Lopez, M Sung, CE\nDutcus, S Kraljevic, T Tamai, N Grunow, G Meier, V Breder. Health-related quality of life (HRQOL) and\ndisease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib\n(LEN) or sorafenib (SOR). Hepatology. Conference: 68th annual meeting of the american association for\nthe study of liver diseases, AASLD 2017. United states, 2017, 66(Supplement 1), 734A | added to\nCENTRAL: 30 November 2017 | 2017 Issue 11, Embase",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "12. A Vogel, S Qin, M Kudo, S Hudgens, T Yamashita, J-H Yoon, L Fartoux, K Simon, C Lopez Lopez, M Sung, C\nDutcus, S Kraljevic, T Tamai, N Grunow, G Meier, V Breder. Health-related quality of Life (HRQOL) and\ndisease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib\n(LEN) or sorafenib (SOR). Annals of oncology. Conference: 42nd ESMO congress, ESMO 2017. Spain,\n2017, 28(Supplement 5), v210 | added to CENTRAL: 31 January 2018 | 2018 Issue 1, Embase",
      "start_page": 97,
      "end_page": 97
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "13. A Vogel, S Qin, M Kudo, S Hudgens, T Yamashita, J Yoon, L Fartoux, K Simon, C Lopez, M Sung, C Dutcus,\nS Kraljevic, T Tamai, N Grunow, G Meier, V Breder. Health-related quality of life (HRQOL) and disease\nsymptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Value in health. Conference: ISPOR 20th annual european congress. United kingdom,\n2017, 20(9), A454‐A455 | added to CENTRAL: 31 January 2018 | 2018 Issue 1, Embase",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "14. A-L Cheng, RS Finn, S Qin, K-H Han, K Ikeda, F Piscaglia, A Baron, J-W Park, G Han, J Jassem, JF Blanc, A\nVogel, D Komov, TJ Evans, C Lopez, C Dutcus, M Ren, S Kraljevic, T Tamai, M Kudo. Phase 3 trial of\nlenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). Oncology research and treatment. Conference: jahrestagung der\ndeutschen, osterreichischen und schweizerischen gesellschaften fur hamatologie und medizinische onkologie 2017. Germany, 2017, 40(Supplement 3), 211 | added to CENTRAL: 30 November 2017 | 2017\nIssue 11, Embase",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "15. A-L Cheng, RS Finn, S Qin, K-H Han, K Ikeda, F Piscaglia, A Baron, J-W Park, G Han, J Jassem, JF Blanc, A\nVogel, D Komov, TRJ Evans, C Lopez, C Dutcus, M Ren, S Kraljevic, T Tamai, J Bower, M Kudo. Phase III\ntrial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (PTS)with unresectable hepatocellular carcinoma (uHCC). Asia-pacific journal of clinical oncology. Conference: 44th annual\nscientific meeting of the clinical oncology society of australia, COSA 2017. Australia, 2017,\n13(Supplement 4), 116 | added to CENTRAL: 31 January 2018 | 2018 Issue 1, Embase",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "16. RS Finn, M Kudo, A-L Cheng, L Wyrwicz, R Ngan, J-F Blanc, AD Baron, A Vogel, M Ikeda, F Piscaglia, K-H\nHan, S Qin, Y Minoshima, Y Funahashi, M Ren, R Dairiki, P Sachdev, T Tamai, C Dutcus, TRJ Evans.\nAnalysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib\n(SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC). Annals of oncology.\nConference: 42nd ESMO congress, ESMO 2017. Spain, 2017, 28(Supplement 5), v617 | added to\nCENTRAL: 31 January 2018 | 2018 Issue 1, Embase",
      "start_page": 98,
      "end_page": 98
    },
    {
      "heading": "CONFERENCE ABSTRACT",
      "text": "17. A Ribeiro de Souza, M Reig, J Bruix. Systemic treatment for advanced hepatocellular carcinoma: the\nsearch of new agents to join sorafenib in the effective therapeutic armamentarium. Expert opinion on\npharmacotherapy, 2016, 17(14), 1923‐1936 | added to CENTRAL: 30 November 2016 | 2016 Issue 11,\nEmbase\n18. J Furuse. Current status and clinical trials in progress of chemotherapy for unresectable hepatobiliary\nand pancreatic cancers in Japan. Journal of hepato-biliary-pancreatic sciences. Conference: joint\ncongress of the 6th biennial congress of the asian-pacific hepato-pancreato-biliary association and the\n29th meeting of japanese society of hepato-biliary-pancreatic surgery. Japan, 2017, 24, A16 | added to\nCENTRAL: 30 September 2017 | 2017 Issue 9, Embase",
      "start_page": 98,
      "end_page": 99
    },
    {
      "heading": "Lenvima AND hepatocellular carcinoma",
      "text": "Search yielded 0 results",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "Exclusion",
      "text": "The articles listed below were excluded because they met at least one of the following exclusion criteria:\n- not a randomized clinical trial\n- phase 1 trial\n- population other than selected\n- did not report at least one of the critical or important effect goals.",
      "start_page": 99,
      "end_page": 99
    },
    {
      "heading": "PubMed",
      "text": "1: Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi\nH, Hirooka M, Tsutsui A, Shibata H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K; Real-life\nPractice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from\n48 clinics in Japan). Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical\npractice: Multicenter analysis. Hepatol Res.2018 Aug 24. doi: 10.1111/hepr.13243.\nReason for exclusion: Open label retrospective multicenter analysis. Not a randomized controlled trial\n2: Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol.\n1: P Gholam. The role of Sorafenib in hepatocellular carcinoma. Clinical advances in hematology &",
      "start_page": 99,
      "end_page": 105
    },
    {
      "heading": "oncology, 2015, 13(4), 232‐234. | added to CENTRAL: 30 June 2015 | 2015 Issue 6, Embase.",
      "text": "Reason for exclusion: Review article / expert interview. Not a randomized controlled trial.\n2: J-C Nault, PR Galle, JU Marquardt. The role of molecular enrichment on future therapies in hepatocellular",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "carcinoma Journal of hepatology, 2018, (no pagination) | added to CENTRAL: 30 June 2018 | 2018 Issue 6,",
      "text": "Embase\nReason for exclusion: Review article. Not a randomized controlled trial.\n3: W Sun, R Cabrera. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "Carcinoma: emergence of Therapies. Journal of gastrointestinal cancer, 2018, 1‐9 | added to CENTRAL: 30",
      "text": "April 2018 | 2018 Issue 4, Embase\nReason for exclusion: Review article. Not a randomized controlled trial.\n4: A Ribeiro de Souza, M Reig, J Bruix. Systemic treatment for advanced hepatocellular carcinoma: the\nsearch of new agents to join sorafenib in the effective therapeutic armamentarium. Expert opinion on",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "pharmacotherapy, 2016, 17(14), 1923‐1936 | added to CENTRAL: 30 November 2016 | 2016 Issue 11,",
      "text": "Embase\nReason for exclusion: Review article. Not a randomized controlled trial.",
      "start_page": 105,
      "end_page": 105
    },
    {
      "heading": "PRISMA",
      "text": "P\nn\no\nit\na\nc\nif\nit\nn\ne\nd",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "I",
      "text": "g\nn\nin\ne\ne\nr\nc\nS",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "y",
      "text": "t\nilib\nig\nilE\nd\ne\nd\nu\nlc\nn",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "I",
      "text": "Applica\nA flow",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "PRIS",
      "text": "ation\nw charts\nSMA 20\nReco\ndatabas\nsear\nhepatoce\nAND he n form ve\n009 Flow ords identifi\nse searching rches: lenva\nellular carci epatocellula\n(n = 86 rsion 2.0\nw Diagra ied through\ng (two Pubm atinib AND\nnoma; Lenv\nar carcinom\nRecords\nFull\nam for Pub h\nmed\nvima\nma)\ns after duplicates\n(n = 43)\nRecords screene\n(n = 43) l-text articles asse",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "for eligibility",
      "text": "(n = 43)\nStudies included\n(n = 1)\nbMed\nAddi\nth\ns remo ed\nessed\nd\nd (M itiona\nhroug\noved\nd\nMedl\nal reco gh othe\n(n =\nline\nords id er sou\nF\ne) se dentifie\nurces\nRe\nFull-tex\nearch\ned\necords exclu\n(n = 0) xt articles e\nwith reason\n(n = 42)\nPag\nuded\nexclud\nns\nge 48 o\nded,\nof 58\nPR\nn\no\nit\na\nc\nif\nit\nn\ne",
      "start_page": 106,
      "end_page": 107
    },
    {
      "heading": "I",
      "text": "g\nn\nin\ne\ne\nr\nc\nS",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "y",
      "text": "t\nilib\nig\nilE",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "d",
      "text": "e",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "d",
      "text": "u\nlc\nn",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "I",
      "text": "Applica",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "RISM",
      "text": "ation\nMA 2009\nReco",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "databas",
      "text": "sear\nhepatoce\nAND he n form ve",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "9 Flow D ords identifi",
      "text": "se searching rches: lenva\nellular carcin epatocellula\n(n = 18 rsion 2.0\nDiagram",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "ied through g (two Pubm",
      "text": "atinib AND noma; Lenv\nar carcinom",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Records",
      "text": "Full\nm for Cochra h",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "med",
      "text": "vima\nma)",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "s after duplicates",
      "text": "(n = 18)",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Records screene",
      "text": "(n = 18) l-text articles asse",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "for eligibility",
      "text": "(n = 5)",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Studies included",
      "text": "(n = 1)\nane",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Addi",
      "text": "th",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "d",
      "text": "e Libr itiona\nhroug",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "rary",
      "text": "al reco gh othe\n(n =",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "y CEN ords id",
      "text": "er sou\nF\nNTR",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "dentifie",
      "text": "urces\nRe\nFull-tex",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "ecords exclu",
      "text": "(n = 13) xt articles e\nwith reason\n(n = 4)\nPag\nrch",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "exclud",
      "text": "ns\nge 49 o",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "ded,",
      "text": "of 58",
      "start_page": 107,
      "end_page": 107
    },
    {
      "heading": "Main characteristics of included studies",
      "text": "Study characteristics\nTABLE 7.2: MAIN STUDY CHARACTERISTICS\nTrial name REFLECT study (304, NCT01761266)\nNCT number 01761266\nObjective The aim was to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular\ncarcinoma.\nPublications – title, Lenvatinib versus sorafenib in first-line treatment of patients with author, journal, year unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority\ntrial, Kudo, M., Finn, R.S., Qin, S., et al. Lancet 2018\nStudy type and design A multicentre, randomised, open-label, non-inferiority Phase III trial.\nComparator-controlled (sorafenib).\nPatients were randomly assigned (1:1) via an interactive voice–web response\nsystem—with region; macroscopic portal vein invasion, extrahepatic spread,\nor both; Eastern Cooperative Oncology Group performance status; and\nbodyweight as stratification factors.\nFollow-up time March 01, 2013 - November 13, 2016 (at 701 deaths)\nThe median duration of follow-up was 27.7 months (IQR 23.3–32.8) in the\nlenvatinib group and 27.2 months (22.6–31.3) in the sorafenib group.\nPopulation (inclusion and\nInclusion Criteria exclusion criteria)\n1. Subjects must have confirmed diagnosis of unresectable HCC with any\nof the following criteria:\no Histologically or cytologically confirmed diagnosis of HCC o Clinically confirmed diagnosis of HCC according to American\nAssociation for the Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology or with chronic hepatitis B\nor C infection criteria\n2. At least one measurable target lesion according to mRECIST meeting\nthe following criteria:\no Hepatic lesion\n1. The lesion can be accurately measured in at least one\ndimension as greater than or equal to 1.0 cm (viable\ntumor for typical; and longest diameter for atypical),\nand\n2. The lesion is suitable for repeat measurement\no Nonhepatic lesion c. Lymph node (LN) lesion that measures at\nleast one dimension as greater than or equal to 1.5 cm in the\nshort axis, except for porta hepatis LN that measures greater\nAp\npplica\nation\nn form\nm ve\nthan or equal to 2.0 cm in the short axis d. Non-nodal lesion\nthat measures greater than or equal to 1.0 cm in the longest\ndiameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of\ndisease progression to be deemed a target lesion.\n3. Subjects categorized to stage B (not applicable for transarterial\nchemoembolization [TACE]) or stage C based on Barcelona Clinic Liver\nCancer (BCLC) staging system\n4. Adequate bone marrow function, defined as:\no Absolute neutrophil count (ANC) greater than or equal to 1.5 X\n10^9/L\no Hemoglobin (Hb) greater than or equal to 8.5 g/dL\no Platelet count greater than or equal to 75 X 10^9/L\n5. Adequate liver function, defined as:\no Albumin greater than or equal to 2.8 g/dL\no Bilirubin less than or equal to 3.0 mg/dL\no Aspartate aminotransferase (AST), alkaline phosphatase (ALP), and alanine aminotransferase (ALT) less than or equal to 5 X\nthe upper limit of normal (ULN)\n6. Adequate blood coagulation function, defined as international\nnormalized ratio (INR) less than or equal to 2.3\n7. Adequate renal function defined as creatinine clearance greater than\n40 mL/min calculated per the Cockcroft and Gault formula\n8. Adequate pancreatic function, defined as amylase and lipase less than\nor equal to 1.5 X ULN\n9. Adequately controlled blood pressure (BP) with up to 3\nantihypertensive agents, defined as BP less than or equal to 150/90 mm Hg at Screening and no change in antihypertensive therapy within\n1 week prior to the Cycle1/Day1\n10. Child-Pugh score A\n11. ECOG-PS 0 or 1\n12. Survival expectation of 12 weeks or longer after starting study drug\n13. Males or females aged at least 18 years (or any age greater than 18\nyears as determined by country legislation) at the time of informed consent\n14. Females must not be lactating or pregnant at Screening or Baseline (as\ndocumented by a negative beta-human chorionic gonadotropin [BhCG] test with a minimum sensitivity of 25 IU/L or equivalent units of\nB-hCG). A separate baseline assessment is required if a negative\nscreening pregnancy test was obtained more than 72 hours before the first dose of study drug.\n15. All females will be considered to be of childbearing potential unless\nthey are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without other known or\nPage 51 of 58 rsion 2.0\nAp\npplica\nation\nn form\nm ve\nsuspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with\nsurgery at least 1 month before dosing)\n16. Females of childbearing potential must not have had unprotected\nsexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total\nabstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an\noral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after\nstudy drug discontinuation. If currently abstinent, the subject must\nagree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after\nstudy drug discontinuation. Females who are using hormonal\ncontraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and must\ncontinue to use the same contraceptive during the study and for 30 days after study drug discontinuation.\n17. Male subjects must have had a successful vasectomy (confirmed\nazoospermia) or they and their female partners must meet the criteria above (i.e., not of childbearing potential or practicing highly effective\ncontraception throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study\nperiod and for 30 days after study drug discontinuation.\n18. Provide written informed consent\n19. Willing and able to comply with all aspects of the protocol\nExclusion Criteria\n1. Imaging findings for HCC corresponding to any of the following:\no HCC with greater than or equal to 50 percent liver occupation o Clear invasion into the bile duct\no Portal vein invasion at the main portal branch (Vp4)\n2. Subjects who have received any systemic chemotherapy, including\nanti-VEGF therapy, or any systemic investigational anticancer agents, including lenvatinib, for advanced/unresectable HCC. Note: Subjects\nwho have received local hepatic injection chemotherapy are eligible.\n3. Subjects who have received any anticancer therapy (including surgery,\npercutaneous ethanol injection, radio frequency ablation, transarterial\n[chemo] embolization, hepatic intra-arterial chemotherapy, biological, immunotherapy, hormonal, or radiotherapy) or any blood enhancing\ntreatment (including blood transfusion, blood products, or agents that stimulate blood cell production, eg, granulocyte colony-stimulating\nfactor [G-CSF]) within 28 days prior to randomization\n4. Subjects who have not recovered from toxicities as a result of prior\nanticancer therapy, except alopecia and infertility. Recovery is defined\nas less than Grade 2 severity per Common Terminology Criteria for\nPage 52 of 58 rsion 2.0\nAp\npplica\nation\nn form\nm ve\nAdverse Events Version 4.0 (CTCAE v4.0).\n5. Significant cardiovascular impairment: history of congestive heart\nfailure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of\nthe first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening\n6. Prolongation of QTc interval to greater than 480 ms\n7. Gastrointestinal malabsorption or any other condition that might\naffect the absorption of lenvatinib in the opinion of the investigator\n8. Bleeding or thrombotic disorders or use of anticoagulants requiring\ntherapeutic INR monitoring, eg, warfarin or similar agents. Treatment\nwith low molecular weight heparin and factor X inhibitors which do not require INR monitoring is permitted. Antiplatelet agents are\nprohibited throughout the study.\n9. Gastrointestinal bleeding event or active hemoptysis (bright red blood\nof at least 0.5 teaspoon) within 28 days prior to randomization\n10. Gastric or esophageal varices that require interventional treatment\nwithin 28 days prior to randomization. Prophylaxis with pharmacologic\ntherapy (eg, nonselective beta-blocker) is permitted.\n11. Active malignancy (except for HCC or definitively treated melanoma\nin-situ, basal or squamous cell carcinoma of the skin, or carcinoma insitu of the cervix) within the past 36 months\n12. Subjects whose only target lesion(s) is in bone will be excluded\n13. Meningeal carcinomatosis\n14. Any history of or current brain or subdural metastases\n15. Subjects having greater than 1+ proteinuria on urine dipstick testing\nwill undergo a 24-hour urine collection for quantitative assessment of proteinuria. Subjects with a urine protein greater than or equal to 1\ng/24 hours will be ineligible.\n16. Surgical arterial-portal venous shunt or arterial-venous shunt\n17. Any medical or other condition that in the opinion of the investigator\nwould preclude the subject's participation in a clinical study\n18. Known intolerance to lenvatinib or sorafenib (or any of the excipients)\n19. Human immunodeficiency virus (HIV) positive or active infection\nrequiring treatment (except for hepatitis virus)\n20. Any history of drug or alcohol dependency or abuse within the prior 6\nmonths\n21. Any subject who cannot be evaluated by either triphasic liver CT or\ntriphasic liver MRI because of allergy or other contraindication to both\nCT and MRI contrast agents\n22. Major surgery within 3 weeks prior to randomization or scheduled for\nsurgery during the study\nPage 53 of 58 rsion 2.0\nInterve\nBaseline\nPrimary\nendpo\nMethod\nApplica\nentio\ne char y and\nints\nd of ation\non\nracte\nseco\nanal\nn form\nristic\nonda\nlysis\nm ve",
      "start_page": 108,
      "end_page": 112
    },
    {
      "heading": "23. Subject has had a liver transplant",
      "text": "Lenvatinib (n=478): 12 mg/day for bodyweight ≥60 kg or 8 mg/day for\nbodyweight <60 kg oral dosing\nSorafenib (n=476): 400 mg twice daily (BID) oral dosing\n28-days cycles cs Patient baseline characteristics were similar between treatment groups,\nexcept for baseline hepatitis C aetiology (lenvatinib 91 (19 %) and sorafenib\n126 (26 %)) and α-fetoprotein concentrations median (IQR) (lenvatinib 133.1\nand sorafenib 71.2 ng/mL).\nAge: median 62 years (range 20-88)\nSex: male 84 %, female 16 %\nBodyweight: < 60 kg 31 %, ≥ 60 kg 69 %\nRegion: Western 33 %, Asia-Pacific 67 %\nRace: White 29 %, Asian 69 %, Other 2 %\nEastern Cooperative Oncology Group performance status: 0 63 %, 1 37 %\nChild-Pugh class A 99 %, B 1 %\nMacroscopic portal vein invasion: yes 21 %, no 79 %\nExtrahepatic spread: yes 61 %, no 39 %\nMacroscopic portal vein invasion, extrahepatic spread, or both: Yes 61 %, No\nUnderlying cirrhosis based on masked independent imaging review: Yes 70 %,\nNo 30 %\nBarcelona Clinic Liver Cancer stage: B (intermediate stage) 21 %, C (advanced\nstage) 79 %\nInvolved disease sites: Liver 91 % , Lung 32 %\nInvolved disease sites per patient: One patient had no baseline target lesion, 1\nAetiology of chronic liver disease: Hepatitis B 50 %, Hepatitis C 23 %, Alcohol 6\n%, Other 7 %, Unknown 14 %\nBaseline α-fetoprotein concentration group (ng/mL): <200 57 %, ≥200 43 %\nConcomitant systemic antiviral therapy for hepatitis B or C: 33 %\nPrevious anticancer procedures: 70 %\nPrevious radiotherapy: 11 %\nry The primary endpoint was overall survival (OS) measured from the date of randomisation until the date of death from any cause.\nSecondary endpoints were progression-free survival (PFS), time to progression\n(TPP), objective response rate (ORR), quality-of-life measurements (HRQoL), and plasma pharmacokinetics lenvatinib exposure parameters.\nThe efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis.\nThe primary endpoint of overall survival was first tested for non-inferiority, then for superiority. Using a non-inferiority test by the 95% CI lower-limit\nmethod on log HR for overall survival with assumed true HR of 0·80 and a noninferiority margin of 1·08.\nPage 54 of 58 rsion 2.0\nSu\nAp\nbgro\npplica\noup a ation\nanaly\nn form\nyses\nm ve\nHR and 95% CI were estimated from a Cox proportional hazard model with treatment group as a factor, and with the analysis stratified according to the\nsame factors applied for randomisation for primary and subgroup analyses where appropriate.\nA fixed sequence procedure was used to control the overall type I error rate of analyses for both the primary and secondary efficacy endpoints at α=0·05\n(two-sided).\nDifferences in progression-free survival and time to progression were evaluated using a stratified log-rank test with randomisation stratification\nfactors, with the associated HR and 95% CI.\nA difference in the objective response rate was evaluated using the Cochran-\nMantel-Haenszel χ² test with randomisation stratification factors as strata, with associated odds ratio (OR) and 95% CI.\nTo assess futility, two interim analyses (at 30% and 70% of the target number of events) were done using Bayesian predictive probability in a non-inferiority\ndesign.\nProgramming and statistical analyses were done with SAS version 9 or higher.\nFor the subgroup analysis, the analyses mentioned above were done within each subgroup: Age, Sex, Region, ECOG-PS, Bodyweight, Macroscopic portal\nvein invasion, AFP at baseline, Aetiology, Barcelona Clinic Liver Cancer staging,\nPost-treatment anticancer therapy, Post-treatment anticancer procedures,\nPost-treatment anticancer medication.\nPage 55 of 58 rsion 2.0\nResults per study\nNote the table below has been difference (Lenva-Sora) and estim\nTABLE 7.3: RESULTS OF STUDY [1]\nOutcome Study arm N\nLenvatinib 478\nMedian overall survival\nSorefenib 476\nLenvatinib 478\n12 months survival rate Sorefenib 476\n24 months Lenvatinib 478 survival rate Sorefenib 476\nTreatment 324.\nLenvatinib\nrelated grade 3- year\n5 TEAEs adjusted by 239.\nSorefenib\nsubject year year\n(SY)\nPercentage of Lenvatinib 476 patients with\ntreatmentrelated TEAEs\nSorefenib 475 leading to drug\nwithdrawal\nPercentage of Lenvatinib 476 patients with Sorefenib 475\nupdated following questions from the auth mated relative difference in effect.\nDifference\nResult (CI)\n(Lenva-Sora)\n1.3 months\nmonths\nCI: (-0.9, 3.4)\nmonths\nmonths\nrs (AE rate diff)\nCI: (-0.42,0.01)\n.1 (CI for the AE rat\nrs diff)\n34 [7%] CI: (-2%, 5%)\n181 [38.1%] CI: (-7%, 5%)\nhorities received on the 22.10.18 and the 02.11.18 to provide values for\nEstimated relative Source in the\nComments\ndifference in effect submission\nHR: 0.92 Figue 5.1\nDiff (Lenva-Sora)\nCI: 0.79-1.06 Table 5.1\nHR and 95% CI were estimated from a Cox\nHR: 0.92\nproportional hazard model Table 5.1\nCI: 0.79-1.06\nwith treatment group as a factor.\nHR: 0.92 Difference adjusted to\nTable 5.1\nCI: 0.79-1.06 account for rounding\nThe Rate Ratio and its C.I. Section\nRate Ratio: 0.89\n) are calculated under the ”Qualitative\nCI: (0.78, 1.01)\nte assumption of Poisson review of adverse\nDistribution. events”\nSection\nRelative Risk: “Treatment\nRR: relative risk calculated\n1.233 discontinuation\nas\nCI: (0.799,1.902) and dose\nreduction due to adverse events”\nRelative Risk: RR: calculated as Section\n0.970 (176/476)/(181/475)=0.970 “Treatment\ntreatmentrelated TEAEs leading to dose\nreduction\nLenvatinib 478\nProgressionfree survival\nSorefenib 476\nQuality of life\nSummrary score for betweengroup\ncomparison for time to clinically\nmeaningful\nworsening of\nEQ-5D, EORTC\nQLQ-C30\ndomains\n7.4 (6.9-8.8) mon\n3.7 (3.6-4.6) mon\nHR: 0.87\nCI: 0.75–1.01\nP value: 0.0742\nths\n3,7 months\nCI: (2.5, 4.8) mont\nths\nCI: (0.824,1\nHR: 0.6\nCI: 0.57–0\nths\nP value: <0\nDifferences were evalu using a stratified log-r\ntest with randomisa\nstratification\nfactors, with the associ\nHR and 95% CI.\ndiscontinuation\nand dose reduction due to\nadverse events” uated\nrank\ntion\nFigure 5.3\niated\nFigure 5.5",
      "start_page": 112,
      "end_page": 115
    },
    {
      "heading": "Results per PICO (clinical question)",
      "text": "Not applicable\nResults referring to clinical ques\nstion 1 are presen\nnted in Table 7.3.\nApplication for the assessment of clinically added value of LENVIMA for Hepatocellular Carcinoma in Denmark\nResponse to questions from DMC received 02.11.18\nQuestions from DMC: we have noted the following:\n1. The CI interval for the relative effect estimate for the outcome “Percentage of patients\nwith treatment-related TEAEs leading to drug withdrawal” is missing. Please provide the\nconfidence interval.\n2. The CI interval for the absolute effect estimate for the outcome “ Treatment related grade\n3-5 TEAEs adjusted by subject year (SY)” is missing. Please provide the confidence interval.\n3. The CI interval for the relative effect estimate for the outcome “Percentage of patients\nwith treatment-related TEAEs leading to dose reduction” is missing. Please provide the\nconfidence interval.\n4. The method for censoring results for PFS is still not clear. Please provide a description on\nhow PFS was censored.\nIf any of the above points is in fact included in your application, please let me know where.\nResponse for questions 1 to 3\nTable 7.3 in the application document has been corrected by our statistics team who ensured all\nappropriate values are provided in the relevant columns “difference Lenva-Sora” and “Estimated relative difference in effect”. If however there is a need for further clarification please do not\nhesitate contact us.",
      "start_page": 116,
      "end_page": 117
    },
    {
      "heading": "Response for question 4",
      "text": "For PFS, censoring rules followed Food and Drug Administration (FDA) guidance (35), where patients were censored when they discontinued treatment for any reason other than disease progression.\nThe PFS censoring rules in the statistical analysis plan (SAP) and definition of progression date follow the Food and Drug Administration (FDA) “Guidance for Industry Clinical Trial Endpoints for the\nApproval of Cancer Drugs and Biologics (2007)” as stated above. To provide further clarity to the\nauthorities, the wording below has been extracted from the statistical plan. We also attach the FDA\ndocument for your reference.\nDefinition of Progression Date: Progression date is assigned to the first time at which radiological\nprogression can be declared (in line with appendix 2 from FDA document).\nFor progression based on a new lesion, the progression date is the date of the initial detection of the new lesion, if there were multiple new lesions detected, then the earliest date of initial\ndetection will be used.\n If multiple assessments based on the sum of target lesion diameters are done at different times, the progression date is the date of the first radiological assessment of target\nlesions that shows a predefined increase of ≥ 20% against the nadir (the smallest sum of target lesion diameters among baseline and post-baseline tumor assessments) in the sum",
      "start_page": 117,
      "end_page": 117
    },
    {
      "heading": "of the target lesion diameters which also must demonstrate at least 5mm absolute increase.",
      "text": " If progression is based on only non-target lesions, the progression date is the date of the first radiological assessment of non-target lesions for the time point that shows\nprogression.",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "Censoring Rules for Analysis of Progression-Free Survival (in line with appendix 3 from the FDA guidelines)",
      "text": "CR = complete response, PD = progressive disease, PR = partial response, SD = stable disease,\n* Adequate tumor assessment is a radiologic assessment of CR, PR, SD, non-CR/non-PD or PD as determined by investigators.\n** More than one missed visit is defined if the duration between the last tumor assessment and death or PD is longer than 16 weeks + 2 weeks (i.e. the date of death or PD – the date of last adequate tumor assessment > 125 days) for subjects on the every 8 week scanning\nschedule in this study: The priority of the censoring rules is as follows:\n1. If the subject had PD or death, the following sequence will be applied:\n If a subject did not have baseline tumor assessment (No. 1), the subject will be censored on date of randomization. However, if\nthe subject died within 56 days (8 weeks) after randomization and did not receive new anticancer treatment, the date of death will be the PFS event date (not censored).\n If a subject had new anticancer treatment before PD or death (No. 4), the subject will be censored on the date of the last tumor\nassessment prior to or on the date of new anticancer treatment.\n If a subject missed more than one assessment before PD or death (No. 7), the subject will be censored on the date of the last\ntumor assessment before PD or death. Note that if a subject is censored by both this criterion and the anticancer treatment\ncriteria, the earliest censoring date will be used.\n Otherwise, if a subject had an event (No. 2, No. 5, or No. 6), the earliest event date will be used.\n2. If a subject did not have PD or death, the censoring date will be the earliest censoring date if the subject met multiple censoring criteria\n(No. 1, No. 3, No. 4, No. 7).",
      "start_page": 118,
      "end_page": 118
    },
    {
      "heading": "Response to draft Clinical Impact Assessment of Medicinal Products for lenvatinib for the treatment of hepatocellular carcinoma (12/12/2018)",
      "text": "Please find enclosed Eisai’s response to the draft clinical impact assessment of lenvatinib in hepatocellular carcinoma (HCC). We would like to supplement our application with additional evidence from, and further\nclarification of, the REFLECT clinical trial results, that show the added clinical value of lenvatinib in the treatment of HCC.\nThe systematic literature review (SLR) has been updated in accordance with guidelines to include all relevant analyses of efficacy and safety from the REFLECT clinical study. The updated protocol and results\nare provided as an appendix to this response and all full text references are included in a separate folder\n(References/SLR References).\nA statement of expert opinion from a clinical expert is also enclosed to provide additional evidence.",
      "start_page": 119,
      "end_page": 119
    },
    {
      "heading": "1. Summary: REFLECT quality of evidence",
      "text": "The Medicines Council used the Cochrane GRADE approach to evaluate evidence quality from the\nREFLECT study. According to the Medicine Council’s assessment report, the open-label nature of REFLECT\nimpacted the level of evidence quality with respect to:\n- Blinding of subjects (performance bias) - adverse events and health-related quality of life (HRQoL)\n- Blinding of outcome assessment (detection bias) - adverse events and HRQoL\nAn open-label design was necessary in the interests of patient safety because dose modification guidelines due to toxicity were different for lenvatinib and sorafenib for the same toxicities. In addition, the differences in\nformulation between lenvatinib (capsule) and sorafenib (tablet) would have required preparation of multiple matching placebo capsules or tablets to permit dose reductions. This would have been confusing for very ill\npatients and would have resulted in a high risk for dosing errors.\nNevertheless, REFLECT provides reliable direct comparative safety and efficacy data from a robust, large, multinational, randomised Phase 3 study versus the only relevant approved comparator in first line treatment\nfor advanced unresectable HCC. Furthermore, the applicant created a Data Integrity Protection Plan, which\nensured that relevant data fields were masked so that the clinical and statistical team members were blinded to treatment for each patient in order to minimise bias. In addition, it is stated in the European\nPharmaceutical Assessment Report (EPAR) that the trial was well–conducted. Very few randomised subjects",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "were not treated (3 in total) and the rate of major protocol deviations was low (2.5%) and balanced across",
      "text": "the treatment arms.",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "It is however important to note that there were some baseline characteristic imbalances with respect to prognostic factors: a greater proportion with baseline alpha-fetoprotein (AFP) >200 ng/ml in the lenvatinib",
      "text": "arm and more subjects with underlying hepatitis C in the sorafenib arm. The EPAR recognised that both of\nthese imbalances may favour the sorafenib arm. Further details are provided in the overall survival section\nThe Medicines Council noted incomplete data for progression-free survival (PFS) due to FDA-preferred analysis used for reporting this efficacy outcome. This has been addressed in the progression-free survival",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "section 2.3.",
      "text": "The sparsity of published results for HRQoL was also highlighted by the Council. The primary manuscript (1)\ndid not include full reporting of HRQoL data from the REFLECT study. However, multiple additional\npublished studies are available and these studies have now been included in the updated SLR.\nSignificantly, despite the open-label study design, baseline scores for all domains were similar at baseline,\n>98% patients completed the questionnaires at each time point, and a separate statistical analysis plan",
      "start_page": 120,
      "end_page": 120
    },
    {
      "heading": "2.1. Overall survival",
      "text": "Medicines council draft assessment report:\nLenvatinib has demonstrated overall survival benefit by statistical confirmation of non-inferiority when compared with sorafenib in the Phase III REFLECT trial. Whilst overall survival (OS) was numerically higher",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "in the lenvatinib group (13.6 months) than the sorafenib group (12.3 months [hazard ratio (HR) 0.92, 95%",
      "text": "confidence interval (CI): 0.79–1.06]), as highlighted in Medicinrådets’ assessement report, the difference was\nnot large enough to confirm statistical superiority of lenvatinib.\nREFLECT included the following stratification factors:\n Region: Region 1 (Asia-Pacific); Region 2 (Western regions, such as EU, North America, other)\n Macroscopic portal vein invasion or extrahepatic spread or both: Yes; No\n Eastern Cooperative Oncology Group Performance Status (ECOG PS): PS = 0; PS = 1\n Body weight: <60 kg; ≥60 kg\nIn order not to compromise the robustness of the data, it was not possible to include alpha-fetoprotein (AFP) as an additional stratification factor. However, the statistical analysis plan (SAP) allowed for baseline\ncharacteristics to be used as covariates in supportive analyses for the endpoints.\nDemographics and baseline characteristics were generally well balanced between the lenvatinib and sorafenib treatment arms of the study, however there were notable exceptions A greater proportion of\npatients had baseline AFP >200 ng/ml (a marker of poor HCC prognosis (2)) in the lenvatinib arm and more subjects with underlying hepatitis C in the sorafenib arm These baseline imbalances had the potential to\nimpact OS in the overall study population in favour of sorafenib. As provided for in the SAP, covariate\nadjustment was used to explore the impact on overall survival. After adjustment for baseline AFP, lenvatinib",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "respectively; HR 0.856 [95% CI:0.736, 0.995], p=0.0342) (1).",
      "text": "Furthermore, there was an imbalance between treatment arms regarding the proportion of patients who received post-treatment anti-cancer therapy during survival follow-up. Fewer patients in the lenvatinib (LEN)",
      "start_page": 121,
      "end_page": 121
    },
    {
      "heading": "arm (43.1%) had post-treatment anti-cancer therapy than patients in the sorafenib (SOR) arm (51.1%) which",
      "text": "may have favoured sorafenib. In the subgroup analysis for efficacy, patients who had post-treatment\nanticancer therapy had a numerically longer overall survival (LEN 19.5 vs SOR 17.0 months) compared to\npatients that did not (LEN 10.5 vs SOR 7.9 months)\nConsidering the effect of post-treatment therapy on overall survival and the imbalance between arms, a posthoc adjustment was conducted and the resulting hazard ratios published in the EPAR. When adjusted for\npost-treatment anticancer therapy, the HR for OS favoured lenvatinib in both regions and in the ITT\npopulation the HR for lenvatinib versus sorafenib reduced to 0.87 (95% CI: 0.75 - 1.01) in the adjusted\nanalysis compared with 0.92 (95% CI 0.79- 1.06) in the unadjusted analysis.",
      "start_page": 121,
      "end_page": 122
    },
    {
      "heading": "Supplementary multivariate analysis on overall survival",
      "text": "Current EMA guidance on adjustment for baseline characteristics in clinical trials suggests that in the presence of imbalances for strong predictors of outcomes, adjustment for such covariates generally\nimproves the precision and efficiency of the analysis and avoids conditional bias from chance covariate imbalance (3). Therefore the applicant conducted a post-hoc supplementary multivariable analysis to\nsimultaneously adjust for all relevant prognostic baseline characteristics which may have impacted overall survival. This analysis is planned to be published and therefore is not included in this document so as not\nto compromise the publication.",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "Statistical survival analysis extrapolation of overall survival",
      "text": "As stated in section 5.1.2 ‘Supplementary exploratory overall survival analysis’ of the applicant’s original",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "submission, at the data cut-off of 13th November 2016, 73.4% of patients in the lenvatinib arm and 73.5% of",
      "text": "patients in the sorafenib arm had died. The Kaplan-Meier estimator for sorafenib PFS was 6% at the last\nobserved data point. Therefore, there is justification for using statistical survival analysis to extrapolate\nbeyond the end of REFLECT.\nAs part of the National Institute for Health and Care Excellence (NICE) review of lenvatinib in HCC, the\nEvidence Review Group (ERG) conducted an independent assessment of the REFLECT clinical data and the applicant’s submission, concluding for the purposes of cost-effectiveness modelling that it was\nappropriate to adjust for baseline imbalances resulting in “an undiscounted incremental mean OS benefit of",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "3.1 months” (4).",
      "text": "In conclusion, imbalances in important prognostic baseline characteristics and post-treatment therapy use between arms may have favoured sorafenib. Pre-specified covariate analysis adjusting\nfor AFP yielded a nominally significant OS HR of 0.856 [95% CI: 0.736, 0.995], highlighting the\nimportance of this characteristic on overall survival. Supplementary multivariable adjustment also\nproduced a nominally significant OS HR when adjusting for all relevant baseline characteristics simultaneously (data not included in this document so as not to compromise the publication). Using\nstatistical survival analysis a mean incremental overall survival gain of 3.1 may be reasonable.",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "2.2. Adverse events (side effects)",
      "text": "Frequency of adverse events, treatment associated dose reduction or discontinuation\nAs noted by the Medicines Council, there was no significant difference between arms in the proportion of patients who had a dose reduction or treatment discontinuation due to treatment adverse events (AEs) (as\nindicated by the relative effect estimates).",
      "start_page": 122,
      "end_page": 122
    },
    {
      "heading": "In addition, the median duration of exposure to therapy was 1.5x longer with lenvatinib than sorafenib. When",
      "text": "AEs were adjusted for treatment duration, the rate of grade ≥3 TEAEs and fatal AEs was similar between treatments.",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "gamma-glutamyl transferase increased. Grade 3 or 4 TEAEs that occurred in ≥5% of the sorafenib arm were",
      "text": "hypertension, aspartate aminotransferase increased, blood bilirubin increased and palmar-plantar erythrodysaesthesia syndrome.\nAlthough, as discussed above, the rate of grade ≥3 TEAEs was similar between treatments, the type of adverse events varied between treatment arms. Indeed, lenvatinib and sorafenib have safety profiles that are\nconsistent with other VEGF/VEGFR-targeted therapies; however, the nature and extent of AEs differed\nbetween the treatments based on their mechanisms of action.\nThe most frequently reported TEAEs (>30% of patients) with lenvatinib were hypertension, diarrhoea, decreased appetite, and weight decreased. The most frequently reported TEAEs (>30% of patients) with\nsorafenib were palmar-plantar erythrodysaesthesia syndrome, diarrhoea, and hypertension.\nThe medicines council specifically highlights “that in patients with skin disorders, there is poor experience with the use of sorafenib and that lenvatinib may be used here. Specifically, fewer cases of ≥ 3 hand-foot\nskin reactions in the lenvatinib arm (3% versus 11%) are seen”\nIt is therefore apparent that lenvatinib offers a different side effect profile to sorafenib and this difference would benefit certain patients. Tolerability of each drug would depend on the patient and physicians may use\nlenvatinib instead of sorafenib based on individual patient characteristics.",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "Adverse events of interest",
      "text": "The medicines council highlights the rates of hepatic toxicity observed in the lenvatinib arm. The increased\nrate of hepatotoxicity (hepatic failure/ hepatic encephalopathy) with lenvatinib can to some extent be attributed to imbalances in baseline risk factors.\nAs presented in Table 1, hepatotoxicity was observed in 47.7% (227/476) of patients in the lenvatinib arm,",
      "start_page": 123,
      "end_page": 123
    },
    {
      "heading": "and in 41.7% (198/475) of patients in the sorafenib arm. Taking into account treatment exposure, the",
      "text": "hepatotoxicity rate was similar in both treatment arms (1.96 episodes/SY in the lenvatinib arm and 2.01\nepisodes in the sorafenib arm).\nTable 1: Overview of Hepatotoxicity – All monotherapy Safety Sets\nAll HCC Non-HCC\nHCC Randomized Safety Set Lenvatinib Lenvatinib\nSafety Set Monotherapy\nLenvatinib Sorafenib Lenvatinib Safety Set\n8 or 12 mg 800 mg 8 or 12 mg Lenvatinib",
      "start_page": 123,
      "end_page": 124
    },
    {
      "heading": "For Hepatotoxicity per CMQ, Subjects with at least 1: (N=476) (N=475) (N=496) (N=1327)",
      "text": "SY=324.2 SY=239.1 SY=340.0 SY=1544.7",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "TEAE, no. of episodes (episodes/SY) 635 (1.96) 481 (2.01) 659 (1.94) 619 (0.50)",
      "text": "TEAEs with maximum CTCAE Grade of,a n (%)\nSAE, n (%) 71 (14.9) 34 (7.2) 73 (14.7) 19 (1.4)\nSAE, no. of episodes (episodes/SY) 97 (0.30) 40 (0.17) 100 (0.29) 25 (0.02)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "TEAE leading to treatment discontinuation, n (%) 26 (5.5) 14 (2.9) 27 (5.4) 11 (0.8)",
      "text": "TEAE leading to study drug modification,b n (%)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "Dose Reduction 35 (7.4) 20 (4 .2) 36 (7 .3) 25 (1.9)",
      "text": "Dose Interruption 58 (12.2) 45 (9.5) 58 (11.7) 50 (3.8)",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "Monotherapy Safety Set: 01 Sep 2016 (for ongoing studies). In the Non-HCC Lenvatinib Monotherapy Safety Set, 85% of subjects received",
      "text": "a starting dose of 24 mg QD. Serious AEs include any events that met the criteria for seriousness, whether fatal or nonfatal. For each row\ncategory, a subject with 2 or more AEs in that category was counted only once. AE Rate (episode/SY) = total occurrence of TEAE episodes\n(n) divided by the total exposure (SY) for the specified treatment group. AE = adverse event; CMQ = customized MedDRA query; CTCAE =\nCommon Terminology Criteria for Adverse\nEvents; HCC = hepatocellular carcinoma; ISS = Integrated Summary of Safety; MedDRA = Medical Dictionary for Regulatory Activities; QD\n= once daily; SAE = serious adverse event; SY = subject year; TEAE = treatment emergent adverse event.\na: If a subject had more than 1 TEAE, the subject was only counted once at the maximum grade.\nb: Study drug modification includes dose reduction or interruption. A subject could be counted in both categories if the subject had TEAEs\nleading to both dose interruption and dose reduction.\nIt is notable that the percentage of subjects with cirrhosis at baseline per the IIR was higher in subjects with hepatic encephalopathy than in the overall population. Lenvatinib-treated subjects who developed hepatic\nencephalopathy, particularly within 30 days of starting study drug, had worse baseline liver disease than subjects in the lenvatinib arm overall and sorafenib-treated subjects who developed hepatic encephalopathy.",
      "start_page": 124,
      "end_page": 124
    },
    {
      "heading": "Baseline characteristics included higher mean/median ammonia concentration, greater frequency of MPVI, greater proportion of subjects with a CP score ≥6 (including 2 subjects with the score of 7), greater liver",
      "text": "tumour burden (measured by sums of the diameters) and cirrhosis. Most subjects had either Grade 0 or\nGrade 1 baseline AST, ALT and ALP levels and no correlation with the occurrence of hepatic encephalopathy was seen.\nIn addition, no significant relationship between lenvatinib exposure and hepatic encephalopathy was detected within the exposure range of the REFLECT study.\nAn observational clinical trial (post-authorisation safety study [PASS] category 3 study in the riskmanagement plan) will be performed to further characterise safety (mainly hepatic-related events). Accurate\nreporting of baseline disease-related, other baseline characteristics and AEs in this study would allow further correlative analysis of risk factor for hepatic-related toxicity.\nFinally, and as stated in the EPAR assessment report, the overall benefit/risk of Lenvima as monotherapy is positive for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have\nreceived no prior systemic therapy.\nIn conclusion, lenvatinib and sorafenib have safety profiles that are consistent with other\nVEGF/VEGFR-targeted therapies. The nature and extent of AEs differed between treatments based on\ntheir mechanisms of action. Significantly, lenvatinib has a different side effect profile than sorafenib\n(e.g. fewer cases of hand-foot skin reactions) which will provide a clinical benefit to certain patients\n(e.g. those with skin disorders), who currently have no other treatment options.",
      "start_page": 124,
      "end_page": 125
    },
    {
      "heading": "2.3. Progression-free survival",
      "text": "The primary analysis of progression-free survival was conducted based on FDA preferred analysis methods\n(5) where patients were censored when they discontinued treatment for any reason other than disease progression. The primary analysis was accepted by the EMA and was included in the lenvatinib summary of\nproduct characteristics.\nPFS according to EMA censoring rules\nA sensitivity analysis (presented in Table 2) was conducted according to EMA censoring rules (6), where all progressive disease and deaths were considered as events (i.e. patients were not censored at",
      "start_page": 125,
      "end_page": 125
    },
    {
      "heading": "months in the sorafenib arm [HR: 0.66; 95% CI: 0.57, 0.77; p<0.00001]).",
      "text": "These results confirm the statistically significant improvement in progression-free survival of lenvatinib compared to sorafenib.\nTable 2: Progression-free survival sensitivity analysis based on randomisation stratification factors\nand treating all progressive disease and deaths as events – Full Analysis Set\nLenvatinib Sorafenib\nN=478 N=476\nPatients with events, n (%) 424 (88.7) 431 (90.5)\nProgressive disease 329 (68.8) 374 (78.6)\nDeath 95 (19.9) 57 (12.0)\nCensored patients, n (%) 54 (11.3) 45 (9.5)\nNo baseline tumour assessment 1 (0.2) 0\nNo post-baseline tumour assessment 6 (1.3) 3 (0.6)\nNo progression at the time of data cut-off 43 (9.0) 39 (8.2)\nNo progression at the time of consent withdrawal 4 (0.8) 3 (0.6)\nProgression-free survival (months)*\nMedian (95% CI) 7.3 (5.8, 7.5) 3.7 (3.6, 4.7)\nQ1 (95% CI) 3.6 (3.4, 3.6) 1.9 (1.8, 1.9)\nQ3 (95% CI) 13.2 (11.3, 14.7) 9.0 (7.4, 9.2)\nProgression-free survival rate (%) (95% CI)† at\n6 Months 54.1 (49.5, 58.5) 36.1 (31.8, 40.5)\n12 Months 28.6 (24.6, 32.9) 16.9 (13.6, 20.5)\n18 Months 13.1 (10.1, 16.5) 11.3 (8.5, 14.4)\n24 Months 6.9 (4.7, 9.8) 8.0 (5.7, 10.9)\nStratified cox model hazard ratio (95% CI)‡,§ 0.72 (0.63, 0.83)\nStratified log-rank test p-value§ p<0.00001\n*Quartiles are estimated by Kaplan-Meier method, and the 95% confidence intervals are estimated with a generalised Brookmeyer and\nCrowley method; †PFS rate and 95% CI were calculated using the Kaplan-Meier product-limit method and the Greenwood Formula;\n‡Hazard ratio is for lenvatinib vs sorafenib, based on a Cox model including treatment group as a factor; §Stratified by region (Region 1:\nAsia-Pacific; Region 2: Western regions), macroscopic portal vein invasion or extrahepatic spread or both (yes, no), ECOG PS (0, 1)\nand body weight (<60 kg, ≥60 kg);\nAbbreviations: CI, confidence interval; PD, progressive disease; PFS, progression-free survival; Q, quartile.",
      "start_page": 125,
      "end_page": 126
    },
    {
      "heading": "2.4. Health-related quality of life (HRQoL)",
      "text": "Assessments of HRQoL scores were performed using the generic cancer HRQoL instrument (EORTC\nQLQC30), the HCC-specific module (EORTC QLQ-HCC18), and the generic HRQoL instrument, EQ-5D.\nDuring the Randomization Phase, the EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D were administered at Baseline, Day 1 of each cycle after Cycle 1, and at the off-treatment visit. During the\nExtension Phase, the EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D were administered on Day 1 of each treatment and during the off-treatment visit.\nCompliance was high (>95%) and consistent for all measures throughout the course of the Randomisation phase (7).Time-to-symptom worsening (TSW) hazard ratio results are reported for all EORTC QLQ-C30,\nEORTC QLQ-HCC18 domains and EQ-5D visual analogue scale (VAS) and health utility index (HUI). The\nmedian months to clinically meaningful worsening for the EQ-5D health utility index (HUI) and visual\nanalogue scale (VAS) domains were numerically higher and in favour of the lenvatinib arm, but were nonsignificant (P > 0.05) (8).\nFor most domains, the impact on HRQoL was generally similar between lenvatinib and sorafenib. There\nwere no nominally significant improvements in any of the HRQoL domains with sorafenib compared to lenvatinib. Domains which did demonstrate a statistically significant delay in TSW in favour of lenvatinib were",
      "start_page": 126,
      "end_page": 127
    },
    {
      "heading": "role functioning, pain, diarrhea, (EORTC QLQ-C30), nutrition and body image (EORTC QLQ-HCC18) (9).",
      "text": " QLQ-C30 domains (median month, HR, p-value [log-rank test]):",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.83 (0.71, 0.97), p = 0.0098",
      "text": " Pain: 2.0 versus 1.8 months, respectively",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.82 (0.70, 0.95), p = 0.0060",
      "text": " Diarrhoea: 4.6 versus 2.7 months, respectively",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.53 (0.45, 0.63), p < 0.0001",
      "text": " QLQ HCC18 domains (median month, HR, p-value [log-rank test]):",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR (95% CI): 0.79 (0.68, 0.93), p = 0.0041",
      "text": " Nutrition: 4.1 versus 2.8 months, respectively;",
      "start_page": 127,
      "end_page": 127
    },
    {
      "heading": "HR: 0.81 (0.68, 0.95), p = 0.0060",
      "text": " All other domains were similar between treatment groups (p > 0.05).\nThese results confirm that for most domains, the impact on HRQoL was generally similar between lenvatinib and sorafenib. Patients on lenvatinib experienced statistically significant and clinically\nmeaningful delays in deterioration in role function, general cancer pain, diarrhea, nutrition, and body image versus sorafenib.\nFigure 1: Tim\nselected EOR\nme-to-sym\nRTC QLQ\nympt\nQ-C3\ntom wor\n30 & EO\nrsen\nORTC\nning and cha\nC QLQ-HCC\nange fro\nC18 dom\nom baseline by visit for mains (Vogel, 2017)",
      "start_page": 127,
      "end_page": 128
    },
    {
      "heading": "3. Treatment guidelines",
      "text": "Lenvatinib is recommended as a first-line, systemic therapy in both the EASL and ESMO guidelines:\n• Lenvatinib has been shown to be non-inferior to sorafenib and is also recommended in first-line\ntherapy for HCC given its approval. It is recommended for patients with well-preserved liver function (Child-\nPugh A class), good performance status and with advanced tumours – BCLC-C without main portal vein invasion – or those tumours progressing upon or unsuitable for loco-regional therapies. Strength of evidence\nwas considered to be high; recommendation strong (10)\n• Lenvatinib showed non-inferiority efficacy compared with sorafenib and can be considered in",
      "start_page": 129,
      "end_page": 129
    },
    {
      "heading": "4.1. Position of lenvatinib in treatment pathway",
      "text": "In the REFLECT trial, around 50% of patients had post-treatment anti-cancer therapy (43.1% in the\nlenvatinib arm, 51.1% in the sorafenib arm). Therefore, a significant number of patients do not undergo posttreatment anti-cancer therapy, and should be given the opportunity to get the best possible treatment option\nas a first line treatment.\nFrom the REFLECT trial, lenvatinib showed a statistically significant and clinically meaningful benefit in terms of progression-free survival (PFS), time-to progression (TTP), objective response rate (ORR), and the\nHRQoL domains of role functioning, pain, diarrhoea, body image, compared with sorafenib. As stated above\nin section 2.2, there are also significant differences in the side-effect profile of lenvatinib and sorafenib, and\nthe choice of treatment will depend on individual patient characteristics. Therefore, lenvatinib offers clear\nbenefits over sorafenib and represents an important treatment option for patients.\nFurther data on treatment sequencing from REFLECT will be published at the ASCO GI 2019 conference, with the title: “Subsequent anticancer medication following first-line lenvatinib: A post hoc responder analysis\nfrom the phase 3 REFLECT study in unresectable hepatocellular carcinoma”",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "4.2. Unmet need",
      "text": "Treatment options for advanced HCC are limited and sorafenib is currently the only EMA approved targeted systemic therapy for the first-line treatment of HCC. Lenvatinib is expected to be used as an alternative to\nsorafenib within its licensed indication. Since the approval of sorafenib in 2006, there have been no new firstline therapies approved for advanced HCC. Several other investigational therapies have failed to meet the\nendpoints of non-inferiority or superiority for OS compared with sorafenib. Median survival for patients with\nadvanced HCC is less than one year; 4–8 months if untreated and 6–11 months with sorafenib treatment",
      "start_page": 130,
      "end_page": 130
    },
    {
      "heading": "(12). There is therefore a clear unmet need for new treatments which delay progression and improve survival",
      "text": "without negatively impacting patients’ quality of life. The most appropriate treatment option should be\nprovided to patients as early as possible; given the median survival for patients with advanced HCC is less\nthan a year.\nLenvatinib has demonstrated a significantly improved PFS and a clear potential to improve OS (nominal superiority vs. sorafenib after adjustment for baseline imbalance in AFP, an established prognostic factor of\nHCC). Furthermore, the overall rate of response (ORR) in the lenvatinib arm was more than double the ORR\nin the sorafenib arm: 24.1% and 9.2%, respectively. The difference between the treatment arms was 14.8%\n(95% CI: 10.2, 19.4), and the odds ratio was 3.13 (95% CI: 2.15, 4.56), which was statistically significant\n(P<0.00001) in favor of lenvatinib treatment. Six subjects in the lenvatinib arm had a CR (1.3%) compared\nwith 2 subjects (<1%) in the sorafenib arm, and 22.8% of lenvatinib compared with 8.8% of sorafenib\nsubjects had PR. Stable disease occurred in 51.5% of subjects in the lenvatinib and 51.3% in the sorafenib\narm.\nThe increased ORR to lenvatinib is relevant in clinical practice because lenvatinib is highly effective in reducing tumor size, and achievement of tumor downstaging facilitates the use of more curative treatments\n(e.g., resection, ablation, and superselective cTACE), which in turn improves patient survival even further\nIn addition, lenvatinib and sorafenib have safety profiles that are consistent with other VEGF/VEGFRtargeted therapies; however, the nature and extent of adverse events (AEs) differed between the two agents\nbased on their different mechanisms of action. The most frequently (>30% of patients) reported TEAEs were\nhypertension, diarrhoea, decreased appetite, and weight decreased with lenvatinib and palmar-plantar erythrodysaesthesia syndrome, diarrhoea, and hypertension with sorafenib. The AE profile of lenvatinib may\nbe more favourable compared with sorafenib from a patient perspective due to lower rates of palmar plantar erythrodysaesthesia syndrome and diarrhoea, which can have a substantial impact for patients.\nIn conclusion, giving physicians and, most importantly, patients an alternative treatment option, depending on individual patient characteristics, will provide the opportunity for a personalised\napproach ensuring patients receive the most appropriate treatment as early as possible. Lenvatinib,\nwith its distinctive side-effect profile, and statistically and clinically significant response rates in comparison to current standard of care, can provide a meaningful benefit to patients who currently\nhave no other treatment options.\n5. Appendices: Systematic literature review - Method",
      "start_page": 130,
      "end_page": 132
    },
    {
      "heading": "5.1.1. Electronic databases",
      "text": "The electronic databases searched for the literature review are outlined in Table 3\nTable 3: Bibliographic databases included in literature review\nDatabase Platform Span of search\nMEDLINE, MEDLINE In-Process Ovid From inception to the day prio and e-publications ahead-of-print search\nCochrane library; CENTRAL Ovid From database inception to Oct\nAbbreviations: CENTRAL, Cochrane Central Register of Controlled Trials.",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "5.1.2. Hand-searching",
      "text": "Additional hand-searching of conference proceedings was conducted as a supp to identify relevant studies not captured by the electronic databases searc\nconferences were searched from the last three years (2016-2018):\n Annual meeting of the American Society of Clinical Oncology (ASCO)\n Annual meeting of the European Society for Medical Oncology (ESMO)\n Annual Meeting of the American Association for the Study of Liver Diseas\n International Society for Pharmacoeconomics and Outcomes Research (IS",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 4: MEDLINE search string",
      "text": "# Searches\n1 Liver Neoplasms/ or Carcinoma, Hepatocellular/\n2 (hepatocellular carcinoma* or carcinoma* hepatocellular or hepatoma* or liver carcino hepatocarcinoma or liver cell carcinoma* or primary carcinoma of liver or hepatic cancer).ti,a\n3 (((liver or hepato*) and (carcinom* or cancer* or neoplasm* or malign* or tumo*)) or HCC).ti,\n4 or/1-3\n5 (unresect* or inoperable or advanced or metastatic).ti,ab.\n6 4 and 5\n7 (lenvatinib or lenvima).ti,ab.\n8 6 and 7\ndology\nDate searched or to 11th December\ntober 11th December\nplementary measure ched. The following\nses (AASLD)\nSPOR)\nResults\noma* or 106764 ab.\n,ab. 222222",
      "start_page": 132,
      "end_page": 132
    },
    {
      "heading": "Table 5: Cochrance CENTRAL search string",
      "text": "# Searches\n1 Liver Neoplasms/ or Carcinoma, Hepatocellular/\n2 (hepatocellular carcinoma* or carcinoma* hepatocellular or hepatoma* or liver carcinoma hepatocarcinoma or liver cell carcinoma* or primary carcinoma of liver or hepatic cancer).ti,ab.\n3 (((liver or hepato*) and (carcinom* or cancer* or neoplasm* or malign* or tumo*)) or HCC).ti,ab.\n4 or/1-3\n5 (unresect* or inoperable or advanced or metastatic).ti,ab.\n6 4 and 5\n7 (lenvatinib or lenvima).ti,ab.\n8 6 and 7",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "5.2. Eligibility criteria",
      "text": "The Population, Intervention, Comparator(s), Outcomes and Study design (PICOS) elem assess study eligibility are shown in Table 6.\nTable 6: Literature review inclusion criteria (PICOS)\nCharacteristic Inclusion criteria\nPopulation Treatment naive adult (aged ≥18 years) patients with advanced, unre metastatic hepatocellular carcinoma\nInterventions/comparators Lenvatinib\nOutcomes  Overall survival (OS)\n Progression free survival (PFS)\n Tumor response rate: complete response (CR), partial respon\nresponse rate (ORR)\n Time to response, duration of response\n Adverse events: Serious, leading to discontinuation, occurring in >\n HRQoL\nStudy design Randomised controlled trials, phase II or phase III\nLanguage English language\nDate limits Unlimited\nCountries Unlimited\nAbbreviations: CR, Complete response; HRQoL, Health-related quality of life; ORR, Overall response rate,\nfree survival; PR, Partial response.\nRes\na* or 337\nments use esectable, or\nnse (PR), ov\n>=5% of patie\n, PFS, Progre\nsults\ned to r/and\nverall\nents\nession",
      "start_page": 133,
      "end_page": 133
    },
    {
      "heading": "5.3.1. Identification of included studies",
      "text": "The electronic database search identified 65 citations, of which 2 were identified as duplicates and excluded. The remaining 63 citations were screened on the basis of title and abstract, and 53 were\nthen excluded leaving 10 citations to be screened on the basis of the full publications. During full\ntext screening, three publications were subsequently excluded resulting in seven publications from the electronic database searches to be included in the literature review. Hand searching identified\nno additional citations that met the eligibility criteria. Therefore, a total of seven studies were\nidentified for final inclusion in the literature review.\nThe overall flow of the studies through the literature review is illustrated in Figure 2. The full list of\nstudies excluded on the basis of full publication is provided in section 5.5, along with the rationale\nfor exclusion.",
      "start_page": 134,
      "end_page": 134
    },
    {
      "heading": "5.4. List of included studies",
      "text": "A full list of the included studies is provided in Table 7.\nTable 7: List of included studies\nReference\nA list of publications excluded based on full text review is provided in Table 8, along with the rationale for exclusion.\nTable 8: List of publications excluded on full text review (n=3)\nReference Rationale for exclusion\nData has recently been made publicly available at the Gastrointestinal Cancers Symposium of the\nAmerican Society of Clinical Oncology (ASCO GI) conference relevant to Lenvima treatment in hepatocellular carcinoma, and are summarized below. The relevant abstracts and posters are\nprovided along with this document.\nSubsequent anticancer medication following first-line lenvatinib (LEN): A posthoc responder\nanalysis from the phase 3 REFLECT study (1)\nA posthoc responder analysis of patients who received first-line LEN in the REFLECT trial and subsequent anti-cancer medication during survival follow up was conducted. In REFLECT,\none third of the overall study population (156/478 patients randomized to LEN and 184/476 to sorafenib (SOR)) received subsequent anticancer medication. ECOG performance status\nand laboratory assessments, including liver function tests, were comparable between arms prior to subsequent treatments.\nThe results are summarized in Table 1 below. Among these patients, median overall survival\n(mOS) was 21 vs 17 months and ORR was 27.6% vs 8.7% for LEN vs SOR arms, respectively.\nIn a subset analysis of LEN responders who received any subsequent anticancer medication\n(n=43), mOS was 26 mo (95% CI 18.5–34.6). For SOR responders who received any\nsubsequent anticancer medication (n=16), mOS was 22 mo (95% CI, 14.6–NE). For LEN\nresponders who subsequently received SOR (n=35), mOS was 26 mo (95% CI 18.2–34.6).\nThese results show that there is data and experience in the use of subsequent anticancer medication following first-line LEN treatment in the REFLECT study.",
      "start_page": 135,
      "end_page": 139
    },
    {
      "heading": "Table 1: Subsequent anticancer medication following first-line treatment",
      "text": "Patients first line Median OS in patients Median OS of Median OS of treatment who received ANY RESPONDERS who RESPONDERS who\nsubsequent anticancer received ANY subsequently received medication subsequent anticancer SORAFENIB\nmedication\nlenvatinib 21 months 26 months (n=43) 26 months (n=35) sorafenib 17 months 22 months (n=16) N/A\nAnalysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT) (2)\nThe relationship between objective response (OR) and overall survival (OS) was analysed in the REFLECT trial. OR assessed by investigators per mRECIST were used to analyze the\nassociation between OR and OS of patients treated with lenvatinib (LEN) or sorafenib (SOR).\nThe median OS of responders (CR or PR) was compared to that of nonresponders (SD, PD, or\nUNK/NE) irrespective of treatment.\nLandmark analyses were performed by OR status at several fixed time points as sensitivity analyses, and the effect on OS was evaluated by Cox regression with OR as a time-\ndepend\nrespon\n2, 4, an\nCI, 0.57\npredict\nReferen\n1. Als\nres\ncar\nhtt\n2. Kud\nhep\ndent covariate, with other prognostic factors. Median OS was 22.4 months for\nnders and 11.4 months for nonresponders. Hazard ratios (HR) of landmark analyses at\nnd 6 months were 0.75 (95% CI, 0.57–0.98), 0.72 (95% CI, 0.56–0.92), and 0.73 (95%\n7–0.93). These results showed that in the REFLECT trial, OR was an independent\ntor of OS in patients with HCC regardless of treatment.\nnces:\nsina et al. Subsequent anticancer medication following first-line lenvatinib: A posthoc\nsponder analysis from the phase 3 REFLECT study in unresectable hepatocellular rcinoma. [Internet]. [cited 2019 Jan 18]. Available from:\ntps://meetinglibrary.asco.org/record/168787/abstract\ndo et al. Analysis of survival and objective response (OR) in patients with\npatocellular carcinoma in a phase III study of lenvatinib (REFLECT). [Internet]. [cited\n19 Jan 18]. Available from:",
      "start_page": 139,
      "end_page": 140
    },
    {
      "heading": "Lenvima HCC treatment sequencing",
      "text": "1. Treatment pathway\n Sorafenib, strictly per indication, is not indicated as a first-line treatment only. According to\nthe EPAR: “Nexavar is indicated for the treatment of hepatocellular carcinoma”\n NCCN guidelines have been updated and list sorafenib as an option after first-line lenvatinib treatment of HCC (recent update, see Figure 1 below)",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "Figure 1: Updated NCCN guidelines",
      "text": "2. Elligibility for second line treatment\n Given the poor survival rates (median overall survival of less than 1 year without treatment), it should be a priority to give the best treatment options as early as possible.\n Based on a real-world German study of over 2000 patients, (1) only 31% of patients go on to a second-line treatment. Therefore, few patients will receive second line treatment",
      "start_page": 141,
      "end_page": 141
    },
    {
      "heading": "Figure 2: HCC treatment pathway",
      "text": " The patient population eligible for second-line regorafenib treatment is limited.\no Regorafenib is recommended “as possible standard treatment for patients with hepatocellular carcinoma with performance status 0-1 and with liver function similar\nto Child Pugh A, as before treated with and have tolerated sorafenib” according to the Medicine Council’s report\no In the real-world GIDEON study looking at the European subpopulation, only 64.8%\nof the patients had Child Pugh A status, with 45.4% with ECOG 0 status, and 39.2%\nof the patients with ECOG 1 status. (2)\n Lenvatinib is recommended as a first-line, systemic therapy in both the EASL and ESMO guidelines. (3)(4)\nReferences:",
      "start_page": 142,
      "end_page": 142
    },
    {
      "heading": "Indhold",
      "text": "1 Formål .....................................\n2 Baggrund.................................\n2.1 Nuværende behandling ..\n2.2 Lenvatinib .......................\n3 Kliniske spørgsmål ..................\n3.1 Klinisk spørgsmål 1 .........\n3.2 Valg af effektmål .............\nKritiske effektmål ................\nVigtige effektmål ................\n4 Litteratursøgning ....................\n5 Databehandling/analyse .........\n6 Andre overvejelser .................\n7 Referencer ..............................\n8 Sammensætning af fagudvalg\nog ko\nontakt\ntinform\nSid\nmation til M de 2 af 13\nMedic\ncinråd\ndet .....\nForko\nBCLC:\nCHMP:\nCI:\nEMA:\nEORTC Q\nEORTC Q\nESMO:\nGRADE:\nHCC:\nHR:\nITT:\nMeSH:\nOR:\nOS:\nPICO:\nRFA:\nRR:\nSAE:\nSD\nortel\nQLQ-C\nQLQ-H\nlser\nC30:\nHCC18\nBarc\nCom\nKon\nEuro\nEuro\nQue\nEuro\nQue\nEuro\nSyst\nDeve\nHep\nHaza\nInte\nMed\nOdd\nSam\nFoku\nKom\nRadi\nRela\nSerio\nStan\ncelona Clinic Liver Cancer mmittee for Medicinal Products for Human Use\nnfidensinterval\nopean Medicines Agency opean Organisation for Research and Treatmen\nestionnaire-Core 30 opean Organisation for Research and Treatmen\nestionnaire-Hepatocellular carcinoma 18 opean Society for Medical Oncology\ntem til vurdering af evidens (Grading of Recom elopment and Evaluation System)\npatocellulært carcinom ard Ratio\nention to treat dical Subject Heading\nds Ratio mlet overlevelse (Overall Survival)\nuserede forskningsspørgsmål baseret på Popu mparator og Outcome (effektmål)\niofrekvensbehandling\nativ Risiko ous Adverse Event\nndard afvigelse (Standard deviation)",
      "start_page": 144,
      "end_page": 145
    },
    {
      "heading": "Side 3 af 13",
      "text": "e\nnt of Cancer Qu nt of Cancer Qu\nmmendations Ass ulation, Interven\nuality of Life uality of Life\nsessment,\nntion,",
      "start_page": 145,
      "end_page": 145
    },
    {
      "heading": "1 Formål",
      "text": "Protokollen har til formål at definere de kliniske spørgsmål, der ønskes belyst i vurderingen af lenvatinib som mulig standardbehandling af patienter med hepatocellulært karcinom. I protokollen angives en\ndefinition af populationer, komparator og effektmål, der skal præsenteres i den endelige ansøgning, samt de metoder der ønskes anvendt til den komparative analyse. Arbejdet med protokollen er igangsat på\nbaggrund af den foreløbige ansøgning vedrørende lenvatinib som er modtaget 25.05.2018.\nProtokollen danner grundlaget for den endelige ansøgning for vurderingen af den kliniske merværdi af lenvatinib sammenlignet med dansk standardbehandling. Alle effektmål, der er opgivet i denne protokol\nskal besvares med en sammenlignende analyse mellem lenvatinib og sorafenib af både absolutte og relative værdier for den udspecificerede population i de angivne måleenheder (se tabel 1).\nLitteratursøgning og databehandling udføres som beskrevet i protokollen.",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "2 Baggrund",
      "text": "Primær leverkræft (hepatocellulært karcinom, HCC) er en mindre hyppigt forekommende kræftform i\nDanmark. Incidensen er for perioden 2011-2015 429 nye tilfælde pr. år (303 tilfælde hos mænd; 126\ntilfælde hos kvinder) [1]. Udvikling af HCC forekommer oftest i patienter der har levercirrose [2].\nLeverfunktionen hos patienter med leversygdomme såsom cirrose kan opdeles efter hvor god leverfunktionen er, og benævnes i kategorierne Child-Pugh A, B og C, fra bedst til værst leverfunktion.\nVed udgangen af 2015 havde 652 patienter HCC, hvilket afspejler den lave overlevelse for denne patientgruppe. Etårsoverlevelsen er således 37 % for mænd og 40 % for kvinder, mens femårsoverlevelsen\nkun er 9 % for mænd og 11 % for kvinder [1].",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "2.1 Nuværende behandling",
      "text": "HCC udgør et sygdomskontinuum, hvor Barcelona Clinic Liver Cancer (BCLC) stadiesystemet ofte bruges til stadieinddeling og ligeledes til at beslutte, hvilken behandling patienten har gavn af. Stadierne inddeles\nefter tumorstadie, leverfunktionsstatus, fysisk status og kræftrelaterede symptomer. Overordnet opdeles\nHCC-patienter i de med tidlig HCC, som har mulighed for kurativ terapi, de med intermediær og fremskreden sygdom, som har gavn af palliative behandlinger, og endeligt patienter der har terminal\nsygdom som tilbydes symptomatisk behandling [3].\nPatienter med tidlig sygdom (BCLC A) vurderes med henblik på kirurgisk fjernelse af tumor, levertransplantation eller perkutan ablation (destruktion af kræftceller ved hjælp af kemiske substanser\neller hyper-/hypotermi, hvor især radiofrekvensbehandling (RFA) har vundet indpas i Danmark) med mulighed for helbredelse og en femårsoverlevelse omkring 50-75 % afhængigt af behandlingen [3].\nI Intermediærstadiet (BCLC stadie B) har patienterne store eller flere levertumorer og leverfunktion svarende til Child-Pugh A eller B, men de har ikke kræftrelaterede symptomer og har ikke makrovaskulær\ninvasion eller ekstrahepatisk spredning. Patienter med sygdom i dette stadie vurderes med henblik på lokal\nkemoterapi i leveren (transarteriel kemoembolisering) [3].",
      "start_page": 146,
      "end_page": 146
    },
    {
      "heading": "Side 4 af 13",
      "text": "I det fremskredne stadie (BCLC stadie C) har patienter stadig leverfunktion svarende til Child-Pugh A eller B, men kandiderer ikke længere til lokal behandling idet de har kræftsymptomer og/eller vaskulær invasion\neller ekstrahepatisk spredning [3]. De vurderes således med henblik på 1. linje systemisk behandling med\nmultikinaseinhibitoren sorafenib. Det anslås, at ca. 40 patienter behandles med sorafenib om året [4].\nDen 30. januar 2018 anbefalede Medicinrådet regorafenib som mulig standardbehandling til 2. linje\nsystemisk behandling til patienter med HCC, med performancestadie 0-1 og leverfunktion svarende til\nChild-Pugh A, som tidligere er behandlet med og har tolereret sorafenib [5].\nPatienter med ekstensiv tumorinvolvering førende til dårlig alment helbred og/eller har leverfunktion svarende til Child-Pugh C behandles symptomatisk [3].",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "2.2 Lenvatinib",
      "text": "Lenvatinib er indiceret til behandling af patienter med HCC i fremskredent stadie eller patienter med inoperabel HCC, som ikke tidligere er behandlet systemisk.\nLenvatinib er en multi-receptortyrosinkinase inhibitor, der hæmmer vækstfaktorreceptorerne VEGF receptor 1-3, FGF receptor 1-4 og PDGF receptor α samt proto-onkogenerne RET og KIT, som alle er\ncentrale for kræftudvikling.\nLenvatinib administreres peroralt som tabletter. Dosis er 8 mg (ved kropsvægt < 60 kg) eller 12 mg (ved\nkropsvægt ≥ 60 kg) en gang dagligt. Fagudvalget vurderer, at hovedparten at de danske HCC patienter vejer\nmere end 60 kg. Lenvatinib administreres så længe klinisk fordel observeres, eller indtil der opstår\nuacceptable bivirkninger.\nLenvatinib er i forvejen indiceret som monoterapi til behandling af voksne patienter med differentieret thyreoideakarcinom refraktært over for radioaktivt jod og i kombination med everolimus til behandling af\nvoksne patienter med fremskreden nyrecellekarcinom efter én forudgående behandling rettet mod vaskulær endothelvækstfaktor [6,7].",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "3 Kliniske spørgsmål",
      "text": "De kliniske spørgsmål skal indeholde specifikation af patientgruppen, interventionen, alternativet/-erne til interventionen og effektmål.",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "3.1 Klinisk spørgsmål 1",
      "text": "1. Hvad er den kliniske merværdi af lenvatinib til voksne patienter med fremskredent eller inoperabelt\nhepatocellulært karcinom, som er kandidater til systemisk behandling, sammenlignet med sorafenib?\nPopulation\nVoksne patienter med HCC i fremskredent stadie og voksne patienter med inoperabel HCC. Patienterne har\nperformance status 0-1 og bevaret leverfunktion svarende til Child-Pugh A og B(7).\nIntervention\nLenvatinib som beskrevet i pkt. 2.2.",
      "start_page": 147,
      "end_page": 147
    },
    {
      "heading": "Side 5 af 13",
      "text": "Komparator\n400 mg sorafenib to gange dagligt så længe klinisk fordel observeres eller indtil der opstår uacceptable bivirkninger. Administreres peroralt som tabletter af 200 mg (2 tabletter 2 gange dagligt)\nEffektmål\nDe valgte effektmål kan ses i tabel 1.",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "3.2 Valg af effektmål",
      "text": "Tabel 1 summerer de valgte effektmål, deres vigtighed, mindste klinisk relevante forskel og kategori.\nFor alle effektmål ønskes både absolutte og relative værdier, jævnfør ansøgningsskemaet. For de relati\nværdier vurderes den klinisk relevans (merværdi), jævnfør væsentlighedskriterierne beskrevet i\nMedicinrådets metodehåndbog for vurdering af nye lægemidler. De relative effektestimater kan angive\nrelativ risiko (RR), odds ratio (OR) eller hazard ratio (HR). Det skal begrundes i ansøgningen, hvis der afv\nfra de ønskede effektmål.\nTabel 1. Oversigt over valgte effektmål. For hvert effektmål er angivet deres vigtighed. For kritiske og vigtige effektmål er de\nangivet den mindste klinisk relevante forskel samt indplacering i de fire kategorier (overlevelse, alvorlige symptomer og bivirkn livskvalitet og ikkealvorlige symptomer og bivirkninger).\nEffektmål* Vigtighed Kategori Måleenhed Mindste klinisk relevante forskelle (absolutte\nværdier)\nSamlet overlevelse Kritisk Dødelighed Median overlevelse 3 måneder\nOverall survival (OS) (antal måneder)\n12 måneders overlevelse 8 procentpoint\n- Andel af patienter,\nder overlever i 12 måneder\n24 måneders overlevelse 4 procentpoint\n- Andel af patienter,\nder overlever i 24 måneder\nBivirkninger Kritisk Alvorlige Andel af patienter, der 5 procentpoint symptomer og ophører behandlingen\nbivirkninger pga. bivirkninger\nAntal grad 3-5 10 procent relativ forøg bivirkninger pr. 100 eller reduktion\npatient-år\nKvalitativ gennemgang af Narrativ vurdering bivirkningstyperne med\nhenblik på at vurdere alvorlighed,\nhåndterbarhed og hyppighed af\nbivirkningerne\nAndel af patienter der 10 procentpoint dosisreduceres\nProgressionsfri Vigtig Alvorlige Median (antal måneder) 3 måneder overlevelse (PFS) symptomer og\nbivirkninger",
      "start_page": 148,
      "end_page": 148
    },
    {
      "heading": "Side 6 af 13",
      "text": "e\nive\nes i viges\nesuden\nninger,\ne\ngelse\nLivskvalitet Vigtig Helbredsrelateret EORTC QLQ-C30 0,5 SD livskvalitet Summary score målt ved\n1, 2 og 3 måneder samt en beskrivelse af hvilke\ndomæner der driver en evt. forskel.\n*Hvis andet ikke er angivet ønskes data for effektmål med længst mulig opfølgningstid.\nHvis andet ikke er angivet, er de mindste kliniske relevante forskelle fastsat for en tidshorisont på 27,7 måneder svarende til den mediane opfølgningstid i REFLECT studiet, som forventes at danne basis for den\nsamlede kliniske merværdi [8].\nKritiske effektmål\nSamlet overlevelse (overall survival, OS)\nOverlevelse er guldstandarden for at demonstrere klinisk effekt i cancerstudier, herunder HCC. Det er et\npatientrelevant effektmål, der belyser patienternes levetid efter en fast opfølgningstid. Overlevelse\ndefineres som tiden fra randomisering eller opstart af behandling til død uanset årsag. Fagudvalget ønsker\neffektmålet opgjort som median overlevelse samt overlevelsesrater ved 12 og 24 måneder.\nMedian overlevelse\nFagudvalget vurderer, at 3 måneder er klinisk relevant. Referencen for dette er ESMO Magnitude of Clinical\nBenefit Scale [9], hvor en gevinst på ≥3 svarer til en grad 4 kategorisering. Denne skala er et redskab til at\nvurdere størrelsen af den kliniske værdi for kræftlægemidler, som er livsforlængende og ikke kurative, hvor grad 1 svarer til en triviel klinisk betydende effekt, og grad 4 er en væsentlig klinisk betydende effekt. Den\nvalgte tærskelværdi er baseret på populationens forventede korte livslængde, som også er påvirket af underliggende komorbiditet, idet størstedelen af patienterne har levercirrose.\nOverlevelsesrate 12 og 24 måneder\nFagudvalget vurderer, at en opgørelse over 12 måneders overlevelse er relevant, idet patienter, som lever efter 12 måneder, må betragtes som langtidsoverlevere. Den mindste klinisk relevante forskel vurderes at\nvære 8 % og er derved sat lidt lavere end ESMO Magnitude of Clinical Benefit Scale. Dette skyldes, at\nhovedparten af patienterne også har levercirrose. Ligeledes ønskes data for overlevelse efter 24 måneder,\nog den mindste klinisk relevante forskel er sat til 4 %",
      "start_page": 148,
      "end_page": 149
    },
    {
      "heading": "Bivirkninger har betydning for den enkelte patients livskvalitet og kompliance. Fagudvalget ønsker",
      "text": "bivirkninger ved lenvatinib belyst, ved andelen af patienter der ophører behandling pga. bivirkninger, og\nantallet af bivirkninger grad 3-5. Dernæst ønsker fagudvalget også at foretage en kvalitativ vurdering af\nbivirkningsprofilerne. Beskrivelser af de enkelte effektmål følger nedenfor.\nBehandlingsophør pga. bivirkninger\nBehandlingsophør på grund af bivirkninger ønskes belyst, idet dette er et mål for, hvor stor en del af patienterne, som oplever så alvorlige eller generende bivirkninger, at de må stoppe behandlingen og\ndermed muligvis ikke har fået gavn af at modtage lægemidlet. Fagudvalget vurderer, at der som regel skal\nmeget til, før patienter ophører behandling, og at dette effektmål derfor er et mål for, hvor tålelig",
      "start_page": 149,
      "end_page": 149
    },
    {
      "heading": "Side 7 af 13",
      "text": "behandlingen er. Fagudvalget vurderer, at en forskel på 5 procentpoint i andel af patienter, som ophører\ngrundet bivirkninger, er klinisk relevant.\nFagudvalget ønsker desuden, at ansøger leverer data over hvilke 5 bivirkninger, som hyppigst giver anledning til ophør for både sorafenib og lenvatinib.\nAntal grad 3-5 bivirkninger pr. 100 patient-år\nAntallet af grad 3-5 bivirkninger vurderes at være relevant for vurderingen. Fagudvalget ønsker dette\nopgjort pr. 100 patient-år, ud fra den observation, at den mediane tid i behandling varierer væsentligt\nmellem de to arme i REFLECT studiet. Den mindste klinisk relevante forskel vurderes at være 10 procent\nrelativ forøgelse eller reduktion sammenlignet med komparator. Mildere bivirkninger forventes at blive\nopfanget af livskvalitetsmål og vurderes ikke at være vigtigt for vurderingen af klinisk merværdi for effektmålet bivirkninger.\nKvalitativ gennemgang af bivirkninger\nFagudvalget vil desuden foretage en kvalitativ gennemgang af bivirkningstyperne med henblik på at vurdere, om der er forskel i bivirkningsprofilerne mht. alvorlighed, håndterbarhed og hyppighed af\nbivirkningerne. Ansøger bedes derfor bidrage med produktresumeet for lægemidlet.\nAndelen af patienter hvor dosis reduceres\nDosis for både lenvatinib og sorafenib kan reduceres i tilfælde af lægemiddel-relateret toksicitet.\nEffektmålet er derfor et mål for sikkerhed af behandlingen, og fagudvalget vurderer, at det er et vigtigt effektmål. Det vurderes, at 10 procentpoint er en klinisk relevant forskel.\nVigtige effektmål\nProgressionsfri overlevelse (PFS)\nProgressionsfri overlevelse defineres som tiden fra randomisering til radiologisk eller klinisk progression eller død. Fagudvalget betragter PFS som et supplement til overlevelsesdata. Effektmålet er relevant, da\ndet måler effekten af førstelinjebehandling, uanset hvilken andenlinjebehandling patienten modtager, hvorimod OS afspejler effekten af både første- og evt. andenlinjebehandling. Fagudvalget vurderer, at 3\nmåneder er den mindste klinisk relevante forskel.",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "Livskvalitet har stor betydning for den enkelte patient og er derfor et patientnært effektmål, der her vurderes at være af vigtig betydning, idet behandlingen er livsforlængende og ikke kurativ. Ligeledes",
      "text": "forventes dette effektmål også at kunne give en indikation af, om bivirkningerne ved produktet påvirker patienternes livskvalitet. Fagudvalget ønsker at belyse livskvalitet med følgende værktøj; European\nOrganisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-\nC30).\nEORTC QLQ-C30\nEORTC QLQ-C30 er udviklet til at måle livskvaliteten hos patienter med kræft. EORTC QLQ-C30 er et\nspørgeskema med 30 spørgsmål, og i alt 15 outcomes herunder fem funktionsskalaer, tre symptomskalaer, seks enkeltstående symptomer/omstændigheder og en ”global” livskvalitetsskala [10]. Der anvendes en\nscoringsskala fra 0-100. Der findes også en opsummerings-score som er gennemsnittet af alle de\novenstående domæner bortset fra den ”globale” livskvalitetsscore og ”financial difficulties” [11].\nFagudvalget ønsker at se data for opsummerings-scoren (”summary score”). Fagudvalget er opmærksom\npå, at EORTC quality of life gruppen anbefaler at benytte summaryscoren som supplement til de øvrige 15",
      "start_page": 150,
      "end_page": 150
    },
    {
      "heading": "Side 8 af 13",
      "text": "domæner. Såfremt der er en forskel på summaryscoren mellem komparator og intervention på de valgt\ntidspunkter, ønsker fagudvalget derfor en narrativ gennemgang af, hvilke domæner der driver forskelle studie har vist, at for hver af de 15 domæner er en klinisk signifikant forskel omtrent svarende til 0,5 SD\nbaselineværdien [12]. Desuden har en systematisk litteraturgennemgang vist at på flere af\nlivskvalitetsskalaerne er en ændring i 0,5 SD fra baseline en klinisk relevant forskel [13]. Derfor fastsætt\nfagudvalget den mindste klinisk relevante forskel til 0,5 SD baseret på poolede data (for de to studiearm ved baseline. Fagudvalget ønsker at se en opgørelse for livskvalitet ved 1, 2 og 3 måneder. Fagudvalget\nforventer, at bivirkninger som kan påvirke livskvaliteten, vil vise sig i starten af behandlingsforløbet. Der\ner den mediane behandlingstid i REFLECT-studiet relativ kort.",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "4 Litteratursøgning",
      "text": "Databaser for søgningen\nRelevant litteratur søges i databaserne MEDLINE (via PubMed eller Ovid) og CENTRAL (via Cochrane\nLibrary).\nDerudover skal EMAs European public assessment reports (EPAR) konsulteres for både det aktuelle lægemiddel og dets komparator(er).\nSøgetermer\nSøgningen skal inkludere det generiske navn og handelsnavnet for det aktuelle lægemiddel, som kombineres med termer for indikationen.\nSøgningen skal som minimum indeholde termer, som er beskrivende for de områder, der angivet i tabe herunder. Både indekseret (f.eks. Medical Subject Headings, MeSH) og fritekstsøgning skal anvendes.",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "Lægemiddel Indikation",
      "text": "Lenvatinib Hepatocellular carcinoma\nI ansøgers foreløbige ansøgning beskrives en direkte sammenligning mellem lenvatinib og sorafenib.\nFagudvalget finder det derfor kun relevant at gennemføre en systematisk søgning på lenvatinib.\nDe anvendte søgetermer, og hvordan de er blevet kombineret, dokumenteres separat for hver af de to databaser.\nKriterier for udvælgelse af litteratur\nDer ekskluderes først på titel- og abstractniveau, dernæst ved gennemlæsning af fuldtekstartikler. Artik\nder ekskluderes ved fuldtekstlæsning, skal fremgå med forfatter, årstal og titel i en eksklusionsliste, hvo eksklusionen begrundes kort. Den samlede udvælgelsesproces skal afrapporteres ved brug af et PRISMA\nflowdiagram\nVed usikkerheder om, hvorvidt en artikel på titel- og abstractniveau lever op til inklusions- og eksklusionskriterierne, skal der anvendes et forsigtighedsprincip til fordel for artiklen, hvorved\nfuldtekstartiklen vurderes.\nInklusions- og eksklusionskriterier:",
      "start_page": 151,
      "end_page": 151
    },
    {
      "heading": "Side 9 af 13",
      "text": "te\nen. Et\nD fra ter\nme)\nrtil\nellen\nkler,\nor\nA-\nStudier som ikke er randomiserede kliniske forsøg ekskluderes. Ligeledes ekskluderes fase 1 forsøg. Studier\nmed anden population end den valgte ekskluderes. Studier, som ikke rapporterer mindst et af de kritiske\neller vigtige effektmål ekskluderes.\nVurderingen af klinisk merværdi baseres på data fra publicerede fuldtekstartikler og data fra EMAs EPAR –\nPublic assessment report. Data skal derudover stemme overens med protokollens beskrivelser.\nUpublicerede data og data fra f.eks. abstracts kan fremsendes og vil indgå i vurderingen, såfremt\nMedicinrådet finder, at de er nødvendige for at sikre en fair sammenligning. Data skal i så fald stamme fra\nde forsøg, hovedpublikationerne rapporterer fra, og ansøger skal acceptere, at Medicinrådet offentliggør dem i ansøgningsskemaet og i rapporten vedr. klinisk merværdi.",
      "start_page": 151,
      "end_page": 152
    },
    {
      "heading": "5 Databehandling/analyse",
      "text": "De inkluderede studier og baselinekarakteristikken af studiepopulationerne beskrives i Medicinrådets ansøgningsskema. Det skal angives, hvilke studier der benyttes til at besvare hvilke kliniske spørgsmål.\nAl relevant data skal som udgangspunkt ekstraheres ved brug af Medicinrådets ansøgningsskema. Der skal\nudføres en komparativ analyse for hvert enkelt effektmål på baggrund af relevant data fra inkluderede studier. For hvert effektmål og studie angives analysepopulation (f.eks. intention-to-treat (ITT), perprotocol) samt metode. Resultater for ITT-populationen skal angives, hvis muligt, hvis komparative analyser\nikke i udgangspunktet er baseret på denne population. Alle ekstraherede data skal krydstjekkes med de\nresultater, der beskrives i EPAR’en. Findes uoverensstemmelser, gives en mulig grund herfor.\nHvis ekstraherede data afviger fra de forhåndsdefinerede PICO-beskrivelser, specielt i forhold til præspecificeret population og effektmål, begrundes dette.\nHvis data for et effektmål ikke er tilgængelig for alle deltagere i et studie, skal der ikke gøres forsøg på at erstatte manglende data med en meningsfuld værdi. Det vil sige, at alle analyser udelukkende baseres på\ntilgængelige data på individniveau.\nFor effektmål (ORR, SAE, behandlingsstop pga. bivirkninger og ikkealvorlige bivirkninger), hvor det er\nnaturligt at beregne både absolut og relativ forskel, vil den relative forskel være basis for statistiske analyser. Den absolutte forskel skal derefter beregnes, baseret på den estimerede relative forskel for et\nantaget niveau på hændelsesraten i komparatorgruppen. Det antagne niveau vil afspejle det forventede\nniveau i Danmark ved behandling med komparator (hvis relativ risiko (RR) = 0,5 og antaget andel med hændelse i komparatorgruppen er 30 %, da er den absolutte risiko reduktion (ARR) = 30 – 30 x 0,5 = 15 %point).\nHvis der er mere end et sammenlignende studie, skal der foretages en metaanalyse for de effektmål, hvor det er metodemæssigt forsvarligt. Hvis der ikke foreligger sammenlignende studier, kan data eventuelt\nsyntetiseres indirekte (evt. i form af formelle netværksmetaanalyser eller ved brug af Buchers metode), hvis\nintervention og komparator er sammenlignet med samme alternative komparator i separate studier.\nMedicinrådet forbeholder sig retten til at foretage sensitivitets- og subgruppeanalyser på baggrund af studiernes validitet og relevans.\nFor effektmål, hvor forskellige måleinstrumenter er brugt på tværs af de inkluderede studier, skal eventuelle metaanalyser baseres på standardized mean difference (SMD). Den estimerede SMD skal",
      "start_page": 152,
      "end_page": 152
    },
    {
      "heading": "Side 10 af 13",
      "text": "omregnes til den foretrukne skala for effektmålet. Til dette formål anvendes medianen af de observerede\nstandardafvigelser i de inkluderede studier.\nHvis det ikke er en mulighed at udarbejde metaanalyser (herunder netværksmetaanalyser), syntetiseres data narrativt. Studie- og patientkarakteristika samt resultater fra de inkluderede studier beskrives narrativt\nog i tabelform med angivelse af resultater pr. effektmål for både intervention og komparator(er). Forskelle i\npatientkarakteristika og studiekontekst (f.eks. geografi og årstal) mellem studier skal beskrives og vurderes\nfor at afgøre, hvorvidt resultaterne er sammenlignelige.\nValget af syntesemetode (metaanalyse eller narrativ beskrivelse) begrundes, og specifikke analysevalg truffet i forhold til metoden skal fremgå tydeligt.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "6 Andre overvejelser",
      "text": "Ligestilling\nFagudvalget vil i forbindelse med vurderingen af lenvatinib tage stilling til, om det er muligt at ligestille de to 1.linjebehandlingsmuligheder sorafenib og lenvatinib.",
      "start_page": 153,
      "end_page": 153
    },
    {
      "heading": "7 Referencer",
      "text": "1. NORDCAN databasen [Internet]. [cited 2017 Sep 15]. Available from:\n2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.\n3. (DLGCG) U af DLGCG. Nationale kliniske retningslinjer for udredning og behandling af primær\nlevercancer (HepatoCellulært Carcinom, HCC). 2012.\n4. Opfølgningsprogram for kræft i øvre mave-tarm (2015) SST [Internet]. 2015 [cited 2017 Sep 15].\nAvailable from:\n5. Medicinrådet. Medicinrådets anbefaling vedrørende regorafenib som standardbehandling til\nhepatocellulært karcinom. 2018.\n6. EMA - European Medicines Agency. Produktresumé lenvatinib nyrecellekarcinom. 2017;1–39.\n7. EMA - European Medicines Agency. Produktresumé lenvatinib thyreoidekarcinom. 2017;1–39.\n8 Sammensætning\nMedicinrådets fagudvalg ve\nFormand\nBritta Weber\nAfdelingslæge\nMedlemmer\nGerda Elisabeth Villadsen\nOverlæge, ph.d., Klinisk lektor\nAleksander Krag\nProfessor\nKirsten Kjeldgaard Vistisen\nOverlæge\nHar ikke udpeget\nHar ikke udpeget\nMette Skalshøi Kjær\nOverlæge, klinisk lektor\nMette Kudsk Brink\nFarmaceut\nAmy Daugaard Asmussen\nKvalitetskoordinator, sygep\nNiels Jessen\nProfessor, overlæge\nTóra Haraldsen",
      "start_page": 154,
      "end_page": 155
    },
    {
      "heading": "Medicinrådets sekretariat",
      "text": "Medicinrådet\nDampfærgevej 27-29, 3.\n2100 København Ø\n+ 45 70 10 36 00 medicinraadet@medicinraa\nSekretariatets arbejdsgrupp\nGedske Thomsen (projekt-\nAnette Pultera Nielsen (koo\nThea Christensen, Annemet\ng af edrøre\nr\nplejers\nadet.d\npe:\nog me ordina\nette An\nfagu\nende l ske, M\ndk\netode\nator)\nnker N\nudva\nleverk\nMHH\neansv\nNielse\nalg o kræft\nvarlig)\nen\nSi\nog konta t\nInds\nLæg\nUdp\nUdp\nform\nUdp\nUdp\nRegi\nRegi\nUdp\nHep\nUdp\nSyge\nInvit\nUdp\nUdp\nide 13 af 1\naktinformation til Med stillet af\ngevidenskabelige Selskaber peget af\npeget af Region Midtjylland og i manden\npeget af Region Syddanmark peget af Region Hovedstaden\nion Sjælland ion Nordjylland\npeget af Dansk Selskab for Gastr patologi\npeget af Dansk Selskab for ehusapoteksledelse\nteret af formanden peget af Dansk Selskab for Klinis\npeget af Danske Patienter\ndicin\ninviter\nroent\nsk Far\nnråd\nret af terolo\nrmako\ndet\nf\nogi og ologi",
      "start_page": 155,
      "end_page": 155
    },
    {
      "heading": "Table 1 on page 4",
      "text": "Table contains the following columns: Lægemidlets oplysninger, Column_2\nRow 1: Lægemidlets oplysninger: Handelsnavn and Column_2: Lenvima\nRow 2: Lægemidlets oplysninger: Generisk navn and Column_2: Lenvatinib\nRow 3: Lægemidlets oplysninger: Firma and Column_2: Eisai\nRow 4: Lægemidlets oplysninger: ATC-kode and Column_2: L01XE29\nRow 5: Lægemidlets oplysninger: Virkningsmekanisme and Column_2: Lenvatinib er en multireceptortyrosinekinase inhibitor der hæmmer vækstfaktorreceptorerne VEGF 1-3, FGF 1-4, PDGF α og proto- onkogenerne KIT og RET.\nRow 6: Lægemidlets oplysninger: Administration/dosis and Column_2: Lenvatinib administreres oralt som tabletter. Dosis er 8 mg (ved kropsvægt < 60 kg) eller 12 mg (ved kropsvægt ≥ 60 kg) én gang dagligt. Behandlingen fortsættes, så længe klinisk fordel observeres, eller indtil der opstår uacceptable bivirkninger.\nRow 7: Lægemidlets oplysninger: EMA-indikation and Column_2: Lenvatinib er indiceret som monoterapi til behandling af voksne patienter med fremskreden eller ikkeresektabelt hepatocellulært karcinom (HCC), som ikke tidligere har fået systemisk behandling.",
      "start_page": 4,
      "end_page": 4,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 4,
        "contains_dosage": true,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": null,
        "narrative_length": 1114,
        "extraction_hints": {
          "key_numbers": [
            "2",
            "1",
            "2",
            "2",
            "2",
            "3",
            "2",
            "4",
            "2",
            "01"
          ],
          "key_terms": [
            "lenvatinib",
            "patient"
          ],
          "relationships": [
            "drug-dose",
            "dose-frequency"
          ]
        }
      }
    },
    {
      "heading": "Table 1 on page 10",
      "text": "Table contains the following columns: Column_1, Dato for Medicinrådsbeslutning, Column_3, Column_4, 10-04-2019, Column_6\nRow 1: Column_1: Firma and Column_4: Eisai (ansøger)\nRow 2: Dato for Medicinrådsbeslutning: Lægemiddel and 10-04-2019: Lenvatinib (Lenvima)\nRow 3: Column_1: Indikation and Column_4: Patienter med ubehandlet, avanceret, inoperabel HCC i voksne med fremskreden stadie (BCLC stadie C) med leverfunktion svarende til Child-Pugh A eller B",
      "start_page": 10,
      "end_page": 10,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 4,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 10,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": null,
        "narrative_length": 454
      }
    },
    {
      "heading": "Table 1 on page 17",
      "text": "Table contains the following columns: Column_1, Ansøgning, Column_3, Column_4\nRow 1: Column_1: Lægemiddelfirma: and Column_3: Eisai\nRow 2: Column_1: Handelsnavn: and Column_3: Lenvima\nRow 3: Column_1: Generisk navn: and Column_3: Lenvatinib\nRow 4: Column_1: Indikation: and Column_3: Behandling til hepatocellulært karcinom\nRow 5: Column_1: ATC-kode: and Column_3: L01XE29",
      "start_page": 17,
      "end_page": 17,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 17,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": null,
        "narrative_length": 372
      }
    },
    {
      "heading": "Table 2 on page 17",
      "text": "Table contains the following columns: Column_1, Proces, Column_3, Column_4\nRow 1: Column_1: Ansøgning modtaget hos Amgros: and Column_3: 14-11-2018\nRow 2: Column_1: Endelig rapport færdig: and Column_3: 27-03-2019\nRow 3: Column_1: Sagsbehandlingstid fra endelig ansøgning: and Column_3: 133 dage\nRow 4: Column_1: Arbejdsgruppe: and Column_3: Louise Greve Dal Line Brøns Jensen Lianna Christensen Mark Friborg Pernille Winther Johansen",
      "start_page": 17,
      "end_page": 17,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 7,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 17,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 434
      }
    },
    {
      "heading": "Table 1 on page 21",
      "text": "Table contains the following columns: Lægemiddel Styrke, Column_2, Column_3, Column_4, Pakningsstørrelse, Column_6, Pris pr pak-, Column_8, Kilde\nRow 1: Pris pr pak-: ning (DKK)\nRow 2: Lægemiddel Styrke: Lenvitinib (Len- vima), Column_3: 4 mg, Pakningsstørrelse: 30 stk. (blister), Column_6: XXXXXXXXX, and Kilde: Amgros\nRow 3: Column_3: 10 mg\nRow 4: Lægemiddel Styrke: Sorafinib, Column_2: 200 mg, Pakningsstørrelse: 112 stk. (blister), Column_6: XXXXXXXXX, and Kilde: Amgros",
      "start_page": 21,
      "end_page": 21,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 7,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 21,
        "contains_dosage": true,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 476,
        "extraction_hints": {
          "key_numbers": [
            "2",
            "3",
            "4",
            "6",
            "8",
            "1",
            "2",
            "3",
            "4",
            "30"
          ],
          "key_terms": [],
          "relationships": [
            "dose-frequency"
          ]
        }
      }
    },
    {
      "heading": "Table 1 on page 24",
      "text": "Table contains the following columns: Column_1, Column_2, Column_3, Column_4, Progressionsfri-stadie (PFS), Column_6, Column_7, Progredierede-stadie (PD), Column_9\nRow 1: Column_2: Hospitalsomkostninger, Progressionsfri-stadie (PFS): 5.762,53 kr., and Column_7: 9.176,40 kr.\nRow 2: Column_1: Kommunale omkostninger, Column_4: 403,81 kr., and Column_7: 807,62 kr.\nRow 3: Column_2: Total, Progressionsfri-stadie (PFS): 6.166,35 kr., and Column_7: 9.984,02 kr.",
      "start_page": 24,
      "end_page": 24,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 24,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 457
      }
    },
    {
      "heading": "Table 1 on page 27",
      "text": "Table contains the following columns: Scenarie, Lenvatinib (Lenvima), Column_3, Sorafenib (Nexavar), Column_5, Column_6, Column_7, Inkrementelle omkostninger (DKK)\nRow 1: Scenarie: 2. linjebehandling inklude- ret, Lenvatinib (Lenvima): XXXXXXX DKK, Sorafenib (Nexavar): XXXXXXX DKK, and Column_7: XXXXXX DKK\nRow 2: Scenarie: Spild inkluderet, Lenvatinib (Lenvima): XXXXXXX DKK, Sorafenib (Nexavar): XXXXXXX DKK, and Column_7: XXXXXX DKK\nRow 3: Scenarie: Kaplan-Meier data brugt, Lenvatinib (Lenvima): XXXXXXX DKK, Column_5: XXXXXXX DKK, and Inkrementelle omkostninger (DKK): XXXXXX DKK",
      "start_page": 27,
      "end_page": 27,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 27,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": null,
        "narrative_length": 585
      }
    },
    {
      "heading": "Table 3 on page 27",
      "text": "Table contains the following columns: Omkostningselement, Lenvatinib (Lenvima), Column_3, Sorafenib (Nexavar), Column_5, Column_6, Column_7, Inkrementelle omkostninger\nRow 1: Inkrementelle omkostninger: (DKK)\nRow 2: Omkostningselement: Lægemiddelomkostninger, Lenvatinib (Lenvima): XXXXXXX DKK, Column_5: XXXXXXX DKK, and Inkrementelle omkostninger: XXXXXX DKK\nRow 3: Omkostningselement: Hospitalsomkostninger, Lenvatinib (Lenvima): 172.070 DKK, Sorafenib (Nexavar): 169.826 DKK, and Column_7: 2.244 DKK\nRow 4: Omkostningselement: Omkostninger udenfor hos- pital, Lenvatinib (Lenvima): 13.854 DKK, Sorafenib (Nexavar): 14.100 DKK, and Column_7: 247 DKK\nRow 5: Omkostningselement: Totale gennemsnitsomkost- ninger per patient, Lenvatinib (Lenvima): XXXXXXX DKK, Sorafenib (Nexavar): XXXXXXX DKK, and Column_7: XXXXXX DKK",
      "start_page": 27,
      "end_page": 27,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 27,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": null,
        "narrative_length": 819
      }
    },
    {
      "heading": "Table 1 on page 30",
      "text": "Table contains the following columns: Column_1, Column_2, Column_3, Anbefales som standardbehandling, Anbefales ikke som standardbehandling\nRow 1: Column_2: Lavt patientantal (8 patien-, Anbefales som standardbehandling: XXXXXXXX DKK, and Anbefales ikke som standardbehandling: 0 DKK\nRow 2: Column_2: ter)\nRow 3: Column_1: Højt patientantal (20 pati- enter), Anbefales som standardbehandling: XXXXXXXX DKK, and Anbefales ikke som standardbehandling: 0 DKK",
      "start_page": 30,
      "end_page": 30,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 30,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 455
      }
    },
    {
      "heading": "Table 1 on page 33",
      "text": "Table contains the following columns: Column_1, REGIONERNES, AMGROS I/S, TLF: 8871 3000\nRow 1: REGIONERNES: LÆGEMIDDELORGANISATION, AMGROS I/S: DAMPFÆRGEVEJ 27-29, and TLF: 8871 3000: WWW.AMGROS.DK\nRow 2: AMGROS I/S: 2100 KØBENHAVN Ø",
      "start_page": 33,
      "end_page": 33,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 4,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 33,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 233
      }
    },
    {
      "heading": "Table 2 on page 45",
      "text": "Table contains the following columns: Patientkarakteristika, Column_2, Column_3\nRow 1: Column_2: Lenvatinib (n = 478) and Column_3: Sorafenib (n = 476)\nRow 2: Patientkarakteristika: Alder (median, interval), Column_2: 63 (20-88), and Column_3: 62 (22-88)\nRow 3: Patientkarakteristika: % kvinder, Column_2: 15 %, and Column_3: 16%\nRow 4: Patientkarakteristika: Eastern Cooperative Oncology Group performance status, Column_2: 0: 64 % 1: 36 %, and Column_3: 0: 63 % 1: 37 %\nRow 5: Patientkarakteristika: Child-Pugh klasse, Column_2: A: 99 % B: 1 %, and Column_3: A: 99 % B: 1%\nRow 6: Patientkarakteristika: Makroskopisk portåre-invasion, Column_2: Ja: 23 % Nej: 77 %, and Column_3: Ja: 19 % Nej: 81 %\nRow 7: Patientkarakteristika: Ekstrahepatisk spredning, Column_2: Ja: 61 % Nej: 39%, and Column_3: Ja: 62 % Nej: 38 %\nRow 8: Patientkarakteristika: Underliggende cirrhosis, Column_2: Ja: 74 % Nej: 26 %, and Column_3: Ja: 76 % Nej: 24 %\nRow 9: Patientkarakteristika: Ætiologi- kronisk leversygdom, Column_2: Hepatitis B: 53 % Hepatitis C: 19 % Alkohol: 8 % Andet: 8 % Ukendt: 13 %, and Column_3: Hepatitis B: 48 % Hepatitis C: 26 % Alkohol: 4 % Andet: 7 % Ukendt: 14 %\nRow 10: Patientkarakteristika: Barcelona Clinic Liver Cancer stadie, Column_2: B (intermediær): 22 % C (fremskreden): 78 %, and Column_3: B (intermediær): 19 % C (fremskreden): 81 %",
      "start_page": 45,
      "end_page": 45,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 11,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 45,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": null,
        "narrative_length": 1348
      }
    },
    {
      "heading": "Table 1 on page 46",
      "text": "Table contains the following columns: Column_1, Forhåndsdefineret grundlag for vurdering, Column_3, Resultater\nRow 1: Column_1: Absolutte forskelle, Forhåndsdefineret grundlag for vurdering: Median overlevelse: 3 måneder 12 måneders overlevelse: 8 %-point 24 måneders overlevelse: 4 %-point, and Resultater: Median overlevelse: 1,3 måneder 12 måneders overlevelse: 5 %-point 24 måneders overlevelse: 3,7 %-point\nRow 2: Column_1: Relative forskelle, Forhåndsdefineret grundlag for vurdering: Stor merværdi, and Column_3: Øvre konfidensgrænse < 0,85\nRow 3: Forhåndsdefineret grundlag for vurdering: Vigtig merværdi and Column_3: Øvre konfidensgrænse < 0,95\nRow 4: Forhåndsdefineret grundlag for vurdering: Lille merværdi and Column_3: Øvre konfidensgrænse < 1,00\nRow 5: Forhåndsdefineret grundlag for vurdering: Ingen merværdi, Column_3: Øvre konfidensgrænse > 1,00, and Resultater: HR: 0,92 [0,79;1,06]\nRow 6: Forhåndsdefineret grundlag for vurdering: Negativ merværdi and Column_3: Nedre konfidensgrænse > 1.00\nRow 7: Column_1: Evidensens kvalitet and Forhåndsdefineret grundlag for vurdering: Lav",
      "start_page": 46,
      "end_page": 46,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 46,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 1097
      }
    },
    {
      "heading": "Table 1 on page 47",
      "text": "Table contains the following columns: Column_1, Forhåndsdefineret grundlag for vurdering, Column_3, Resultater\nRow 1: Column_1: Absolutte forskelle, Forhåndsdefineret grundlag for vurdering: 5 %-point, and Resultater: 2 %-point [-2;5]\nRow 2: Column_1: Relative forskelle, Forhåndsdefineret grundlag for vurdering: Stor merværdi, and Column_3: Øvre konfidensgrænse < 0,75\nRow 3: Forhåndsdefineret grundlag for vurdering: Vigtig merværdi and Column_3: Øvre konfidensgrænse < 0,90\nRow 4: Forhåndsdefineret grundlag for vurdering: Lille merværdi and Column_3: Øvre konfidensgrænse < 1,00\nRow 5: Forhåndsdefineret grundlag for vurdering: Ingen merværdi, Column_3: Øvre konfidensgrænse > 1,00, and Resultater: RR: 1,23 [0,79;1,90]\nRow 6: Forhåndsdefineret grundlag for vurdering: Negativ merværdi and Column_3: Nedre konfidensgrænse > 1.00\nRow 7: Column_1: Evidensens kvalitet and Forhåndsdefineret grundlag for vurdering: Meget lav",
      "start_page": 47,
      "end_page": 47,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 47,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 926
      }
    },
    {
      "heading": "Table 1 on page 48",
      "text": "Table contains the following columns: Column_1, Forhåndsdefineret grundlag for vurdering, Column_3, Resultater\nRow 1: Column_1: Absolutte forskelle, Forhåndsdefineret grundlag for vurdering: 10 %-point, and Resultater: -1 %-point [-7; 5]\nRow 2: Column_1: Relative forskelle, Forhåndsdefineret grundlag for vurdering: Stor merværdi, and Column_3: Øvre konfidensgrænse < 0,75\nRow 3: Forhåndsdefineret grundlag for vurdering: Vigtig merværdi and Column_3: Øvre konfidensgrænse < 0,90\nRow 4: Forhåndsdefineret grundlag for vurdering: Lille merværdi and Column_3: Øvre konfidensgrænse < 1,00\nRow 5: Forhåndsdefineret grundlag for vurdering: Ingen merværdi, Column_3: Øvre konfidensgrænse > 1,00, and Resultater: RR: 0,97 [0,82; 1,14]\nRow 6: Forhåndsdefineret grundlag for vurdering: Negativ merværdi and Column_3: Nedre konfidensgrænse > 1.00\nRow 7: Column_1: Evidensens kvalitet and Forhåndsdefineret grundlag for vurdering: Meget lav",
      "start_page": 48,
      "end_page": 48,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 48,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 930
      }
    },
    {
      "heading": "Table 1 on page 49",
      "text": "Table contains the following columns: Column_1, Forhåndsdefineret grundlag for vurdering, Column_3, Resultater\nRow 1: Column_1: Absolutte forskelle, Forhåndsdefineret grundlag for vurdering: 10 % relativ forøgelse eller reduktion svarende til 0,18 events/patient-år, and Resultater: -0,20 [-0,42; 0,01] events/patient-år\nRow 2: Column_1: Relative forskelle, Forhåndsdefineret grundlag for vurdering: Stor merværdi, and Column_3: Øvre konfidensgrænse < 0,75\nRow 3: Forhåndsdefineret grundlag for vurdering: Vigtig merværdi and Column_3: Øvre konfidensgrænse < 0,90\nRow 4: Forhåndsdefineret grundlag for vurdering: Lille merværdi and Column_3: Øvre konfidensgrænse < 1,00\nRow 5: Forhåndsdefineret grundlag for vurdering: Ingen merværdi, Column_3: Øvre konfidensgrænse > 1,00, and Resultater: Rate ratio: 0,89 [0,78;1,01]\nRow 6: Forhåndsdefineret grundlag for vurdering: Negativ merværdi and Column_3: Nedre konfidensgrænse > 1,00\nRow 7: Column_1: Evidensens kvalitet and Forhåndsdefineret grundlag for vurdering: Meget lav",
      "start_page": 49,
      "end_page": 49,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 49,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 1020
      }
    },
    {
      "heading": "Table 1 on page 51",
      "text": "Table contains the following columns: Column_1, Forhåndsdefineret grundlag for vurdering, Column_3, Resultater\nRow 1: Column_1: Absolutte forskelle, Forhåndsdefineret grundlag for vurdering: Median progressionsfri overlevelse: 3 måneder, and Resultater: 3,7 måneder\nRow 2: Column_1: Relative forskelle, Forhåndsdefineret grundlag for vurdering: Stor merværdi, and Column_3: Øvre konfidensgrænse < 0,75\nRow 3: Forhåndsdefineret grundlag for vurdering: Vigtig merværdi, Column_3: Øvre konfidensgrænse < 0,90, and Resultater: HR: 0,66 [0,57;0,77]\nRow 4: Forhåndsdefineret grundlag for vurdering: Lille merværdi and Column_3: Øvre konfidensgrænse < 0,10\nRow 5: Forhåndsdefineret grundlag for vurdering: Ingen merværdi and Column_3: Øvre konfidensgrænse > 1,00\nRow 6: Forhåndsdefineret grundlag for vurdering: Negativ merværdi and Column_3: Nedre konfidensgrænse > 1.00\nRow 7: Column_1: Evidensens kvalitet and Forhåndsdefineret grundlag for vurdering: Meget lav",
      "start_page": 51,
      "end_page": 51,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_1_standard",
        "has_title": false,
        "page": 51,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 957
      }
    },
    {
      "heading": "Table 1 on page 52",
      "text": "Table contains the following columns: Effektmål, Vigtighed, Merværdi\nRow 1: Effektmål: Samlet overlevelse, Vigtighed: Kritisk, and Merværdi: Ingen\nRow 2: Effektmål: Bivirkninger, Vigtighed: Kritisk, and Merværdi: Ingen\nRow 3: Effektmål: Progressionsfri overlevelse, Vigtighed: Vigtig, and Merværdi: Vigtig\nRow 4: Effektmål: Livskvalitet, Vigtighed: Vigtig, and Merværdi: Ikkedokumenterbar\nRow 5: Effektmål: Samlet vurdering Ingen klinisk merværdi",
      "start_page": 52,
      "end_page": 52,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 52,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 446
      }
    },
    {
      "heading": "ratio to one of the following treatment groups:",
      "text": "Table Title: ratio to one of the following treatment groups:\n\nTable contains the following columns: Reference (title, author, journal, year), Trial name, Column_3, NCT, Column_5, Column_6, Dates of study (start and, Column_8\nRow 1: NCT: number and Dates of study (start and: expected completion date)\nRow 2: Reference (title, author, journal, year): Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Kudo, M., Finn, R.S., Qin, S., et al. Lancet 2018 [1], Trial name: REFLECT study (E7080- G000-304), Column_3: 01761266, and Column_6: Study Start March 14, 2013. Expected completion date March 2019",
      "start_page": 65,
      "end_page": 65,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 3,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 65,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "ratio to one of the following treatment groups:",
        "narrative_length": 698
      }
    },
    {
      "heading": "TABLE 5.1: OVERALL SURVIVAL BASED ON RANDOMIZATION STRATIFICATION FACTORS RECORDED IN THE IXRS - FAS",
      "text": "Table Title: TABLE 5.1: OVERALL SURVIVAL BASED ON RANDOMIZATION STRATIFICATION FACTORS RECORDED IN THE IXRS - FAS\n\nTable contains the following columns: Column_1, Column_2, Lenvatinib, Column_4, Column_5, Sorafenib, Column_7\nRow 1: Lenvatinib: (N=478) and Sorafenib: (N=476)\nRow 2: Lenvatinib: n (%) and Sorafenib: n (%)\nRow 3: Column_1: Deaths, n (%), Column_2: 351 (73.4), and Column_5: 350 (73.5)\nRow 4: Column_1: Censored Subjects, n (%) Lost to follow-up Withdrawal of consent Alive, Column_2: 127 (26.6) 5 (1.0) 13 (2.7) 109 (22.8), and Column_5: 126 (26.5) 11 (2.3) 8 (1.7) 107 (22.5)\nRow 5: Column_1: Median Overall Survival (months)a (95% CI), Column_2: 13.6 (12.1, 14.9), and Column_5: 12.3 (10.4, 13.9)\nRow 6: Column_1: Overall Survival Rate (%) (95% CI) b at 6 Months 12 Months 24 Months, Column_2: 80.8 (76.9, 84.1) 55.0 (50.4, 59.4) 29.9 (25.6, 34.2), and Column_5: 75.2 (71.0, 78.8) 50.0 (45.4, 54.5) 26.2 (22.1, 30.5)\nRow 7: Column_1: Stratified Cox Model Hazard Ratio (95% CI) c,d and Column_2: 0.92 (0.79, 1.06)",
      "start_page": 70,
      "end_page": 70,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 8,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 70,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "TABLE 5.1: OVERALL SURVIVAL BASED ON RANDOMIZATION STRATIFICATION FACTORS RECORDED IN THE IXRS - FAS",
        "narrative_length": 1029
      }
    },
    {
      "heading": "There was an imbalance between the treatment arms regarding the proportion of patients who received",
      "text": "Table Title: There was an imbalance between the treatment arms regarding the proportion of patients who received\n\nTable contains the following columns: Baseline Characteristics, Column_2, Hazard Ratio for, Column_4\nRow 1: Hazard Ratio for: (Lenvatinib: Sorafenib)\nRow 2: Hazard Ratio for: (95% CI)\nRow 3: Baseline Characteristics: Age (<65, ≥65 to <75, ≥75 yrs.) Sex (Male, Female) Region (Asia-Pacific, Western Region) Macroscopic Portal Vein Invasion (Yes, No) Extrahepatic Spread (Yes, No) Macroscopic Portal Vein Invasion, Extrahepatic Spread or Both (Yes, No) ECOG PS (0, ≥1) Body Weight (<60 kg, ≥60 kg) Alpha-fetoprotein level at Baseline (<200 ng/mL, ≥200 ng/mL) Antiviral Therapy for Hepatitis B or Hepatitis C (Yes, No) No. of Disease Sites at Baseline (1, 2, ≥3) Aetiology (HBV, HCV, Alcohol) Underlying Cirrhosis (Yes, No) BCLC Staging (Stage B, Stage C) Prior Procedure (Yes, No) and Column_2: 0.919 (0.791, 1.067) 0.916 (0.789, 1.064) 0.915 (0.789, 1.062) 0.910 (0.784, 1.057) 0.915 (0.788, 1.062) 0.908 (0.783, 1.054) 0.923 (0.795, 1.071) 0.923 (0.796, 1.071) 0.856 (0.736, 0.995) 0.912 (0.785, 1.059) 0.878 (0.755, 1.020) 0.855 (0.721, 1.013) 0.916 (0.789, 1.063) 0.918 (0.791, 1.067) 0.902 (0.777, 1.048)",
      "start_page": 72,
      "end_page": 72,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 4,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 72,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "There was an imbalance between the treatment arms regarding the proportion of patients who received",
        "narrative_length": 1221
      }
    },
    {
      "heading": "discussion [1,2] which include information about the treatment-emergent adverse events (TEAE). TEAEs",
      "text": "Table Title: discussion [1,2] which include information about the treatment-emergent adverse events (TEAE). TEAEs\n\nTable contains the following columns: Column_1, with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm, Column_3\nRow 1: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: (26% vs 19%, respectively), an imbalance that may favor sorafenib, since HCV aetiology has been recently\nRow 2: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: shown to be a predictive indicator for sorafenib treatment effect and subjects with HCV appear to derive\nRow 3: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: more clinical benefit from sorafenib therapy than subjects with other aetiologies, particularly hepatitis B\nRow 4: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: virus (HBV) [7]. Of principal concern was the imbalance in baseline AFP levels between treatment arms; AFP\nRow 5: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: has been demonstrated to be a strong independent predictor of outcomes regardless of treatment type [8],\nRow 6: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: and the proportion of patients with AFP levels ≥200 ng/mL was higher in the lenvatinib arm (46.4%) than\nRow 7: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: the sorafenib arm (39.3%).\nRow 8: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: As presented in section 5.1.2 Effect of post-treatment anticancer therapy on Overall Survival there was an\nRow 9: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: imbalance between the treatment arms regarding the proportion of patients who received post-treatment\nRow 10: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: anti-cancer therapy.\nRow 11: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: Survival analysis\nRow 12: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: At the data cut-off of 13th November 2016, 73.4% of patients in the lenvatinib arm and 73.5% of patients in\nRow 13: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: the sorafenib arm had died. The Kaplan-Meier estimator for sorafenib PFS was 6% at the last observed data\nRow 14: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: point. Therefore, there is justification for using statistical survival analysis to extrapolate beyond the end of\nRow 15: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: REFLECT. Survival analysis is commonly used in cost-effectiveness analysis to model health benefits for the\nRow 16: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: lifetime of the average patient. The imbalances in baseline characteristics and post-treatment therapy can\nRow 17: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: be explored within estimation of parametric survival models.\nRow 18: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: The National Institute for Health and Care Excellence (NICE) is currently evaluating Lenvatinib (ID1089) [9].\nRow 19: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: The Company Submission used a multivariable adjustment to account for the imbalance in baseline\nRow 20: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: characteristics.\nRow 21: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm:  Current EMA guidance on adjustment for baseline characteristics in clinical trials suggests that in\nRow 22: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: the presence of imbalances for strong predictors of outcomes, adjustment for such covariates\nRow 23: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: generally improves the precision and efficiency of the analysis and avoids conditional bias from\nRow 24: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: chance covariate imbalance [10].\nRow 25: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: The Evidence Review Group (ERG) conducted an independent assessment of the REFLECT clinical data and\nRow 26: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: the company submission concluding it was appropriate to adjust for baseline imbalances resulting in “an\nRow 27: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: undiscounted incremental mean OS benefit of 3.1 months”. Furthermore the ERG preferred to include the\nRow 28: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: effect of imbalances in post-treatment therapy which resulted in an “undiscounted incremental mean OS\nRow 29: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: benefit of 4.1 months” [9].\nRow 30: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: These results demonstrate that, based on the REFLECT data adjusted for imbalances in baseline\nRow 31: with an HCC aetiology of hepatitis C virus (HCV) was higher in the sorafenib arm than in the lenvatinib arm: characteristics an incremental modelled mean OS benefit of at least three months may be reasonable.",
      "start_page": 75,
      "end_page": 75,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 37,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 75,
        "contains_dosage": false,
        "contains_pricing": true,
        "contains_medication": true,
        "table_title": "discussion [1,2] which include information about the treatment-emergent adverse events (TEAE). TEAEs",
        "narrative_length": 6590,
        "extraction_hints": {
          "key_numbers": [
            "1,2",
            "1",
            "3",
            "1",
            "26%",
            "19%",
            "2",
            "3",
            "4",
            "7"
          ],
          "key_terms": [
            "sorafenib",
            "lenvatinib",
            "treatment",
            "therapy",
            "cost",
            "patient"
          ],
          "relationships": [
            "drug-cost"
          ]
        }
      }
    },
    {
      "heading": "have also been adjusted by treatment duration (",
      "text": "Table Title: have also been adjusted by treatment duration (\n\nTable contains the following columns: Adverse events, Lenvatinib (N=476) n (%), Column_3, Sorafenib, Column_5\nRow 1: Sorafenib: (N=475)\nRow 2: Sorafenib: n (%)\nRow 3: Adverse events: Patient with any TEAE, Lenvatinib (N=476) n (%): 470 (98.7), and Column_3: 472 (99.4)\nRow 4: Adverse events: Patients with any related TEAE, Lenvatinib (N=476) n (%): 447 (93.9), and Column_3: 452 (95.2)\nRow 5: Adverse events: Patients with any TEAE ≥grade 3, Lenvatinib (N=476) n (%): 357 (75.0), and Column_3: 316 (66.5)\nRow 6: Adverse events: Patient with any related TEAE ≥grade 3, Lenvatinib (N=476) n (%): 270 (56.7), and Column_3: 231 (48.6)",
      "start_page": 76,
      "end_page": 76,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 7,
        "extraction_method": "pass_1_standard",
        "has_title": true,
        "page": 76,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "have also been adjusted by treatment duration (",
        "narrative_length": 693
      }
    },
    {
      "heading": "censored when they discontinued treatment for any reason other than disease progression.",
      "text": "Table Title: censored when they discontinued treatment for any reason other than disease progression.\n\nTable contains the following columns: Adverse events, Column_2, Lenvatinib, Column_4, Column_5, Sorafenib, Column_7\nRow 1: Lenvatinib: (N=476) and Sorafenib: (N=475)\nRow 2: Lenvatinib: Total duration= 324.2 years n (AE rate) and Sorafenib: Total duration= 239.1 years n (AE rate)\nRow 3: Adverse events: Any TEAE episodes Related TEAE episodes Any TEAE ≥grade 3 episodes Related TEAE ≥grade 3 episodes Serious AE episodes Fatal serious TEAE episodes † Non-fatal serious TEAE episodes, Column_2: 6,124 (18.89) 3,546 (10.94) 1,023 (3.16) 517 (1.59) 409 (1.26) 61 (0.19) 379 (1.17), and Column_5: 4,718 (19.73) 2,865 (11.98) 795 (3.33) 430 (1.80) 232 (0.97) 36 (0.15) 207 (0.87)",
      "start_page": 78,
      "end_page": 78,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 4,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 78,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "censored when they discontinued treatment for any reason other than disease progression.",
        "narrative_length": 777
      }
    },
    {
      "heading": "patients who received treatment were included in the safety analysis.",
      "text": "Table Title: patients who received treatment were included in the safety analysis.\n\nRow 1: 23. Subject has had a liver transplant\nRow 2 contains: 'Intervention', 'Lenvatinib (n=478): 12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg oral dosing Sorafenib (n=476): 400 mg twice daily (BID) oral dosing 28-days cycles'\nRow 3 contains: 'Baseline characteristics', 'Patient baseline characteristics were similar between treatment groups, except for baseline hepatitis C aetiology (lenvatinib 91 (19 %) and sorafenib 126 (26 %)) and α-fetoprotein concentrations median (IQR) (lenvatinib 133.1 and sorafenib 71.2 ng/mL). Age: median 62 years (range 20-88) Sex: male 84 %, female 16 % Bodyweight: < 60 kg 31 %, ≥ 60 kg 69 % Region: Western 33 %, Asia-Pacific 67 % Race: White 29 %, Asian 69 %, Other 2 % Eastern Cooperative Oncology Group performance status: 0 63 %, 1 37 % Child-Pugh class A 99 %, B 1 % Macroscopic portal vein invasion: yes 21 %, no 79 % Extrahepatic spread: yes 61 %, no 39 % Macroscopic portal vein invasion, extrahepatic spread, or both: Yes 61 %, No 39 % Underlying cirrhosis based on masked independent imaging review: Yes 70 %, No 30 % Barcelona Clinic Liver Cancer stage: B (intermediate stage) 21 %, C (advanced stage) 79 % Involved disease sites: Liver 91 % , Lung 32 % Involved disease sites per patient: One patient had no baseline target lesion, 1 43 %, 2 37 %, ≥3 20 % Aetiology of chronic liver disease: Hepatitis B 50 %, Hepatitis C 23 %, Alcohol 6 %, Other 7 %, Unknown 14 % Baseline α-fetoprotein concentration group (ng/mL): <200 57 %, ≥200 43 % Concomitant systemic antiviral therapy for hepatitis B or C: 33 % Previous anticancer procedures: 70 % Previous radiotherapy: 11 %'\nRow 4 contains: 'Primary and secondary endpoints', 'The primary endpoint was overall survival (OS) measured from the date of randomisation until the date of death from any cause. Secondary endpoints were progression-free survival (PFS), time to progression (TPP), objective response rate (ORR), quality-of-life measurements (HRQoL), and plasma pharmacokinetics lenvatinib exposure parameters.'\nRow 5 contains: 'Method of analysis', 'The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. The primary endpoint of overall survival was first tested for non-inferiority, then for superiority. Using a non-inferiority test by the 95% CI lower-limit method on log HR for overall survival with assumed true HR of 0·80 and a non- inferiority margin of 1·08.'",
      "start_page": 112,
      "end_page": 112,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 5,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 112,
        "contains_dosage": true,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "patients who received treatment were included in the safety analysis.",
        "narrative_length": 2563,
        "extraction_hints": {
          "key_numbers": [
            "1",
            "23",
            "2",
            "478",
            "12",
            "60",
            "8",
            "60",
            "476",
            "400"
          ],
          "key_terms": [
            "sorafenib",
            "lenvatinib",
            "treatment",
            "therapy",
            "patient"
          ],
          "relationships": [
            "drug-dose",
            "dose-frequency"
          ]
        }
      }
    },
    {
      "heading": "each treatment and during the off-treatment visit.",
      "text": "Table Title: each treatment and during the off-treatment visit.\n\nTable contains the following columns: Column_1, Column_2, Lenvatinib, Column_4, Column_5, Sorafenib, Column_7\nRow 1: Lenvatinib: N=478 and Sorafenib: N=476\nRow 2: Column_1: Patients with events, n (%) Progressive disease Death, Column_2: 424 (88.7) 329 (68.8) 95 (19.9), and Column_5: 431 (90.5) 374 (78.6) 57 (12.0)\nRow 3: Column_1: Censored patients, n (%) No baseline tumour assessment No post-baseline tumour assessment No progression at the time of data cut-off No progression at the time of consent withdrawal, Column_2: 54 (11.3) 1 (0.2) 6 (1.3) 43 (9.0) 4 (0.8), and Column_5: 45 (9.5) 0 3 (0.6) 39 (8.2) 3 (0.6)\nRow 4: Column_1: Progression-free survival (months)* Median (95% CI) Q1 (95% CI) Q3 (95% CI), Column_2: 7.3 (5.8, 7.5) 3.6 (3.4, 3.6) 13.2 (11.3, 14.7), and Column_5: 3.7 (3.6, 4.7) 1.9 (1.8, 1.9) 9.0 (7.4, 9.2)\nRow 5: Column_1: Progression-free survival rate (%) (95% CI)† at 6 Months 12 Months 18 Months 24 Months Stratified cox model hazard ratio (95% CI)‡,§ Stratified log-rank test p-value§ and Column_2: 54.1 (49.5, 58.5) 36.1 (31.8, 40.5) 28.6 (24.6, 32.9) 16.9 (13.6, 20.5) 13.1 (10.1, 16.5) 11.3 (8.5, 14.4) 6.9 (4.7, 9.8) 8.0 (5.7, 10.9) 0.72 (0.63, 0.83) p<0.00001",
      "start_page": 126,
      "end_page": 126,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 6,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 126,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "each treatment and during the off-treatment visit.",
        "narrative_length": 1261
      }
    },
    {
      "heading": "UNK/NE) irrespective of treatment.",
      "text": "Table Title: UNK/NE) irrespective of treatment.\n\nTable contains the following columns: Patients first line treatment, Median OS in patients who received ANY subsequent anticancer medication, Median OS of RESPONDERS who received ANY subsequent anticancer medication, Column_4, Median OS of RESPONDERS who subsequently received SORAFENIB\nRow 1: Patients first line treatment: lenvatinib, Median OS in patients who received ANY subsequent anticancer medication: 21 months, Median OS of RESPONDERS who received ANY subsequent anticancer medication: 26 months (n=43), and Median OS of RESPONDERS who subsequently received SORAFENIB: 26 months (n=35)\nRow 2: Patients first line treatment: sorafenib, Median OS in patients who received ANY subsequent anticancer medication: 17 months, Median OS of RESPONDERS who received ANY subsequent anticancer medication: 22 months (n=16), and Median OS of RESPONDERS who subsequently received SORAFENIB: N/A",
      "start_page": 139,
      "end_page": 139,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 3,
        "extraction_method": "pass_1_standard",
        "has_title": true,
        "page": 139,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "UNK/NE) irrespective of treatment.",
        "narrative_length": 939
      }
    },
    {
      "heading": "Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Jan 31;",
      "text": "Table Title: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Jan 31;\n\nTable contains the following columns:  The patient population eligible for second-line regorafenib treatment is limited., Column_2, Column_3\nRow 1: Column_2: o Regorafenib is recommended “as possible standard treatment for patients with\nRow 2: Column_2: hepatocellular carcinoma with performance status 0-1 and with liver function similar\nRow 3: Column_2: to Child Pugh A, as before treated with and have tolerated sorafenib” according to\nRow 4: Column_2: the Medicine Council’s report\nRow 5: Column_2: o In the real-world GIDEON study looking at the European subpopulation, only 64.8%\nRow 6: Column_2: of the patients had Child Pugh A status, with 45.4% with ECOG 0 status, and 39.2%\nRow 7: Column_2: of the patients with ECOG 1 status. (2)\nRow 8:  The patient population eligible for second-line regorafenib treatment is limited.:  Lenvatinib is recommended as a first-line, systemic therapy in both the EASL and ESMO\nRow 9:  The patient population eligible for second-line regorafenib treatment is limited.: guidelines. (3)(4)",
      "start_page": 142,
      "end_page": 142,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 11,
        "extraction_method": "pass_2_relaxed",
        "has_title": true,
        "page": 142,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": true,
        "table_title": "Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Jan 31;",
        "narrative_length": 1140
      }
    },
    {
      "heading": "Table 1 on page 148",
      "text": "Row 1 contains: 'Effektmål*', 'Vigtighed', 'Kategori', 'Måleenhed', 'Mindste klinisk relevante forskelle (absolutte værdier)'\nRow 2 contains: 'Samlet overlevelse Overall survival (OS)', 'Kritisk', 'Dødelighed', 'Median overlevelse (antal måneder)', '3 måneder'\nRow 3 contains: '12 måneders overlevelse - Andel af patienter, der overlever i 12 måneder', '8 procentpoint'\nRow 4 contains: '24 måneders overlevelse - Andel af patienter, der overlever i 24 måneder', '4 procentpoint'\nRow 5 contains: 'Bivirkninger', 'Kritisk', 'Alvorlige symptomer og bivirkninger', 'Andel af patienter, der ophører behandlingen pga. bivirkninger', '5 procentpoint'\nRow 6 contains: 'Antal grad 3-5 bivirkninger pr. 100 patient-år', '10 procent relativ forøgelse eller reduktion'\nRow 7 contains: 'Kvalitativ gennemgang af bivirkningstyperne med henblik på at vurdere alvorlighed, håndterbarhed og hyppighed af bivirkningerne', 'Narrativ vurdering'\nRow 8 contains: 'Andel af patienter der dosisreduceres', '10 procentpoint'\nRow 9 contains: 'Progressionsfri overlevelse (PFS)', 'Vigtig', 'Alvorlige symptomer og bivirkninger', 'Median (antal måneder)', '3 måneder'",
      "start_page": 148,
      "end_page": 148,
      "table_type": "multi_pass_validated_table",
      "table_metadata": {
        "original_rows": 9,
        "extraction_method": "pass_2_relaxed",
        "has_title": false,
        "page": 148,
        "contains_dosage": false,
        "contains_pricing": false,
        "contains_medication": false,
        "table_title": null,
        "narrative_length": 1139
      }
    }
  ],
  "_table_detection_summary": {
    "total_tables_found": 28,
    "tables_by_page": {
      "4": [
        {
          "heading": "Table 1 on page 4",
          "narrative_length": 1114,
          "extraction_method": "pass_1_standard",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "10": [
        {
          "heading": "Table 1 on page 10",
          "narrative_length": 454,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 4,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "17": [
        {
          "heading": "Table 1 on page 17",
          "narrative_length": 372,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": true
        },
        {
          "heading": "Table 2 on page 17",
          "narrative_length": 434,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 7,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "21": [
        {
          "heading": "Table 1 on page 21",
          "narrative_length": 476,
          "extraction_method": "pass_1_standard",
          "original_rows": 7,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "24": [
        {
          "heading": "Table 1 on page 24",
          "narrative_length": 457,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "27": [
        {
          "heading": "Table 1 on page 27",
          "narrative_length": 585,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": true
        },
        {
          "heading": "Table 3 on page 27",
          "narrative_length": 819,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "30": [
        {
          "heading": "Table 1 on page 30",
          "narrative_length": 455,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "33": [
        {
          "heading": "Table 1 on page 33",
          "narrative_length": 233,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 4,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "45": [
        {
          "heading": "Table 2 on page 45",
          "narrative_length": 1348,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 11,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "46": [
        {
          "heading": "Table 1 on page 46",
          "narrative_length": 1097,
          "extraction_method": "pass_1_standard",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "47": [
        {
          "heading": "Table 1 on page 47",
          "narrative_length": 926,
          "extraction_method": "pass_1_standard",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "48": [
        {
          "heading": "Table 1 on page 48",
          "narrative_length": 930,
          "extraction_method": "pass_1_standard",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "49": [
        {
          "heading": "Table 1 on page 49",
          "narrative_length": 1020,
          "extraction_method": "pass_1_standard",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "51": [
        {
          "heading": "Table 1 on page 51",
          "narrative_length": 957,
          "extraction_method": "pass_1_standard",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "52": [
        {
          "heading": "Table 1 on page 52",
          "narrative_length": 446,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ],
      "65": [
        {
          "heading": "ratio to one of the following treatment groups:",
          "narrative_length": 698,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 3,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "70": [
        {
          "heading": "TABLE 5.1: OVERALL SURVIVAL BASED ON RANDOMIZATION STRATIFICATION FACTORS RECORDED IN THE IXRS - FAS",
          "narrative_length": 1029,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 8,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "72": [
        {
          "heading": "There was an imbalance between the treatment arms regarding the proportion of patients who received",
          "narrative_length": 1221,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 4,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "75": [
        {
          "heading": "discussion [1,2] which include information about the treatment-emergent adverse events (TEAE). TEAEs",
          "narrative_length": 6590,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 37,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "76": [
        {
          "heading": "have also been adjusted by treatment duration (",
          "narrative_length": 693,
          "extraction_method": "pass_1_standard",
          "original_rows": 7,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "78": [
        {
          "heading": "censored when they discontinued treatment for any reason other than disease progression.",
          "narrative_length": 777,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 4,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "112": [
        {
          "heading": "patients who received treatment were included in the safety analysis.",
          "narrative_length": 2563,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 5,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "126": [
        {
          "heading": "each treatment and during the off-treatment visit.",
          "narrative_length": 1261,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 6,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "139": [
        {
          "heading": "UNK/NE) irrespective of treatment.",
          "narrative_length": 939,
          "extraction_method": "pass_1_standard",
          "original_rows": 3,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "142": [
        {
          "heading": "Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Jan 31;",
          "narrative_length": 1140,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 11,
          "primary_content_type": "general",
          "contains_medical_data": true
        }
      ],
      "148": [
        {
          "heading": "Table 1 on page 148",
          "narrative_length": 1139,
          "extraction_method": "pass_2_relaxed",
          "original_rows": 9,
          "primary_content_type": "general",
          "contains_medical_data": false
        }
      ]
    },
    "table_storage_info": "Tables stored as individual chunks with hybrid metadata (narrative + structured)",
    "medical_table_insights": {
      "pricing_tables": 1,
      "dosage_tables": 3,
      "medication_tables": 16,
      "multi_pass_detection_summary": {
        "pass_1_standard": 9,
        "pass_2_relaxed": 19,
        "pass_3_medical": 0
      }
    }
  }
}